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Abstract 
Peptidic natural products have been the focus of many recent research projects as they 
exhibit a variety of biological properties due to the large diversity of amino acid building 
blocks. Modified peptides have found uses in medicinal chemistry as therapeutics and 
as tools for the analysis of disease. Through sidechain modification, the conformation, 
physical properties and hence the function of the peptide can be altered, however, 
traditional modifications target reactive heteroatoms that may be crucial for peptide 
function. Post-synthetic modification of peptides enables the manipulation of natural 
amino acids in a peptide after the sequence has been set.  
Palladium-catalysed cross-coupling reactions are a relatively new approach to peptide 
modification, which enable selective functionalization of the aromatic side chains. 
However, these reactions require the incorporation of non-natural, halogen-containing 
amino acids into the peptide sequence. In contrast, direct C-H functionalization is a 
more efficient strategy for peptide modification, which crucially enables post-synthetic 
modification of the natural peptide. 
When this project started, there had been some research on the C-H functionalization of 
tryptophan residues in peptides. To expand the opportunities for peptide modification, 
the primary aim of this investigation was to develop methods for the modification of 
phenylalanine containing peptides.  
The work documented in this thesis describes the development of a new C-H 
functionalization method for the direct modification of phenylalanine residues in 
peptides. By employing catalytic palladium, phenylalanine aromatic side chains were 
modified with alkenes, to produce functionalized side chains in a single step. The 
methodology was applied to di-, tri and tetrapeptides and also accommodated a range of 
alkenes. The olefination of phenylalanine appears to be selective; targeting mid 
sequence and C-terminal residues. Bidentate coordination of the metal catalyst to the 
peptide backbone is critical for the olefination of phenylalanine residues. 
The methodology was successfully applied to tryptophan residues, where the amino 
acid can be modified throughout a peptide sequence. The installation of a Boc directing 
group appears crucial for the functionalization of tryptophan residues.   
The work described for the modification of phenylalanine and tryptophan residues 
expands the current methodologies for peptide modification. 
 
 iv 
 
Acknowledgements 
I would like to thank the following people who have helped me throughout my PhD 
Firstly, I would like to thank my supervisor Dr Warren Cross who was kind enough to 
take a chance on me and let me undertake this research project. His encouragement 
has helped me throughout my time working for him. He has been invaluable and most 
importantly he listened whenever I needed an ear. 
Next, I would like to thank Professor Carole Perry who took me in as one of her 
inorganic bunch and helped me develop my presentation and writing skills and above all 
improve my confidence. 
I would like to thank Professor John Wallis for sitting in as my examiner throughout my 
experience. I’ll miss the weekly cricket catch ups.  
To Dr Chris Garner, Dr Ray Leslie and Mark Sladen for entertaining me throughout 
demonstrating with the undergraduates. 
To the CELs bunch who consisted of Karen Davies, Tom Pearson, Laurence Grey and 
Dan Cotton.  
To the ERD117 crew, Johnathan Bristow, Ryan Hemming, Axel Larson and Liam Duffy: 
the founders of office cricket and a fun bunch of guys to share a workspace with. 
Finally, to Lauren who has stuck by me throughout my irritable times and frequent 
moaning about chemistry. It will all be over soon!  
 
And to anyone that has worked with me over the past couple of years. 
 
Cheers everyone. 
 
 
 
 
  
 v 
 
Publications 
Below is a list of associated publications generated from the work documented in 
this thesis: 
 
1. Terrey, M. J.; Perry, C. C.; Cross, W. B. Org. Lett. 2019, 21 (1), 104–108. 
 
DOI: 10.1021/acs.orglett.8b03536 
 
2. Terrey, M. J.; Holmes, A.; Perry, C. C.; Cross, W. B. Org. Lett. 2019, 21 (19), 
7902–7907. 
 
DOI: 10.1021/acs.orglett.9b02894 
 
 
 
 
 
  
 vi 
 
Abbreviations 
Ac  Acetyl 
AMLA  Ambiphilic Metal Ligand Activation  
8-AQ 8 aminoquinoline 
Boc tert-butyl carbonate 
Br   Broad 
CMD  Concerted Metallation-Deprotonation  
COSY  Correlation Spectroscopy  
d  Doublet  
DCE 1,2-Dichloroethane 
DCM  Dichloromethane  
DG Directing group 
DMF  Dimethyl formamide  
eq.  Equivalents  
Hz  Hertz  
in vacuo  Under vacuum (reduced pressure)  
m  Multiplet  
Me  Methyl  
mol  Moles  
MS  Mass Spectrometry  
NaHMDS  Sodium hexamethyldisilazide  
NMR  Nuclear Magnetic Resonance  
Ph  Phenyl  
ppm  Parts per million  
q  Quartet  
s  Singlet 
t  Triplet  
TLC  Thin Layer Chromatography  
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran  
TMS  Trimethylsilyl  
  
 vii 
 
Contents 
 Introduction ................................................................................ 1 
1.1 An introduction to peptide modification ....................................................................................... 1 
1.1.1 Modification of heteroatoms on peptide side chains .......................................................... 2 
1.1.2 Modification with pre-functionalized amino acids .............................................................. 6 
1.2 C-H functionalization .................................................................................................................... 8 
1.2.1 Mechanisms of C-H activation ........................................................................................... 10 
1.2.2 Directing groups ................................................................................................................. 13 
1.2.3 C-H functionalization of amino acids ................................................................................. 15 
1.3 C-H functionalization of peptides ................................................................................................ 19 
1.3.1 C-H functionalization of peptides using pre-installed directing groups ............................. 19 
1.3.2 C-H functionalization of peptides using native amide backbone ....................................... 22 
1.3.3 Generating conformational constraints in peptides by C-H functionalization................... 25 
1.4 Aims ............................................................................................................................................ 28 
1.4.1 Project aims overview ........................................................................................................ 28 
1.4.2 C-H functionalization of phenylalanine containing peptides ............................................. 28 
1.4.3 C-H functionalization of tryptophan containing peptides.................................................. 29 
1.4.4 C-H functionalization of peptides containing multiple aromatic amino acids ................... 30 
1.4.5 Project aims summary ....................................................................................................... 30 
 Results and discussion ........................................................... 31 
2.1 C-H functionalization of phenylalanine containing peptides ...................................................... 31 
2.1.1 Olefination of model peptide Ac-Gly-Phe-OMe ................................................................. 31 
2.1.2 Optimisation ...................................................................................................................... 32 
2.1.3 Scope of the alkene ............................................................................................................ 34 
2.1.4 Investigating N-Protecting groups ..................................................................................... 36 
2.1.5 Amino acid sequence ......................................................................................................... 37 
2.1.6 Olefination of phenylalanine at the N-terminus ................................................................ 40 
2.1.7 Olefination of tri-, and tetrapeptides ................................................................................. 41 
2.2 Investigating the reaction mechanism........................................................................................ 44 
2.2.1 C-H activation of C-terminal phenylalanine residues ......................................................... 44 
2.2.2 Palladation of Ac-Gly-Phe-OMe (1a) .................................................................................. 46 
2.2.3 C-H activation of N-terminal phenylalanine residues ........................................................ 48 
2.2.4 Olefination of phenylglycine residues ................................................................................ 50 
2.2.5 Olefination of Ac-Pro-Phe-OMe (9e) .................................................................................. 51 
 viii 
 
2.2.6 Olefination of N-alkylated Phenylalanine residues ............................................................ 52 
2.2.7 Olefination of Phth-Gly-Phe-OMe (5) ................................................................................ 53 
2.2.8 Oxidative Heck reaction ..................................................................................................... 54 
2.3 C-H olefination of tryptophan containing peptides .................................................................... 56 
2.3.1 Olefination of Ac-Gly-Trp-OMe .......................................................................................... 56 
2.3.2 Boc protection of the tryptophan side chain ..................................................................... 57 
2.3.3 Reaction optimisation ........................................................................................................ 60 
2.3.4 Scope of the alkene ............................................................................................................ 64 
2.3.5 Changing the neighbouring amino acid ............................................................................. 64 
2.3.6 Olefination of tryptophan containing tripeptides .............................................................. 66 
2.4 Investigating the reaction mechanism for the olefination of tryptophan residues .................... 69 
2.4.1 Olefination of N-terminal tryptophan residues ................................................................. 69 
2.4.2 Modification of the amino acid tryptophan ....................................................................... 71 
2.4.3 Olefination of silyl protected tryptophan residues ............................................................ 73 
2.4.4 Installation of a pyrimidine directing group to tryptophan residues ................................. 75 
2.4.5 Installation of sulfonyl directing groups to tryptophan residues ....................................... 77 
2.5 Olefination of peptides containing multiple aromatic amino acids ............................................ 80 
2.5.1 Introduction ....................................................................................................................... 80 
2.5.2 Olefination of Ac-Trp(Boc)-Phe-OMe ................................................................................. 80 
2.5.3 Selective phenylalanine modification in the presence of tryptophan residues ................. 82 
 Conclusion ............................................................................... 84 
3.1 Olefination of phenylalanine and tryptophan residues in peptides ............................................ 84 
3.2 Current literature ........................................................................................................................ 89 
3.3 Future work ................................................................................................................................. 92 
3.3.1 Olefination of tyrosine and histidine containing peptides ................................................. 92 
3.3.2 Generating conformational constraints in peptides by C-H olefination reactions ............ 94 
 Experimental ............................................................................ 96 
4.1 General Experimental Information ............................................................................................. 96 
4.2 Synthesis of phenylalanine containing peptides ......................................................................... 97 
4.2.1 General procedure for the preparation of phenylalanine containing dipeptides.............. 97 
4.2.2 Ac-Gly-Phe-OMe (1a) ......................................................................................................... 98 
4.3 General procedure for the olefination of phenylalanine containing peptides ............................ 99 
4.3.1 C-H olefination of model dipeptide 1a; synthesis of modified peptides 2a and 2a’ ........ 100 
4.3.2 Synthesis of modified peptide 3a..................................................................................... 102 
 ix 
 
4.3.3 Synthesis of modified peptide 3b .................................................................................... 103 
4.3.4 Synthesis of modified peptide 3c ..................................................................................... 104 
4.3.5 Synthesis of modified peptide 3d .................................................................................... 105 
4.3.6 Synthesis of modified peptide 3e .................................................................................... 106 
4.3.7 Synthesis of modified peptide 3f ..................................................................................... 107 
4.3.8 Synthesis of modified peptide 3g ..................................................................................... 108 
4.3.9 Synthesis of modified peptide 3h .................................................................................... 109 
4.3.10 Synthesis of modified peptide 3i...................................................................................... 110 
4.3.11 Synthesis of modified peptide 3j ..................................................................................... 111 
4.4 Scope of the N-protecting group ............................................................................................... 112 
4.4.1 Synthesis of N-Phthaloyl glycine (Phth-Gly-OH) (4) ......................................................... 112 
4.4.2 Phth-Gly-Phe-OMe (5)...................................................................................................... 113 
4.4.3 Fmoc-Gly-Phe-OMe (6a) .................................................................................................. 114 
4.4.4 Boc-Gly-Phe-OMe (6b) ..................................................................................................... 115 
4.4.5 Cbz-Gly-Phe-OMe (6c) ...................................................................................................... 116 
4.4.6 Synthesis of modified peptide 8a..................................................................................... 117 
4.4.7 Synthesis of modified peptide 8b .................................................................................... 118 
4.4.8 Synthesis of modified peptide 8c ..................................................................................... 119 
4.5 Synthesis of dipeptides 9a-k...................................................................................................... 120 
4.5.1 Ac-Ala-Phe-OMe (9a) ....................................................................................................... 120 
4.5.2 Ac-Val-Phe-OMe (9b) ....................................................................................................... 121 
4.5.3 Ac-Ile-Phe-OMe (9c) ......................................................................................................... 122 
4.5.4 Ac-Leu-Phe-OMe (9d) ...................................................................................................... 123 
4.5.5 Ac-Pro-Phe-OMe (9e) ....................................................................................................... 124 
4.5.6 Ac-Phe-Phe-OMe (9f) ....................................................................................................... 125 
4.5.7 Ac-Tyr-Phe-OMe (9g) ....................................................................................................... 126 
4.5.8 Ac-Trp-Phe-OMe (9h) ....................................................................................................... 127 
4.5.9 Ac-Thr-Phe-OMe (9i) ........................................................................................................ 128 
4.5.10 Ac-Cys-Phe-OMe (9j) ........................................................................................................ 129 
4.5.11 Ac-Met-Phe-OMe (9k) ...................................................................................................... 130 
4.6 Modification of Phe dipeptides 9a-f, 9k .................................................................................... 131 
4.6.1 Synthesis of modified peptide10a ................................................................................... 131 
4.6.2 Synthesis of modified peptide 10b .................................................................................. 132 
4.6.3 Synthesis of modified peptide 10c ................................................................................... 133 
4.6.4 Synthesis of modified peptide 10d .................................................................................. 134 
4.6.5 Synthesis of modified peptide 10e .................................................................................. 135 
4.6.6 Synthesis of modified peptide 10f ................................................................................... 136 
4.6.7 Synthesis of modified peptide 10k ................................................................................... 137 
 x 
 
4.7 Synthesis of peptides bearing C-terminal glycine residues ....................................................... 138 
4.7.1 Ac-Phe-Gly-OMe (11) ....................................................................................................... 138 
4.8 General procedure for the synthesis of phenylalanine containing tripeptides ......................... 139 
4.8.1 Ac-Gly-Leu-OMe (12) ....................................................................................................... 140 
4.8.2 Ac-Gly-Phe-Leu-OMe (13a) .............................................................................................. 141 
4.8.3 Ac-Gly-Leu-Phe-OMe (13b) .............................................................................................. 142 
4.8.4 Ac-Phe-Gly-Leu-OMe (13c) .............................................................................................. 143 
4.8.5 Ac-Gly-Leu-Leu-OMe (13d) .............................................................................................. 144 
4.9 General procedure for the synthesis of phenylalanine containing tetrapeptides ..................... 145 
4.9.1 Ac-Gly-Phe-Leu-Leu-OMe (14a) ....................................................................................... 146 
4.9.2 Ac-Gly-Leu-Phe-Leu-OMe (14b) ....................................................................................... 147 
4.9.3 Ac-Gly-Leu-Leu-Phe-OMe (14c)........................................................................................ 148 
4.9.4 Ac-Phe-Gly-Leu-Leu-OMe (14d) ....................................................................................... 149 
4.10 Modification of phenylalanine containing tri- and tetra-peptides ..................................... 150 
4.10.1 Synthesis of modified peptide 15a................................................................................... 150 
4.10.2 Synthesis of modified peptide 15b .................................................................................. 151 
4.10.3 Synthesis of modified peptide 16a................................................................................... 152 
4.10.4 Synthesis of modified peptide 16b .................................................................................. 153 
4.10.5 Synthesis of modified peptide 16c ................................................................................... 154 
4.11 Preparation of unnatural phenylalanine derived peptides ....................................................... 155 
4.11.1 Ac-Gly-Phg-OMe (17) ....................................................................................................... 155 
4.11.2 N-methyl-l-phenylalanine methyl Ester hydrochloride (Me-Phe-OMe.HCl) (18)............. 156 
4.11.3 Ac-Gly-(N-Me)Phe-OMe (19)............................................................................................ 157 
4.12 General procedure for the preparation of tryptophan containing peptides ............................. 158 
4.12.1 Ac-Gly-Trp-OMe (20) ........................................................................................................ 159 
4.13 General procedure for the Boc protection of tryptophan residues ........................................... 160 
4.13.1 Ac-Gly-Trp(Boc)-OMe (22) ............................................................................................... 161 
4.14 General procedure for the olefination of tryptophan containing peptides ............................... 162 
4.14.1 Synthesis of modified peptide 23a................................................................................... 163 
4.15 Removal of the Boc protecting group from tryptophan residues ............................................. 165 
4.15.1 Synthesis of modified peptide 21 .................................................................................... 165 
4.16 Synthesis of modified peptide 23b-f.......................................................................................... 166 
4.16.1 Synthesis of modified peptide 23b .................................................................................. 166 
4.16.2 Synthesis of modified peptide 23c ................................................................................... 167 
4.16.3 Synthesis of modified peptide 23d .................................................................................. 168 
4.16.4 Synthesis of modified peptide 23e .................................................................................. 169 
 xi 
 
4.16.5 Synthesis of modified peptide 23f ................................................................................... 170 
4.17 Synthesis of dipeptides 25a-d ................................................................................................... 171 
4.17.1 Ac-Ala-Trp-OMe (24a) ...................................................................................................... 171 
4.17.2 Ac-Leu-Trp-OMe (24b) ..................................................................................................... 172 
4.17.3 Ac-Phe-Trp-OMe (24c) ..................................................................................................... 173 
4.17.4 Ac-Met-Trp-OMe (24d) .................................................................................................... 174 
4.17.5 Ac-Ala-Trp(Boc)-OMe (25a) .............................................................................................. 175 
4.17.6 Ac-Leu-Trp(Boc)-OMe (25b) ............................................................................................. 176 
4.17.7 Ac-Phe-Trp(Boc)-OMe (25c) ............................................................................................. 177 
4.17.8 Ac-Met-Trp(Boc)-OMe (25d) ............................................................................................ 178 
4.18 Synthesis of modifed dipeptides 26a-d ..................................................................................... 179 
4.18.1 Synthesis of modified peptide 26a................................................................................... 179 
4.18.2 Synthesis of modified peptide 26b .................................................................................. 180 
4.18.3 Synthesis of modified peptide 26c ................................................................................... 181 
4.18.4 Synthesis of modified peptide 26d .................................................................................. 182 
4.19 Synthesis of dipeptides 28a-d ................................................................................................... 183 
4.19.1 Ac-Trp-Leu-OMe (27a) ..................................................................................................... 183 
4.19.2 Ac-Trp-Met-OMe (27b) .................................................................................................... 184 
4.19.3 Ac-Trp(Boc)-Leu-OMe (28a) ............................................................................................. 185 
4.19.4 Ac-Trp(Boc)-Met-OMe (28b) ............................................................................................ 186 
4.20 Synthesis of modified peptides 29a-b ....................................................................................... 187 
4.20.1 Synthesis of modified peptide 29a................................................................................... 187 
4.20.2 Synthesis of modified peptide 29b .................................................................................. 188 
4.21 General procedure for the synthesis of tryptophan containing tripeptides .............................. 189 
4.21.1 Ac-Trp-Leu-Leu-OMe (30a) .............................................................................................. 190 
4.21.2 Ac-Leu-Trp-Leu-OMe (30b) .............................................................................................. 191 
4.21.3 Ac-Met-Trp-Met-OMe (30c) ............................................................................................. 192 
4.21.4 Ac-Gly-Leu-Trp-OMe (30d) ............................................................................................... 193 
4.22.1 Ac-Trp(Boc)-Leu-Leu-OMe (31a) ...................................................................................... 194 
4.22.2 Ac-Leu-Trp(Boc)-Leu-OMe (31b) ...................................................................................... 195 
4.22.3 Ac-Met-Trp(Boc)-Met-OMe (31c) .................................................................................... 196 
4.22.4 Ac-Gly-Leu-Trp(Boc)-OMe (31d) ...................................................................................... 197 
4.23 Synthesis of modified tryptophan containing tripeptides 33a-d ............................................... 198 
4.23.1 Synthesis of modified peptide 33a................................................................................... 198 
4.23.2 Synthesis of modified peptide 33b .................................................................................. 199 
4.23.3 Synthesis of modified peptide 33c ................................................................................... 200 
4.23.4 Synthesis of modified peptide 33d .................................................................................. 201 
 xii 
 
4.24 Synthesis of unnatural tryptophan derived amino acids .......................................................... 202 
4.24.1 Synthesis of Ac-Trp-OMe (34) .......................................................................................... 202 
4.24.2 Preparation of Ac-Trp(Boc)-OMe (35) .............................................................................. 203 
4.24.3 Synthesis of amino acid (35a) .......................................................................................... 204 
4.25 Preparation of silyl protected peptides 36a-b ........................................................................... 205 
4.25.1 Ac-Gly-Trp(TIPS)-OMe (36a) ............................................................................................. 205 
4.25.2 Ac-Gly-Trp(TBDMS)-OMe (36b) ........................................................................................ 206 
4.26 Synthesis of Ac-Trp(Pym)-OMe (39) .......................................................................................... 207 
4.27 Synthesis of modified peptides 43a-e ....................................................................................... 208 
4.27.1 Synthesis of Ac-Trp(Boc)-Phe-OMe (42) .......................................................................... 208 
4.27.2 Olefination of Ac-Trp(Boc)-Phe-OMe 43a-e ..................................................................... 209 
4.27.3 Synthesis of modified peptide 43a................................................................................... 210 
4.27.4 Synthesis of modified peptide 43b .................................................................................. 211 
4.27.5 Synthesis of modified peptide 43c ................................................................................... 212 
4.27.6 Synthesis of modified peptide 43d .................................................................................. 213 
4.27.7 Synthesis of modified peptide 43e .................................................................................. 214 
4.28 Synthesis of modified peptide 45 .............................................................................................. 215 
4.28.1 Synthesis of Ac-Trp(TIPS)-Phe-OMe (44) ......................................................................... 215 
4.28.2 Synthesis of modified peptide 45 .................................................................................... 216 
 References ............................................................................. 217 
 1 
 
 Introduction 
1.1 An introduction to peptide modification 
Peptides and proteins are key components of carbon-based life on this planet, often 
governing many biological processes such as cell signalling and metabolism.1–5 Peptide 
structure plays a vital role in the biochemistry of peptides, shape and peptide function. 
Primary peptide structure is determined by the order of amino acids, which in turn gives 
a peptide sequence a specific shape such as an α-helix, β-sheet or β-turn. Altering the 
sequence of amino acids or the bonding between amino acid side chains, leads to 
changes in peptide function. Modified peptides are then used to explore biological 
function that was not possible with a native peptide.6 For example, the development of 
fluorescent peptides through peptide modification, enables further understanding of 
disease and can be used a fluorescent marker to aid surgical treatment.7–10  
Modified peptides have also found uses as therapeutic agents, which when compared to 
small molecule drugs, often possess higher target specificity and afinity.11 Many peptide 
therapeutics although highly active, suffer from poor pharmacokinetics when tested. One 
reason for this is the increased flexibility of peptides compared to small molecule drugs. 
Generating a more constrained, rigid structure through peptide modification can lead to 
an increase in potency.  
For example, N-methylation of amide residues reduces hydrogen bonding, cyclisation of 
peptide chains increases the rigidity of a peptide and the incorporation of non-natural 
amino acids can improve potency.12 Cyclosporine A is an 11 amino acid peptide 
sequence, in which all of these features have been included into the drug candidate, 
improving the potency and pharmacokinetic properties of the drug (Figure 1).13  
 
Figure 1: Structure of Cyclosporine A. 
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Site-specific peptide modification is a crucial tool in the development of peptide 
therapeutics to combat the disadvantages to contemporary peptide therapeutics.14–18  
 
Figure 2: A display of some of the approaches to peptide modification.  
 
Peptide modification strategies have mainly focussed upon reactions targeting 
heteroatoms on amino acid side chains and termini, (Figure 2, strategy 1). These side 
chains are often crucial for peptide function and modification of these sites is not always 
a suitable approach.19–21 Heteroatom modifications are the most abundant modification 
as these heteroatoms are generally reactive. The modification of less reactive centres in 
peptides is troublesome and site selectivity can be a major issue.22,23 
For reactions at carbon atoms, improving site selectivity can be achieved through 
targeting unnatural amino acids or adding in pre-functionalized amino acids to a peptide 
sequence (Figure 2, strategy 2).  The inclusion of these pre-functionalized amino acids 
increases the number of synthetic steps and means that native peptides cannot be 
modified in the same way. Post-synthetic modifications (such as C-H functionalization) 
are desirable alternatives to pre-functionalization as they enable modifications upon 
natural peptides in a single step, (Figure 2, strategy 3).24–26 
 
1.1.1 Modification of heteroatoms on peptide side chains 
Perhaps the most widely reported method of peptide modification are transformations 
upon heteroatoms on peptide side chains.27 Thiol side chains upon cysteine are often 
the chosen site of modification, due to the increased nucleophilicity when compared to 
amine side chains of lysine and arginine side chains for example, as well as the lower 
natural abundance in peptides.28 Crosslinking of cysteine side chains between peptides 
is a common feature in natural peptides and proteins. The alkylation of cysteine residues 
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provides a convenient route to modified peptides, such as those displayed in Scheme 
1.29  
 
Scheme 1: Alkylation of cysteine residues in a peptide sequence.29 
 
The methodology developed for the S-alkylation of cysteine residues has also been 
demonstrated on the intramolecular cyclisation of a septa-peptide. The alkylation of the 
cysteine side chain in Scheme 2, lead to the formation of a carbavasopressin analogue 
and is an example of side chain modification to form a natural peptide derivative. The 
alkylation was performed in the presence of a nucleophilic arginine residue and the 
acidic tyrosine side chain.30 
 
Scheme 2: Synthesis of a carbavasopressin analogue by cysteine alkylation.30  
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As well as reactions involving cysteine residues, the modification of reactive amine 
residues have been extensively explored. The post-synthetic modification of lysine is 
one such example in which the side chain of a peptide is modified by selective N-
alkylation, Scheme 3.31 The free amine is first protected by the addition of a nosyl group 
before N-alkylation using benzyl bromide under mild conditions. The nosyl group was 
then removed to give the N-alkylated peptide. The reaction accommodates a variety of 
different functionality present within a peptide: from sulphide bridges to histidine and 
tryptophan residues.  
 
Scheme 3: Alkylation of a lysine residues in a peptide.31 
 
The development of new amino acids that can undergo simple organic reactions to 
make peptide derivatives is highly sought after. Koehler et al. reported the production 
and installation of a non-natural amino acid that can undergo Michael additions to give 
structurally complex peptides, Scheme 4.32 The maleimide functionalized amino acid is 
incorporated into a peptide sequence during peptide synthesis. The maleimide residue 
was found to react readily with nucleophiles to create highly functionalized side chains. 
Moreover, the nucleophilic cysteine side chain was reacted with the maleimide amino 
acid via a Michael addition to create a modified cyclic peptide.  
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Scheme 4: The incorporation of maleimide into a peptide sequence and the cyclisation via 
Michael addition.32 
 
A recently reported study into the addition of electrophilic pyridazine units to peptides 
demonstrates this approach, Scheme 5.33 The nucleophilic amino acids (such as serine 
and tyrosine) are targets for modification, in which pyridizine based electrophiles are 
added to amino acid side chains in a nucleophilic aromatic substitution reaction. The 
cyclic peptide oxytocin was also modified by the pyridazine analogues. In the study, two 
perfluoropyridazine units were added to the peptide at the tyrosine OH and the free 
amine on the peptide backbone. The investigation aimed to improve the enzymatic 
stability of the peptide. The modified oxytocin was found to have an increased 
resistance to enzymatic digestion compared to the unmodified peptide, in which the 
cyclic structure is easily broken. Heteroatom selectivity becomes increasing more 
challenging upon larger peptide sequences.  
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Scheme 5: Modification of oxytocin.33 
 
1.1.2 Modification with pre-functionalized amino acids 
The challenge for peptide chemists is to develop methodologies for the direct 
modification of less reactive amino acid side chains. The modification of aliphatic and 
aromatic amino acid residues has been under explored due to the lack of a functional 
handle, making residue selectivity difficult. The inclusion of pre-functionalized amino 
acids into a peptide sequence, allow the direct modification of a specific amino acid, 
increasing selectivity over natural residues. Draw backs of using pre-functionalized 
amino acids include an increased cost in materials and the requirement of additional 
steps to product the non-natural amino acids in question. 
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The iodination of tyrosine is one such example of pre-functionalization, Scheme 6.9 The 
olefination of iodo-tyrosine using catalytic palladium was found to give highly fluorescent 
modified amino acids. The reaction proceeds via a Heck reaction to give the mono-, di-
olefinated amino acid depending on the whether the di-iodo or mono-iodo-tyrosine 
derivative was used.  
 
 
Scheme 6: Olefination of unnatural iodo-tyrosine amino acid. 9 
 
The olefination of iodo-tyrosine at the meta-position within a peptide requires the non-
natural tyrosine amino acid be placed into the sequence during peptide synthesis. The 
olefinated peptide displays increased fluorescent characteristics compared to the 
unmodified starting material, making it a suitable tool for fluorescent imaging. The 
olefination of tyrosine containing peptides is limited, however to non-natural species, 
pre-functionalized amino acids. The olefination of natural tyrosine containing peptides 
has yet to be reported. 
The incorporation of pre-functionalize amino acids into a peptide sequence allows 
further modification of a peptide allowing greater selectivity and control. These non-
natural residues are then the targets for selective modifications by C-C cross coupling.34 
One such example of this is demonstrated in Scheme 7.  
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Scheme 7: Suzuki cross coupling of pre-functionalized phenylalanine.35 
 
The non-natural amino acid 4-iodophenylalanine has been inserted into a peptide as the 
sequence was created. An aryl boronic acid derivative was then reacted with the peptide 
in the presence of a palladium catalyst to create a bi-aryl peptide. The inclusion of the 
non-natural amino acid allows for selective arylation at the para position of 
phenylalanine derivative.  
The inclusion of pre-functionalized amino acids, however, increases the number of steps 
in the synthesis. The challenge for synthetic chemists is to develop new methods in 
which less reactive amino acids are modified without the use of pre-functionalization. 
 
1.2 C-H functionalization   
In the search for new C-C bond forming processes, cross coupling reactions have until 
recently been the primary way of creating new C-C bonds.36 Cross coupling reactions 
arose in the early 1970s as new ways of generating previously impossible C-C bonds 
using a metal catalyst. The early pioneers of C-C cross couplings were Heck, Negishi 
and Suzuki, who were awarded the Nobel prize for chemistry in 2010 for development of 
cross coupling reactions.36 The Negishi and Suzuki reactions require the use of a pre-
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functionalized organozinc and organoborane species for the cross coupling reaction to 
occur, however, Heck reactions do not require the generation of an organometallic 
reagent prior to catalysis.  
 
Scheme 8: Examples of [a] Heck reaction, [b] Negishi coupling and [c] Suzuki cross coupling reactions. 
 
C-H activation has developed into a desirable alternative to cross coupling reactions by 
manipulating non-acidic C-H bonds.37 Both C-C cross coupling and C-H activation 
methods allow the modification inert carbon bonds in the presence of a metal catalyst. 
C-H functionalization reactions differ to that of cross couplings in that they do not 
necessarily require the inclusion of organo halides or pre-functionalization prior to the 
reaction. Furthermore, C-H functionalization allows the generation of new compounds by 
generating unique disconnections in retrosynthetic challenges. 
 
Figure 3: A representation of C-H functionalization compared to traditional C-C bond formation reactions. 
 
C-H functionalization unlocks the ability to design molecules using fewer synthetic steps, 
and cheaper starting materials. The modification of natural amino acids and peptides 
can be exploited using C-H functionalization. Peptide modifications usually require the 
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incorporation of non-natural amino acids that are expensive or require many synthetic 
steps to install. Designing a synthesis using C-H activation allows the generation of a 
new library of peptides without the incorporation of pre-functionalized materials, thus 
reducing the number of synthetic steps and the cost of synthesising the desired modified 
peptide.38  
 
1.2.1 Mechanisms of C-H activation 
Since the early reports of C-H activation, there has been a dramatic increase in the 
number of reported transformations by C-H activation. C-H activation can be divided into 
four mechanisms as illustrated in Figure 4. 
 
 
Figure 4: Mechanisms of C-H activation. 
 
Oxidative addition is defined by the addition of a C-H bond to an electron rich metal, 
increasing the oxidation state and coordination number of the complex.39 The addition 
results in the formation of a new metal hydride and metal carbon bond. The C-H bond is 
cleaved as the M-C and M-H bonds are formed through a three-membered transition 
state, Scheme 9. For oxidative addition to occur the metal must be relatively electron-
rich and be able to accommodate the new M-C and M-H bonds around the metal 
centre.37,40–42  
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Scheme 9: Mechanism of oxidative addition by C-H activation. 
 
Early examples of C-H activation via an oxidative addition mechanism were reported by 
Chatt, in which the ruthenium complex Ru(dpme)2 activates the sp2 naphthalene proton 
and also the sp3 C-H bonds on the metal ligand,43 Scheme 10. 
 
Scheme 10: C-H activation of Ru(dmpe)2 through oxidative addition.43 
 
Electrophilic substitution mechanisms are defined by the coordination of a C-H bond to 
an electrophilic metal, forming a cationic metal complex which weakens the C-H bond, 
allowing deprotonation, Scheme 11. Electrophilic C-H activation was first observed with 
the isotopic H/D change of methane in a solution of D2O with a metal complex K2PtCl4  
by Shilov.44  
 
Scheme 11: Mechanism for electrophilic substitution in C-H activation. 
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σ-Bond metathesis (Figure 4, Pathway 3), is the cleavage of two σ-bonds and the 
formation of two new σ-bonds, within a four-centre transition state.45 Notably the formal 
oxidation state does not change, Scheme 12. The most appropriate metals for σ-bond 
metathesis are electron deficient metals such as the early transition metals and the 
lanthanides and actinides. The first reported observation of σ-Bond metathesis was 
observed by Watson for the exchange of the methyl ligand of Cp*2LuMe with 
radiolabelled 13CH4.46 Further examples were reported by Bercaw with alkyl and aryl 
organo-scandium complexes.47   
 
 
Scheme 12: Mechanism for σ-bond metathesis in C-H activation. 
 
CMD (concerted metalation deprotonation) or AMLA (amphiphilic metal ligand 
activation) as it is also known, is the combined interaction of both the metal and the 
ligand with the C-H bond, and subsequent deprotonation by the ligand.48–50 The 
mechanism comprises of the activation of a Lewis acidic metal followed by 
deprotonation by an intramolecular base which affords a low energy pathway for C-H 
activation.  
One early example of this mechanism was reported by Ryabov in the cyclometallation of 
dimethylbenzylamine (DMBA) with Pd(OAc)2.51 The work was followed up by a 
computational study by Davies to suggest the mechanism shown in Scheme 13.52 The 
reaction proceeds by the coordination of the metal catalyst to the substrate through a 
monodentate amine directing group. The acetate ligand is aligned close to the ortho 
protons of the substrate and C-H bond cleavage is achieved through the interaction of 
the ligand and the ortho protons.  
 
Scheme 13: Proposed C-H activation pathway of the reaction of DMBA with Pd(OAc)2 via a CMD/AMLA 
mechanism. 
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C-H activation using an AMLA/CMD mechanism is the most diverse method for C-H 
functionalization. The mechanism can accommodate a variety of different metal catalyst 
and directing groups for C-H activation.  
 
1.2.2 Directing groups 
C-H bonds are the most abundant bond present in organic molecules and are generally 
the least reactive species in a compound and in many species high in abundance. The 
challenge for chemists has been to develop methods for the selective modification of C-
H bonds.53 The use of metal coordinating species as directing groups for C-H 
functionalization has become a useful tool to enhance the selectivity of C-H bond 
activation. Directing groups allow the coordination of the metal to the substrate close to 
the site of the desired C-H activation, Figure 5.54,55  
 
Figure 5: Representation of directing group assisted C-H activation. 
Although the installation of directing groups are not always essential for C-H 
functionalization, it increases the selectivity of the reaction and increase the reactivity of 
the metal ligand complex.56 Common directing groups for C-H activation include 
examples such as bipyridyl, amides and carbonyls. In order to function successfully as a 
directing group, the substrate must be weakly coordinating to the metal atom, so that the 
metal complex is not rendered inert through binding.57  
The use of bidentate directing groups allows the formation of metallacycles that would 
not be possible by coordination through monodentate systems. The 8-aminoquinoline 
(8-AQ) directing group is among one of the most commonly used directing groups for C-
H functionalization.58 First reported in 2005 by Daugulis, 8-AQ was used as a bidentate 
directing group for the arylation of C-H sp3 bonds using Pd(OAc)2, Figure 6.59 
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Figure 6: Palladium catalysed C-H arylation using 8-aminoquinoline as a directing group.59 
 
The bidentate coordination of the metal centre forms a stable five-membered 
metallacycle. Subsequent C-H activation at the β-carbon occurs through an AMLA 
mechanism, to form a five-five ring system. The incoming aryl halide oxidatively adds to 
the metal centre before the formation of a new C-C bond. The pre-installed directing 
group can then be easily removed thereafter by treatment with base, Scheme 14.58 
 
Scheme 14: Removal of 8-AQ directing group.58 
 
To date, a diverse library of directing groups have been reported including; amides, 
amines, imines, carboxylic acids, ketones, esters and hydroxyl groups.60 These directing 
groups have been allied to modifications such as arylations, alkylations and 
alkenylations to name but a few.  
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1.2.3 C-H functionalization of amino acids 
One of the earliest reported modifications of amino acids was completed by Daugulis.61 
Following on from his previous work using the bidentate 8-AQ directing group, the 
palladium catalysed sp3 alkylation of amino acid side chains was then reported, Scheme 
15. The methodology provided a route to the synthesis of substituted phenylalanine 
derivatives through C-H functionalization, generating a small library of unnatural aryl 
containing amino acids. 62 
 
Scheme 15: Arylation of sp3 amino acid side chains using 8-AQ directing group.61 
 
Interestingly, the arylation of alanine using the 8-AQ directing group, lead to a mixture of 
mono- and di-arylated products. The synthesis of the mono-arylated product was 
achieved by changing the directing group to a 2-thiomethylaniline derivative, which gave 
selective mono-arylation. Inspired by the work of Dauglulis, a number of other groups 
have reported selective mono-arylation through varied directing groups such as Shi,63 
Caretto,64 and Ma,65 Scheme 16.  
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Scheme 16: Mono-arylation of sp2 amino acid side chains by Daugulis,61 Shi,63 Caretto,64 and Ma,65 
 
Many of the C-H functionalization methodologies have focussed upon creating unnatural 
aromatic amino acid side chains via sp3 arylations. The appropriate aryl halide is 
installed via a C-H arylation reaction. Modifications of natural aromatic amino acids have 
been less explored. Research into the direct C-H functionalization of aromatic amino 
acids has been largely dominated by studies focussing on tryptophan.66–69 Key 
examples of tryptophan modification have been demonstrated by Alberico and 
Ackermann, Scheme 17. 66,70 
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Scheme 17: C-H arylation of tryptophan by Albericio66 and alkynylation by Ackermann.70 
 
The C-H sp2 modifications of tryptophan has largely focused on modifying the highly 
reactive C-2 position of the indole ring. However, olefination at the less reactive C-4 
position have been demonstrated by installation of a TIPS protecting group, Scheme 
18.71  
 
Scheme 18: C-H Olefination of tryptophan at the C-4 position.71 
 
The imidazole containing amino acid histidine is another common target for 
modification.72,73 The arylation of histidine was achieved by using a palladium catalyst 
under microwave conditions, Scheme 19.72 The reaction was found to tolerate a variety 
of different aryl halides in a relatively short reaction time to give highly functionalised 
amino acids that can be readily incorporated into a peptide sequence. 
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Scheme 19: Direct C-H arylation of hisitidine.72 
 
The electron rich phenol side chain in tyrosine permits modifications ortho to the 
phenolic OH. The C-H arylation of tyrosine was reported by Bedford et al., Scheme 
20.74 The methodology developed requires pre-functionalization of tyrosine to achieve 
mono-arylation. The tert-butyl group can then be removed so that a second arylation 
using a different aryl bromide can be used. The use of pre-functionalized amino acid 
makes the transformation less desirable than direct C-H arylation reactions. 
 
 
Scheme 20: Mono-arylation of tyrosine by Bedford and co-workers.74 
 
In the literature, phenylalanine derivatives have been readily modified using pre-
functionalization strategies.75–77 Strategies for phenylalanine modification have focused 
upon borylation78 and iodination79 methodologies. However, only the direct ortho-
olefination of the amino acid phenylalanine has been reported.80 Strategies for 
phenylalanine modification have focused upon borylation78 and iodination79 
methodologies. 
The olefination of the amino acid phenylalanine required the installation of a pyridyl 
sulfone directing group at the N-terminus, Scheme 21. Applying the methodology 
reported by Garcia and co-workers to phenylalanine containing peptides would be a 
problem, as the phenylalanine residue could only be located at the N-terminus of the 
peptide. To place the phenylalanine residue in other location of a peptide sequence 
would require the modified amino acid residue to be placed into a sequence when 
required.  
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Scheme 21: The olefination of phenylalanine using a pre-installed sulfonamide directing group.80 
 
The modification of amino acids by C-H functionailzation provides an efficient route to 
the synthesis of a variety of complex and diverse amino acids. These unnatural amino 
acids, however, are synthesised prior to peptide coupling and are incorporated into a 
peptide sequence after modification. This increases the number of steps before the 
desired modified peptide can be isolated. The aim for chemists is to develop methods 
for the direct modification of amino acids in peptide sequences, after the synthesis of the 
peptide.   
 
1.3 C-H functionalization of peptides 
C-H functionalization methods have been developed for many amino acids, however, 
there are fewer instances in which peptide modification has been achieved by C-H 
functionalization.26,81,82 Compared to modifications on amino acids, the C-H 
functionalization of peptides is noticeably harder due to a number of factors; Peptides 
contain multiple acidic C-H bonds, making selective C-H functionalization difficult 
compared to modifications of amino acids, the incorporation of highly functionalized side 
chains can affect metal binding, and also, peptides contain multiple coordination sites, 
which complicates metal binding.83 The combination of these factors makes the C-H 
functionalization of peptides challenging. 
Achieving peptide modification by C-H functionalization allows for the generation of 
peptide libraries through late-stage diversification. Developing C-H functionailzation 
methodologies is therefore a useful strategy for the development of peptide based 
chemical libraries. 
 
1.3.1 C-H functionalization of peptides using pre-installed directing groups 
The modification of aliphatic amino acid side chains has been underexplored, as the 
aliphatic side chains do not contain a functional handle. Applying C-H functionalization 
strategies to relatively inert bonds, is a way of producing derivatives of these simple 
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amino acid side chains. However, site selectivity remains a problem. One such way of 
overcoming the selectivity problems associated with the C-H functionalization of 
peptides is by installing a directing group for selective modifications. As described in 
Section 1.2.2, 8-AQ is a useful bidentate directing group for C-H functionalization. The 
arylation of piperidine based amino acids in peptides by Kazmaier and co-workers is an 
example of the C-H functionalization of an amino acid residue using the 8-AQ directing 
group,84 Scheme 22. This methodology, however, is limited to modifications at the C-
terminal amino acid residues, as the directing group is tethered to the C-terminus of the 
peptide.  
 
Scheme 22: Arylation of piperidine based amino acids in a dipeptide using 8-amino quinoline directing 
group.84 
 
Contrastingly, the reported C-H arylation of peptides by Ackermann utilised a triazole 
directing group,85 Scheme 23. The method developed by Ackerman generates new 
unnatural amino acid side chains by the C-H arylation of sp3 amino acid residues. The 
triazole directing group was installed within the peptide backbone and allows for the C-H 
arylation of sp3 amino acids proximal to the directing group. The methodology was 
applied to amino acids at the N-terminal and the middle of a peptide sequence.  
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Scheme 23: C-H Arylation of alanine residues using a triazole based directing group located in the peptide 
backbone.85 
 
The C-H arylation of tryptophan residues have flourished using pyridine-based directing 
groups installed upon the indole nitrogen. The methodology for the arylation of indoles 
using a pyridine directing group was reported by Ackermann. 86 The methodology was 
developed on the amino acid tryptophan and then applied to tryptophan residues within 
peptides,87 Scheme 24. Impressively, the pyrimidine directed arylation of tryptophan 
accommodated the native tryptophan residue within a peptide sequence. Selectivity had 
been established through the installation of the pyrimidine directing group. 
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Scheme 24: Pyrimidine directed C-H arylation of a) tryptophan 86 and b) tryptophan containing peptides.87 
 
The installed directing groups improve residue selectivity, however, the installation and 
removal of directing groups increase the number of synthetic steps needed for a given 
C-H functionalization reaction.  
 
1.3.2 C-H functionalization of peptides using native amide backbone 
Despite the development of new peptide modification methodologies by C-H 
functionalization, the installation of directing groups remains necessary for selective 
modifications. The pre-installation of directing groups increases the number of synthetic 
steps needed for C-H functionalization, making the methods less desirable.  
A critical development in the C-H functionalization of peptides was reported by Yu and 
co-workers on the C-H functionalization of sp3 amino acid residues in di-, tri- and 
tetrapeptides,88 Scheme 25. The report demonstrated the C-H arylation of alanine 
residues upon peptide side chains without the need for the installation of a directing 
group such as 8-aminoquinoline. Here the peptide backbone acts a directing group for 
the incoming palladium catalyst, allowing direct alkylation of the alanine residue. 
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Impressively the methodology has been shown to work well on larger peptide systems 
such as tri-, and tetrapeptides as well as a variety of aryl substituents.  
 
 
Scheme 25: C-H Arylation of sp3 amino acid residues by Yu et al.88 
 
The methodology details the selective N-terminal C-H arylation of peptides without the 
preinstallation of a directing group. C-H activation of dipeptides was achieved by the 
formation of a metal-nitrogen bond with the amide nitrogen and free C-terminal 
carboxylic acid. The modification of tri- and tetrapeptides was achieved through 
bidentate coordination, only this time through two amide residues rather than the C-
terminal carboxylic acid. A peptide backbone consists of multiple amide nitrogen atoms 
that can act as directing groups for C-H activation.89,90 Coordination of a metal to a 
peptide backbone to aid in C-H functionalization has been reported by Yu et al,  in the 
C-H arylation of small peptides.88 Bidentate coordination of a palladium atom to a 
peptide back bone forms a five-five ring system which is setup for C-H activation, 
Scheme 26. 
 
Scheme 26: C-H Arylation of peptide side chains by bidentate coordination to the peptide backbone.88 
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Since Yu proposed the bidentate coordination of a metal catalyst to the peptide 
backbone, there has been a number of reported C-H modification of peptides through 
backbone coordination to the metal catalyst.  
Table 1: Arylation of tryptophan residues in tri- and tetrapeptides by Alberico.66 
 
Entry Sequence Yield / % 
1 Ac-Ala-Trp-Ala-OH 57 
2 Ac-Trp-Leu-Asp-Phe-OH 68 
3 Ac-Tyr-Pro-Trp-Phe-OH 75 
4 Ac-Arg-Gly-Trp-Ala-OH 94 
5 Ac-His-Gly-Trp-Ala-OH 51 
6 Ac-Lys-Gly-Trp-Ala-OH 95 
7 Ac-Ser-Gly-Trp-Ala-OH 62 
8 Ac-Gln-Phe-Ala-Trp-OH 88 
 
 
Alberico et al., developed a method for the direct C-H arylation of tryptophan containing 
tri-, and tetrapeptides, Table 1.66 The C-H arylation strategy was developed first from 
the arylation of the native tryptophan amino acids.91,92 The mild conditions developed for 
the C-H arylation were found to tolerate a wide variety of amino acid side chains 
containing; carboxylic acids (aspartic acid (entry 2)) amines (arginine and lysine, 
entries 4 and 6), aromatic residues (phenylalanine (entries 2, 3 and 8), tyrosine (entry 
3) and histidine (entry 5)), alcohols (serine (entry 7)) and amides (glutamine (entry 8)). 
The location of the tryptophan residue does not appear to influence the C-H arylation 
reaction, as tryptophan residues in the middle (entries 1, 3-7) and at the N-terminus 
(entry 2) and C-terminus (entry 8) were modified under the reaction conditions.  
Since the reported C-H arylation of tryptophan containing peptides by Albericio, a 
handful of other reported arylations of tryptophan containing peptides have been 
developed by Fairlamb,93,94 amongst others,95 Figure 7. 
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Figure 7: Arylation of tryptophan containing by peptides by a) phenylboronic acids 93 and b) phenyl 
diazonium salts.94 
 
The arylation of tryptophan residues by Fairlamb was achieved from phenylboronic 
acids at 40 °C, to give arylated tryptophan peptides in excellent yields.93 Complimentary 
methods have also been developed by Fairlamb utilizing phenyl diazonium salts for the 
arylation of tryptophan.94 Despite the development of the arylation of tryptophan 
residues, there are however, no examples of the olefination of tryptophan containing 
peptides in the literature.  
 
1.3.3 Generating conformational constraints in peptides by C-H functionalization 
Small peptides with conformational flexibility are easily synthesised by current 
methodologies, however, chemists are looking to produce peptides with unique 
conformations.96 Therapeutics often suffer from a lack of potency when the molecule 
can adopt multiple conformations. Linear peptide therapeutics tend to adopt many more 
conformations than a standard small drug molecule, and therefore often suffer from a 
lack of potency. Reducing the flexibility of a peptide therapeutic could lead to an 
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increase in the potency of the peptide, making constrained peptides a more desirable 
drug candidate than their linear precursors .97,98  
One way of generating new constrained peptides is through the cross linking of amino 
acid side chains.99,100 Many of the reported peptide C-H functionalization methodologies 
have been developed to cross link amino acid side chains together, Scheme 27.87,100,101 
 
Scheme 27: Peptide cross linking between amino acids side chains through a) 8-AQ directing group, 88 b) 
pyridine directing group, 76 c) using the native peptide backbone. 87 
 
García et al. reported the stapling of a pre-functionalized phenylalanine/tyrosine side 
chains with tryptophan residues.99 The initial peptide was synthesised using SPPS with 
the installation of the iodo-aromatic amino acid during the synthesis. The C-H arylation 
reaction between the aromatic residues is performed whilst the peptide remains on the 
resin. Microwave irradiation results in the formation of a new C-C bond between the 
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phenylalanine and tyrosine side chains and tryptophan residue, changing the 
conformation of the molecule by changing the linear structure to a stapled cyclic peptide, 
Scheme 28.   
 
Scheme 28: Peptide stapling between 3-iodo-phenylalanine and 3-iodo-tyrosine residues and 
tryptophan residues.99 
 
C-H functionalization is a useful tool for the cross linking of amino acid residues and 
could provide chemists with more tools to generate new conformations for existing 
peptides. There are, however, no examples of stapling between two residues without a 
pre-functionalized amino acid. It is essential that a method for the stapling of natural 
amino acids be investigated to make peptide stapling available to natural peptides such 
as those found in the body, to reduce the cost of synthesis by avoiding the need for pre-
functionalized amino acids and reduce the number of steps. 
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1.4 Aims 
1.4.1 Project aims overview 
As described in Section 1.2.3, the transition metal catalysed, C-H functionalization of 
peptides is an attractive approach to the generation of modified peptides. C-H 
functionalization allows for the direct modification of natural amino acids, without the 
need for potentially expensive pre-functionalized materials. The primary aims of this 
project was to develop methods for the C-H functionalization of phenylalanine residues 
in peptides. The methods for phenylalanine modification were then applied to other 
aromatic amino acids, to investigate site selectivity. The methods explored will be useful 
in expanding the number of modifications available to peptide chemists. 
 
1.4.2 C-H functionalization of phenylalanine containing peptides 
To date, there are very few reported examples of phenylalanine modifications in the 
literature.27,80,102 There is a need for chemists to develop and apply methodologies for 
the modification of phenylalanine to increase the number of synthetic methods available 
for peptide scientists. The initial reaction conditions were taken from the reported 
olefination of various aryl amines as potential tetrahydroquinoline precursors. In the 
study, Yu et al. screened a variety of substrates including protected phenylalanine, 
tyrosine and tryptophan residues, Scheme 29.79 
 
Scheme 29: Olefination of phenylalanine and tyrosine by C-H functionalization.79  
 
The methodology reported by Yu et al., is an example of an oxidative Heck (Fujiwara-
Moritani) reaction and an early example of phenylalanine modification by C-H 
functionalization.103 The first body of work will look at developing a method for the direct 
C-H functionalization of phenylalanine in peptides using conditions developed by Yu for 
the olefination of amino aryl species79 as a starting point, Scheme 30. 
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Scheme 30: Proposed C-H olefination of phenylalanine containing peptides. 
 
1.4.3 C-H functionalization of tryptophan containing peptides 
Tryptophan residues are less prevalent than phenylalanine residues in natural peptides 
yet the modification of tryptophan by C-H functionalization has attracted significant study 
by the community.66,68,94,104–106 The olefination of tryptophan residues in peptides has yet 
to be reported, whereas arylation reactions have been extensively studied. As shown in 
Scheme 31, Yu et al., successfully olefinated tryptophan by C-H functionalization using 
the same reaction conditions for the olefination of phenylalanine.79   
 
Scheme 31: C-H olefination of tryptophan by Yu et al.79 
 
The aim of this investigation is to develop a method for the C-H olefination of tryptophan 
residues in peptides using the C-H olefination study established for the modification of 
phenylalanine containing peptides and apply the methodology to tryptophan containing 
peptides. Scheme 32 depicts the proposed starting point for the olefination of 
tryptophan containing peptides. 
 
Scheme 32: Proposed C-H olefination of tryptophan containing peptides. 
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1.4.4 C-H functionalization of peptides containing multiple aromatic amino acids 
The methods developed for the modification of aromatic amino acids are important tools 
that open up more strategies for peptide modification. The model peptides in which the 
C-H olefination methodologies are investigated are however, limited in scope as many 
natural peptides contain multiple aromatic residues.107 The final investigations will focus 
on applying the methodology used for the C-H olefination of phenylalanine and 
tryptophan containing peptides to peptides with more than one aromatic amino acid, 
Scheme 33. The aim is to explore the selectivity of the C-H functionalization reactions 
on complex peptide containing more than one aromatic amino acid.  
 
Scheme 33: C-H functionalization of peptides bearing multiple aromatic residues. 
 
1.4.5 Project aims summary  
The aims of the project are summarised as:  
• To develop and optimise a method for the C-H functionalization of phenylalanine 
residues within peptides. 
• To expand upon the methodology developed for the functionailzation of 
phenylalanine containing peptides by applying the conditions to tryptophan 
containing peptides. 
• To investigate the selectivity of C-H functionalization to peptides containing 
multiple aromatic amino acids. 
The methods developed and documented will provide peptide chemists with more 
synthetic methods for the direct functionalization of aromatic residues in peptides and 
therefore maximise the options available for peptide modification.  
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 Results and discussion 
2.1 C-H functionalization of phenylalanine containing peptides 
As described in Section 1.4, the aim of this investigation was to develop a method for 
the C-H functionailzation of phenylalanine containing peptides. The olefination 
methodology developed by Yu et al., for the modification of the amino acid 
phenylalanine,79 was applied to phenylalanine residues in peptides. The following 
section describes the investigations performed on the C-H olefination of phenylalanine 
containing peptides. 
 
2.1.1 Olefination of model peptide Ac-Gly-Phe-OMe 
Investigating the C-H olefination of phenylalanine residues required the synthesis of a 
model dipeptide. Dipeptide 1a (Ac-Gly-Phe-OMe) was chosen as a suitable model 
substrate for study. Glycine was selected as the neighbouring amino acid as the 
incorporation of glycine unit increases the flexibility of the peptide and will not interfere 
with the reaction. Scheme 34 depicts the synthesis of the dipeptide Ac-Gly-Phe-OMe 
(1a). The reaction of N-acetyl glycine and L-phenylalanine methyl ester hydrochloride in 
the presence of a coupling reagent (HBTU) and base (DIPEA), gave peptide 1a in a 
78% yield.  
 
Scheme 34: Synthesis of Ac-Gly-Phe-OMe (1a). 
 
Initial studies involved the reaction of dipeptide 1a with styrene, in the presence of 
Pd(OAc)2 and AgOAc, Scheme 35. The reaction was performed at 130 °C for 48 hours. 
The crude material was then purified by flash column chromatography to afford the di-
olefinated peptide 2a as a yellow solid (35% yield). Peptide 1a was also recovered along 
with mono-olefinated peptide 2a’. Both the dipeptide and the mono olefinated peptide 
co-eluted during the purification and were not isolated.  
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Scheme 35: Palladium catalysed C-H olefination of model dipeptide (1a). 
 
The 1H NMR spectrum of peptide 1a contained a 2H doublet at 7.08 ppm from the ortho 
protons on the phenyl ring. In the 1H NMR spectrum for 2a, the ortho protons are not 
present, indicating substitution at the ortho site on the phenylalanine ring.  
The 1H NMR spectrum of 2a contained a pair of 2H doublets at 7.01 and 7.47 ppm, with 
a coupling constant of 16.0 Hz, that is consistent with the presence of a trans alkene 
which is consistent with a Heck reaction.   
 
2.1.2 Optimisation 
Following the discovery that model dipeptide 1a could be modified to afford peptide 2a 
by C-H functionalization, optimisation of the reaction was carried out, Table 2. 
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Table 2: Optimisation of the C-H functionalization of peptide 1a.  
 
Entry Oxidant 
Equiv. 
oxidant 
Solvent 
Equiv. 
styrene 
Temp 
/ °C 
Time 
/ h 
Yield 
/ % 
1 AgOAc 2.5 DCE/DMFa 4.0 130 48 35 
2 AgOAc 2.5 DCE/DMFa 1.0 130 48 19 
3 AgOAc 2.5 DCE/DMFa 2.0 130 48 31 
4 AgOAc 2.5 DCE/DMFa 10.0 130 48 39 
5 AgOAc 2.5 DCE/DMFa 4.0 100 48 20 
6 AgOAc 2.5 DCE/DMFa 4.0 80 48 8 
7 AgOAc 2.5 DCE/DMFa 4.0 25 48 Trace 
8 AgOAc 2.5 DCE/DMFa 4.0 130 96 38 
9 AgOAc 2.5 DCE/DMFa 4.0 80 96 12 
10 AgOAc 2.5 DCE/DMFa 4.0 130 24 8 
11 AgOAc 2.5 Toluene 4.0 130 48 26 
12 AgOAc 2.5 DMF 4.0 130 48 26 
13 AgOAc 2.5 MeCN 4.0 130 48 23 
14 AgOAc 2.5 HFIP 4.0 130 48 Trace 
15 AgOAc 2.5 t-amyl-OH 4.0 130 48 67 
16 AgOAc 2.5 t-amyl-OH/DMFb 4.0 130 48 48 
17 Cu(OAc)2 2.5 t-amyl-OH 4.0 130 48 34 
18 AgCO3 2.5 t-amyl-OH 4.0 130 48 11 
19 Ag(OPiv)2 2.5 t-amyl-OH 4.0 130 48 16 
20 Benzoquinonec 2.5 t-amyl-OH 4.0 130 48 24 
21 AgOAc 5.0 t-amyl-OH 4.0 130 24 83 
22 AgOAc 5.0 t-amyl-OH 4.0 130 12 81d 
23 AgOAc 5.0 t-amyl-OH 4.0 130 6 70 
24 AgOAc 5.0 t-amyl-OH 4.0 100 12 76 
25 AgOAc 5.0 t-amyl-OH 4.0 80 12 68 
a DCE/DMF = 20:1;  
b t-amyl-OH/DMF = 20:1;  
c 5 eq. of NaOAc were also included in the reaction mixture;  
d The mono-olefinated peptide 2aʹ was also isolated in 8% yield. 
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The olefination of peptide 1a (0.359 mmol) was carried out in a sealed vessel in the 
appropriate solvent (0.12 M). After the allotted time, the reaction mixture was filtered, 
and purified by flash column chromatography, eluting with EtOAc. The yields quoted in 
Table 2 are isolated yields after purification. Firstly, the equivalents of styrene were 
investigated. Using 1.0 equivalent gave modified peptide 2a in a 19% yield, whereas 2.0 
equivalents gave the peptide in a 31% yield. Employing 10.0 equivalents of styrene 
produced little change in the yield of 2a (39%, entry 4). Lowering the reaction 
temperature from 130 °C to 100 °C and 80 °C gave the diolefinated peptide 2a in yields 
of 20% and 8% (entry 5 and 6). When the reaction was performed at 25 °C, the 
olefinated peptide was observed by 1H NMR spectroscopy, however, isolated as a trace 
amount. Increasing the reaction duration from 48 h to 96 h had very little effect on the 
isolated yield of 2a (38% yield, entry 8). Likewise running the reaction at 80 °C for 96 h 
afforded 2a in a 12% yield. Changing the solvent however, gave a larger variety of 
yields. Running the reaction in toluene, DMF or MeCN gave 2a in lower yields than 
using a mixture of DCE/DMF (26%, 26% and 23%, entries 11, 12 and 13). 
Hexafluoroisoproanol (HFIP) is commonly used in peptide chemistry and more recently 
as a solvent in C-H functionalization.108 When using HFIP, the reaction did not proceed 
(entry 14). The use of another commonly used reaction solvent for C-H functionalization 
(t-amyl-OH) was studied and found to give 2a, in a 67% yield (entry 15), much higher 
than the previous reactions conditions investigated. Using a combination of t-amyl-OH 
and DMF as the solvent gave a reduced yield from 67% to 48% (entry 16). Changing 
the oxidant proved to be detrimental to the reaction, with isolated yields of 34%, 11% 
and 16% when Cu(OAc)2, AgCO3 and Ag(OPiv)2 were used (entries 17, 18 and 19 
respectively). Employing a combination of benzoquinone and NaOAc gave 2a in a 24% 
yield. It was discovered that increasing the equivalents of AgOAc from 2.5 to 5.0, gave 
modified peptide 2a in a remarkably high yield (83%) in just 12 hours (entry 22). The 
mono-olefinated peptide 2a’ was also recovered in an 8% yield as the minor product of 
the reaction. Running the reaction at lower temperatures with 5.0 equivalents of AgOAc 
also gave satisfactory yields of 2a (76% and 68% at 100 °C and 80 °C, entries 24 and 
25 respectively).  
 
2.1.3 Scope of the alkene 
With an optimised method, the next stage of the investigation involved screening a 
variety of olefins against peptide 1a, Scheme 36. The reaction was found to 
accommodate a range of substituted styrenes. Olefins containing electron donating 
groups (CH3, OMe) (3a, 3b), were well tolerated (77% and 50%). Likewise, alkenes 
bearing electron withdrawing groups (F3C-, N2O- and NC-), gave the corresponding 
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olefinated peptide (3c-3e) in excellent yields (73%, 60% and 76%). The incorporation of 
styrenes with extended conjugation (phenyl- and naphthyl-) (3f, 3g) were also tolerated 
(33% and 38% yields). The incorporation of further conjugation to the phenylalanine 
residue could be used as an introduction of new fluorophores in a single step.9 The 
olefination of model peptide 1a with a variety of halogen containing styrenes (F-, Cl-, 
and Br-), were successful, affording the corresponding modified peptide in good yields 
(69%, 61% and 49%) (3h-3j). 
 
Scheme 36: Investigating the scope of the olefin with peptide 1a. 
 
The incorporation of the bromo-substituted styrene moiety 3j into a peptide sequence 
could lead to a variety of different post-synthetic transformations. A second 
transformation after the C-H olefination could be used together with a C-C cross 
coupling reaction to increasingly complex functionalized peptides. The potential for 
further functionalization after C-H olefination of the phenylalanine residues, makes the 
palladium catalysed olefination reaction a highly desirable method to produce 
functionalised peptides. 
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2.1.4 Investigating N-Protecting groups 
Model dipeptide 1a contains an acetyl protecting group at the N-terminus. However, in 
SPPS acetyl protected amino acids are discouraged, as the acetyl N-protecting group 
cannot be easily removed without destroying the peptide in the process.109 The most 
common nitrogen protecting group used in SPPS is the Fmoc protecting group, followed 
closely by Boc and Cbz groups. Phthaloyl protected amino acids are an alternative to 
traditional amine protecting groups (Fmoc, Boc, Cbz), that differ in functionality as the 
nitrogen lone pair is part of the π-system, reducing the basicity of the lone pair 
dramatically compared to Fmoc.110 Investigations then focused on the modification of 
phenylalanine residues on peptides bearing different N-protecting groups. 
The phthaloyl protected amino acid 4 was prepared by refluxing glycine with phthalic 
anhydride and NEt3 under Dean-Stark conditions. The N-protected amino acid was then 
precipitated with concentrated HCl to give a 4 as a white solid. N-protected amino acid 
4, was then coupled using HBTU and DIPEA, with L-phenylalanine methyl ester to give 
dipeptide 5, Scheme 37.    
 
Scheme 37: [a] Preparation of Phth-Gly-OH (4) and [b] peptide coupling to give 5. 
 
A series of dipeptides bearing different amine protecting groups were prepared and 
subjected to the optimised olefination reaction conditions, Scheme 38. The C-H 
olefination reaction proceeded well in the presence of a variety of peptides bearing 
different N-protecting groups, affording the modification of peptides with Fmoc 8a, Boc 
8b and Cbz 8c N-protecting groups (yields of 52%, 71% and 70% respectively). When 
the phthaloyl protected peptide 5 was subjected to the olefination conditions, the 
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reaction did not proceed and the unmodified peptide 5 was recovered exclusively. A 
theory as to why peptide 5 was not modified in the olefination reaction is proposed in 
Section 2.2.7. 
 
Scheme 38: Scope of the N-protecting group. 
 
2.1.5 Amino acid sequence 
The choice of the neighbouring amino acid in the model dipeptide 1a and the peptides 
studied in Section 2.1.4, was limited to glycine. With a view to investigate the olefination 
of phenylalanine residues on long chain peptides containing multiple neighbouring 
amino acids, a series of dipeptides were synthesised with phenylalanine residues at the 
C-terminus. The neighbouring N-terminal amino acid was changed each time. The 
olefination reaction of dipeptides 9a-f were then performed, and the results shown in 
Scheme 39. 
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Scheme 39: Olefination of phenylalanine containing peptide 9a-f. 
 
Dipeptides with neighbouring alkyl amino acid side chains (2a, 10a-d) were modified in 
good yields (60-76% yield). The olefination of Ac-Pro-Phe-OMe (9e) gave modified 
peptide 10e in a lower yield than the other examples displayed in Scheme 39 (24%). A 
reason for the observed reduction in the isolated yield of 10e is discussed in Section 
2.2.5. 
The reaction of the diphenylalanine containing peptide Ac-Phe-Phe-OMe (10f) with 
styrene was of interest to see whether both phenylalanine residues could be modified by 
the olefination reaction. After purification by flash column chromatography, modified 
peptide 10f was obtained, in which only the C-terminal phenylalanine had been 
functionalized. There was no evidence of the modification of the N-terminal 
phenylalanine residue. In the previous investigations up to this point, the phenylalanine 
residue was located at the C-terminus, and the olefination reaction gave the 
corresponding modified peptide. The modification of peptide 9f displays the first 
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example of site selectivity of the olefination reaction. The olefination of N-terminal 
residues was investigated further, and the results documented in Section 2.1.6. 
Following the modification of dipeptides bearing simple aliphatic neighbouring amino 
acids (Scheme 40), the subsequent reactions focused on the olefination of 
phenylalanine residues in the presence of amino acids containing heteroatoms, Scheme 
39.  
 
Scheme 40: Olefination of heteroatom containing dipeptides 9g-k. 
 
The incorporation of the aromatic side chains of tryptophan (9j) and tyrosine (9k), 
afforded the peptide starting material only. Similarly, the olefination of phenylalanine 
residues in the presence of threonine and cysteine residues (9h and 9i), were 
unsuccessful: yielding only the unmodified peptide. In SPPS, amino acids that contain 
highly reactive side chains are protected prior to peptide coupling.111 The thioether 
containing amino acid methionine is an example of a pseudo protected cysteine residue: 
albeit methionine side chain is one carbon longer in length. Peptide 9k, was compatible 
with the reaction conditions, and gave the corresponding olefinated peptide in a good 
yield (10k, 60%). A potential strategy to olefinate phenylalanine residues within peptides 
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in the presence of amino acid side chains that contain heteroatoms, might be to protect 
the side chains prior to C-H functionalization.  
 
2.1.6 Olefination of phenylalanine at the N-terminus 
In Scheme 39, only the C-terminal phenylalanine residue of dipeptide Ac-Phe-Phe-OMe 
(9f) had been modified by the olefination reaction. The N-terminal phenylalanine was 
unaffected. The C-H olefination reaction appeared to select the C-terminal residue only. 
To investigate the olefination of N-terminal phenylalanine residues, the dipeptide Ac-
Phe-Gly-OMe (11) was synthesised by first removing the hydrochloride salt from the 
amino ester. Treating glycine methyl ester hydrochloride with K2CO3 and extracting the 
free amine into an organic solvent proved unsuccessful. Instead, dissolving the C-
protected amino acid in water and adding a basic ionic exchange resin (Amberlyst A21) 
gave the free amine. The resulting residue was slurried in DCM along with HBTU and 
DIPEA to give 11 in a satisfactory yield (28%), Scheme 41. 
 
Scheme 41: Synthesis of Ac-Phe-Gly-OMe (11). 
 
Diolefinated peptide 11a was not observed from the reaction of 11 in Scheme 42. The 
unsuccessful olefination of peptide 11 posed the question: does the position of the 
phenylalanine residue within a peptide sequence influence the outcome of the reaction? 
The unsuccessful olefination of N-terminal phenylalanine residues is discussed in 
Section 2.2.3. 
 
Scheme 42: Attempted olefination of Ac-Phe-Gly-OMe (11). 
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2.1.7 Olefination of tri-, and tetrapeptides  
Investigations thus far had focussed on the olefination of phenylalanine containing 
dipeptides. In Section 2.1.6, the position of the phenylalanine residue within the peptide 
sequence dictated the success of the olefination reaction. This may suggest that the 
reaction is site selective as modification was not observed in peptide 11, when 
phenylalanine was located at the N-terminus. The position of phenylalanine residues in 
dipeptides are limited to either N-, or C-termini. In larger peptides however, 
phenylalanine residues can lie at the middle of the sequence and not necessarily limited 
to the termini. To evaluate the viability of the olefination reaction to phenylalanine 
residues on larger peptide chains, a series of tri-, and tetrapeptides were synthesised 
from the corresponding dipeptide.  
The C-terminus of the appropriate dipeptide or tripeptide was first deprotected by 
treating the methyl ester with a base to give the free carboxylic acid. The peptide acid 
was then coupled with a C-protected amino acid with HBTU to give the appropriate 
peptide, Scheme 43. The phenylalanine residues in peptides 13a-c, 14a-d were located 
at either the N-terminus, the C terminus or in the middle of the peptide sequence.  
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Scheme 43: Preparation of tripeptides 13a-c, and tetrapeptides 14a-d. 
 
Tripeptides 13a-c were characterised by 1H and 13C NMR spectroscopy. Analysis of 
tetrapeptides 14a-d by 1H NMR spectroscopy proved challenging at first as the 1H NMR 
spectra is not very well defined, with areas of indistinguishable multiplets. The messy 1H 
NMR spectra may be due to the longer chain length of tetrapeptides. Peptides 14a-d 
can adopt more confirmations in solution compared to tripeptides 13a-c.  
Peptides 14a-d were dissolved in many different NMR solvents. Polar NMR solvents 
(Acetonitrile-d3 and DMSO-d6) had little effect on the resolution, while NMR solvents that 
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promote hydrogen bonding in solution (Methanol-d4 and Acetone-d6) did not improve the 
1H NMR spectra either. Mass spectrometry was used to aid in the characterisation. 
HRMS data was used to identify the exact mass of each peptide. From the 
fragmentation pattern in the mass spectrum of peptides 14a-d, there was no evidence of 
any unreacted starting material in the sample. Confident that the samples were suitably 
pure, the modification of peptides in Scheme 43 was then studied, Scheme 44. 
 
Scheme 44: Olefination of peptides (13a-c, 14a-d). 
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The C-H olefination methodology worked well on phenylalanine residues at the C-
terminus, and in the middle of tripeptides, giving the modified peptides 15a and 15b in 
good yields (59% and 63%), Scheme 44. As was the case with the modification of Ac-
Phe-Gly-OMe (11) in Scheme 42, tripeptide 13c was not modified by the reaction 
conditions. Tetrapeptides 14a-c were found to tolerate the C-H olefination, giving 
modified peptides 16a-c in moderate yields (30%, 43% and 40%). Unsurprisingly, when 
the phenylalanine residue was located at the N-terminus (peptides 13c and 14d), there 
was no reaction. Analysis of the olefinated tetrapeptides 16a-c in Scheme 44, proved 
challenging compared to the analysis of modified tripeptides 15a and 15b. The trans-
alkenes were easily identified in the 1H NMR spectra, however, the signals correlating to 
the aromatic system and the peptide backbone were not as easily identifiable. 
Compared to tripeptides, tetrapeptides can adopt more conformations in solution, which 
could account for the difficulties in interpreting the NMR spectra. HRMS spectra of 
modified peptides 16a-c confirmed the diolefinated product had been formed. The 
olefination of larger peptides demonstrates the olefination method is robust and has the 
potential for the modification of phenylalanine residues in much larger peptide systems. 
 
2.2 Investigating the reaction mechanism 
C-H functionalization of phenylalanine has been shown in Section 2.1 on peptides with 
phenylalanine at the C-terminus or in the middle of a peptide. In Section 2.1.5, peptide 
9h contained two phenylalanine residues that could be modified. Olefination of the C-
terminal phenylalanine residue proceeded well, whilst leaving the N-terminal residue 
unmodified. This led to the question; why are N-terminal residues unaffected by the 
reaction? Investigations looked at the C-H activation of the peptide, and how C-H 
activation was achieved. 
 
2.2.1 C-H activation of C-terminal phenylalanine residues 
Investigations started by examining the coordination of palladium to the model peptide 
1a. Coordination of a metal catalyst to a substrate for C-H activation is usually achieved 
via directing groups. In Section 1.2.2 directing groups have been shown to be crucial for 
most examples of C-H activation. Directing groups allow the selective activation of 
specific C-H bonds.54,57,112–114 Both mono- and bidentate directing groups allow the 
coordination of the metal catalyst to the C-H bond, however, bidentate systems can 
provide a lower energy pathway for C-H activation over monodentate directing 
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groups.115 Coordination of a metal to a bidentate directing group forms a 
thermodynamically stable metalacyclic intermediate, Figure 8.116 
 
Figure 8: Examples of palladation via [a] monodentate and [b] bidentate directing groups. 
 
Usually, directing groups must be installed onto a molecule before C-H activation. 
However, in all the peptides studies in Section 2.1, a directing group was not 
specifically installed. Instead the reaction uses the native amide backbone to coordinate 
to a metal for C-H activation. As documented in Section 1.2.2, amides can be used as 
directing groups for C-H activation. Dipeptide 1a contains two secondary amides, that 
make up the peptide backbone. The mechanism of C-H activation occurs first through 
bidentate coordination to the amide nitrogen atoms, before C-H activation by an AMLA / 
CMD type mechanism, Scheme 45. 
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Scheme 45: Proposed bidentate coordination of peptide 1a with Pd(OAc)2. 
 
Coordination of palladium to the peptide backbone forms the stable five-, six-membered 
palladacycle. This bicyclic ring system is key, as it stabilises the energy of the metalated 
complex. PdII must adopt square planar geometry for C-H functionalization. Peptide 1a 
must be able to adopt the required conformation, so that the amide nitrogen atoms can 
sit in a square planar conformation. The proximal and distal coordinating atoms must be 
able to adopt this conformation for C-H activation to occur.    
The C-H activation of larger peptides must go through the same reaction pathway as 
peptide 1a. Tripeptides 13a and 13b contain three amide residues for coordination and 
tetrapeptides 14a-c contain four potential coordination sites. Despite these multiple 
coordination sites, phenylalanine residues in larger peptides are modified by the 
reaction, Scheme 44. Coordination through the amide residues in peptides acts as a 
discrete directing group that does not need to be removed after C-H functionalization. 
This makes peptide modification by C-H functionalization through the backbone an 
extremely attractive process.   
 
2.2.2 Palladation of Ac-Gly-Phe-OMe (1a) 
In literature there have been a handful of examples of the palladation of 
phenylalanine117,118 and phenylglycine.119–121 However, the palladation of a 
phenylalanine containing dipeptides has not been reported. It was envisioned that by 
treating peptide 1a with stoichiometric Pd(OAc)2, the palladated peptide could be 
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synthesised. The palladated peptide could confirm the proposed bidentate coordination 
through amide residues in Scheme 45. 
The palladation of phenylalanine was reported Bautista et al.117 In the study, the 
palladated amino acid was isolated with a bridged chloride ligand. Bautista 
demonstrated that the mono-nuclear complex could be isolated by first treated with NaBr 
and then DMAP. The metallacycle contains a six-membered ring with coordination 
through the free amine group. This is consistent with the proposed coordination of 
palladium in Scheme 45. 
 
Scheme 46: Ortho palladation of phenylalanine by Bautista et a.117 
 
Using the reaction in Scheme 46 as inspiration, work commenced on synthesising a 
palladated peptide. Peptide 1a with treated with stoichiometric Pd(OAc)2 and heated to 
50 ˚C for 48 h in a variety of solvents, Scheme 47. As with Bautista’s example, 
decomposition of PdII to Pd0 was witnessed by the appearance of a black solid in the 
reaction. The solid was filtered before the addition the addition of pyridine. The solution 
was again heated to 50 ˚C for a further 48 hours. Analysis of the final mixture by 1H 
NMR spectroscopy showed peptide 1a only. There was no evidence of the palladated 
peptide. The crude mixture was also analysed by mass spectrometry, which displayed 
peptide 1a, pyridine and Pd(OAc)2. The reaction had not taken place.  
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Scheme 47: Attempted palladation of peptide 1a at 50 ˚C and ligand exchange to 1c. 
 
The reaction in Scheme 47 to give peptide 1b may not have worked due to the low 
temperature compared to the olefination reaction. Instead the reaction of 1a with 
Pd(OAc)2 was operated at 130 ˚C for 6 days, Scheme 48. The crude mixture was left to 
evaporate slowly in DCM, to afford a crystalline solid. Analysis by x-ray crystallography 
showed the solid to be peptide 1a. There was no evidence of the palladate compound 
by 1H NMR spectroscopy or x-ray crystallography.  
 
Scheme 48: Attempted palladation of peptide 1a at 130 ˚C. 
 
All these endeavours were unsuccessful. This is not to say that the reaction does not 
proceed via the proposed pathway, it may mean that the intermediate may not be 
isolatable or stable at room temperature.  
 
2.2.3 C-H activation of N-terminal phenylalanine residues 
In the previous section, C-H olefination of phenylalanine is achieved by bidentate 
coordination of the catalyst to the amide backbone. In Section 2.1.6 however, the N-
terminal phenylalanine residue was unaffected by the reaction. This is even the case in 
peptide bearing multiple coordination site, such as tripeptide 13c and tetrapeptide 14d. 
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Bidentate coordination of peptide 11 does not lead to the formation of a palladacycle 
that’s is capable of C-H activation, Figure 9. 
 
Figure 9: Bidentate coordination of peptide 11 to Pd(OAc)2. 
 
Monodentate coordination in peptides bearing N-terminal phenylalanine residues is still 
possible, Figure 10. The monodentate complex is not as stable as the chelated complex 
in Figure 9. Despite monodentate complexation affording the correct square planar 
geometry for PdII C-H activation, the reaction does not proceed.  
 
Figure 10: Monodentate of Pd(OAc)2 to peptide 11. 
 
The proposed C-H activation of 11 through monodentate or bidentate coordination does 
not afford the olefinated peptide. This is consistent with the reaction of other N-terminal 
phenylalanine residues. In Section 2.1.5, only the C-terminal phenylalanine residue was 
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modified in peptide 9h (Ac-Phe-Phe-OMe). The N-terminal residue was unaffected. This 
was also the case with tripeptide 13c and tetrapeptide 14d, Scheme 44. 
 
2.2.4 Olefination of phenylglycine residues 
Phenylglycine is an unnatural amino acid, but a common feature in some peptide-based 
therapeutics such as virginiamycin S and streptogramin B.122,123 The modification of 
phenylglycine by C-H functionalization has been investigated by Yu et al.124  
 
Scheme 49: Olefination of Phenylglycine by Yu et al. 
 
The C-H olefination reaction developed in this study was the applied to the 
phenylglycine containing peptide 17, to see if the methodology could be extended to 
unnatural aromatic residues. There was no evidence of the modified peptide 17a when 
the reaction was performed using the optimised conditions for the modification of 
phenylalanine residues within peptides. Scheme 50. 
 
Scheme 50: Attempted olefination of Ac-Gly-Phg-OMe (17). 
 
The absence of the modified peptide in Scheme 50 was surprising. We had already 
seen that the C-terminal phenylalanine residues are modified in the olefination reaction. 
In Scheme 50 the phenylglycine residue is also located at the C-terminus and under the 
devised conditions, should be modified by the C-H olefination reaction. Coordination of 
the metal catalyst to the peptide backbone by the bidentate directing group is still 
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available. The five-, five-ring system is most likely higher in energy than the one formed 
by peptide 1a in Scheme 45, and is not formed in the reaction.  
 
Scheme 51: Proposed bidentate coordination of Pd(OAc)2 peptide 17. 
 
2.2.5 Olefination of Ac-Pro-Phe-OMe (9e) 
Coordination through the amide residues can be strengthened by deprotonation of the 
amide nitrogen, creating a more stable metallacycle. But what happens if one of these 
amide protons is not present: Does the olefination reaction still take place? The amide 
proton from the peptide backbone can be removed by installation of an imide. In 
Section 2.1.5, the proline containing peptide 9e was modified by the reaction conditions 
to afford the modified peptide in a low yield (24%). Despite the lower yield than modified 
peptide 1a (81%), the reaction still proceeds. Proline is the only natural amino acid that 
creates an imide in a peptide sequence. The inclusion of proline causes conformational 
change to the peptide, creating beta turns in large peptide chains. Peptide 9e contains 
an imide at the N-terminus and still afforded the modified peptide 10e. The side chain of 
proline residues contains a 5-membered aliphatic ring, Scheme 52. When the palladium 
catalyst chelates to the nitrogen amides in peptide 9e, the proline side chain produces a 
greater strain on the ring system. However, the peptide can still adopt the required 
conformation for C-H activation as modified peptide 10e was recovered. The strained 
ring system is less stable than other bidentate system in Scheme 45.This could account 
for the reduction in yield of the modified peptide. None the less, the reaction works with 
a neighbouring proline residue, and can accommodate an imide at the distal nitrogen.  
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Scheme 52: Proposed coordination and C-H activation of peptide 9e with Pd(OAc)2. 
 
2.2.6 Olefination of N-alkylated Phenylalanine residues 
The imide residue was then moved to the proximal amide. Peptide 19 was first prepared 
by the N-methylation of phenylalanine. The N-alkylated amino acid 18 was prepared by 
treating phenylalanine methyl ester hydrochloride with LiOH.H2O in dry DMF, before the 
addition of iodomethane. After stirring at room temperature for 16 hours, the suspension 
was filtered and worked up with aqueous washings. Purification by flash column 
chromatography afforded the mono-alkylated amino acid 18 in a 64% yield, with the di-
alkylated phenylalanine in 22%, Scheme 53. 
 
Scheme 53: Alkylation of phenylalanine methyl ester hydrochloride to give amino acid 18. 
 
The N-methylated amino acid 18 was then coupled with N-acetyl glycine under the 
conditions in Scheme 54, to give peptide 19 in a good yield (56%).  
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Scheme 54: Synthesis of peptide 19. 
 
The N-methylated peptide 19 was then subjected to the olefination reaction. There was 
no evidence of modified peptide 19a from the reaction. The installation of an imide 
proximal to the phenylalanine residue does not allow C-H activation. The methyl group 
may not allow the peptide to coordinate to palladium, despite increasing the 
nucleophilicity of the proximal amide. Peptide 19 may not be able to adopt the square 
planar geometry that is required for C-H activation. Presumably, monodentate 
coordination is formed by N-terminal nitrogen only. 
 
Scheme 55: Attempted olefination of peptide 18. 
 
Peptides bearing multiple phenylalanine residues can be selectively modified by 
installing N-alkyl phenylalanine residues at sites where modification of the aromatic side 
chain is not desired. The draw back to this process is that the N-alky phenylalanine 
amino acid must be installed during peptide synthesis and cannot be added post-
synthetically.   
 
2.2.7 Olefination of Phth-Gly-Phe-OMe (5) 
In Section 2.1.4, the incorporation of the phthaloyl protect amino acid at the C-terminus 
stopped functionalization of the neighbouring phenylalanine residue. Peptide 5 contains 
an imide at the N-terminus. The nitrogen lone pair in the phthaloyl amide is less 
nucleophilic than the distal amide of peptide 9e. The phthaloyl nitrogen lone pair lies in 
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conjugation with two carbonyls, making it a poor Lewis base. The bidentate complex is 
not formed in peptide 5, due to the poor Lewis basicity of the phthaloyl amide. The C-H 
activation pathway by monodentate coordination is too high in energy (see Section 
2.2.3). Thus, the olefination reaction does not work with neighbouring phthaloyl 
protected amino acids.  
 
Scheme 56: Proposed coordination of Pd(OAc)2 to peptide 7. 
 
2.2.8 Oxidative Heck reaction  
The direct olefination of peptide 1a (Scheme 35), is an example of an oxidative-Heck 
reaction (also known as a Fujiwara-Moritana reaction), which unlike classic Heck 
reactions, does not require an organo-halide to facilitate metal-carbon bond formation.125 
An oxidative-Heck reaction produces a characteristic trans alkene. After the alkene 
insertion to palladium, the C-C bond rotates to the lowest energy confirmation to reduce 
the tortional strain on the molecule, creating the trans geometry. β-H elimination the 
proceeds to afford the trans alkene and the corresponding metal hydride complex, 
Figure 11.  
 
Figure 11: β-H elimination to form a trans alkene. 
 
The proposed catalytic cycle for the olefination of peptide 1a is shown in Figure 12. In a 
traditional Heck reaction, the metal carbon bond is formed by the loss of a halogen on 
the phenyl ring. Instead the metal coordinates to the peptide via the bidentate amide 
directing group.  The ortho phenylalanine protons are then removed via the AMLA 6 / 
CMD mechanism. The acetate ligand aids in deprotonation, creating a new metal-
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carbon bond. The reaction then proceeds with the insertion of the olefin to the metal by 
carbopalladation. A new C-C bond is then formed from the alkene to the phenyl ring. 
The complex, however, is still bound to the metal catalyst and dissociates by β-H 
elimination, producing a trans alkene and at first, the mono-olefinated peptide. The 
catalyst is regenerated by the oxidation of Pd0 to PdII using AgOAc. The catalytic cycle is 
then repeated using the mono-olefinated peptide 2a’ to give di-olefinated peptide 2a. 
 
 
Figure 12: Proposed catalytic cycle for the olefination of peptide 1a. 
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2.3 C-H olefination of tryptophan containing peptides 
In Section 2.1, methods were devised for the direct C-H functionalization of 
phenylalanine residues in peptides. However, phenylalanine represents one of four 
naturally occurring aromatic amino acids; the others being histidine, tyrosine and 
tryptophan. To extend the methodology developed in Section 2.1, the olefination of 
other aromatic residues must be explored. The work described in this section details 
investigations into the C-H olefination of tryptophan containing peptides. 
 
2.3.1 Olefination of Ac-Gly-Trp-OMe 
Initial investigations focussed on the olefination of a model substrate: Ac-Gly-Trp-OMe 
(20). The dipeptide was synthesised by reacting N-acetyl glycine with L-tryptophan 
methyl ester, using the same methodology for the production of phenylalanine 
containing peptides, in Scheme 34. 
The olefination methodology developed for the C-H functionalization of phenylalanine 
residues was then applied to the model tryptophan containing dipeptide 20, Scheme 57. 
Under C-H olefination conditions  
 
Scheme 57: Attempted olefination of Ac-Gly-Trp-OMe (1a) 
 
Previously, the olefination of phenylalanine residues in peptides that contained 
unprotected heteroatoms proved unsuccessful, Section 2.1.5. However, the olefination 
of the thioether containing peptide Ac-Met-Phe-OMe (9k), gave the desired di-olefinated 
peptide (10k), Scheme 40. The attempted olefination of the thiol containing peptide Ac-
Thr-Phe-OMe (10j) indicates that heteroatoms on amino acid side chains require 
protection for the C-H olefination reaction.   
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2.3.2 Boc protection of the tryptophan side chain 
Protection of the nitrogen heteroatom became a priority to negate competitive binding 
between the side chain and the peptide backbone. In order to investigate the olefination 
of tryptophan residues, the indole side chain was protected with a Boc protecting group, 
Scheme 58. Boc protecting groups are a common feature in peptide chemistry as they 
are chemically robust and resistant to cleavage with base. Boc groups are a 
complimentary alternative to Fmoc protecting groups and can be easily installed from 
the corresponding anhydride. Peptide 20 was treated with Boc anhydride, in the 
presence of triethylamine to give the protected product in good yield (77%). The 
installation of Boc protecting group was confirmed by the 1H NMR spectrum of 21 in 
which the tert-butyl group appears as a 9H singlet at 1.66 ppm. 
 
Scheme 58: Installation of the Boc protecting group. 
 
Next, peptide 22 was subjected to the C-H olefination conditions as shown in Scheme 
59. The olefination of peptide 22 afforded the mono-olefinated peptide 21 without the 
Boc protecting group, in a satisfactory yield (38%). The 1H NMR spectrum of peptide 21 
displayed a pair of doublets at 6.78 ppm and another set of doublets contained within a 
multiplet at 7.27-7.34 ppm. The trans alkene was identified by a coupling constant of 
16.6 Hz for the alkene proton at 6.78 ppm.  
The other material recovered from the reaction did not contain the Boc protecting group. 
Peptide 20 accounted for the other species from the reaction. The Boc protecting group 
had been removed from both isolated products. Nevertheless, the direct olefination of 22 
gave the olefination tryptophan residue is the first time that such a transformation had 
been achieved on a tryptophan containing peptide.    
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Scheme 59: C-H Olefination of peptide 22 at 130 °C. 
 
Modified peptide 21 was recovered without the Boc protecting group. The in-situ 
cleavage of the protecting group may be a desirable feature in some synthetic reactions. 
However, the uncontrolled cleavage of the protecting group poses a problem in this 
reaction. As the reaction progresses, the concentration of the unprotected material 
increases, and the unprotected peptide will compete with the protected material in 
binding to the metal catalyst. The indole nitrogen binds more strongly than the peptide 
backbone, and poisons the metal catalyst, leading to a reduction in the yield of modified 
product. The reaction therefore can only progress to form a small amount of the 
modified material before the reaction stops and all that is produced is the unprotected 
materials 21 and 20.    
Boc protecting groups are routinely removed in the presence of acid; most commonly 
trifluoroacetic acid (TFA). In Scheme 59, acetic acid is generated as a by-product of the 
reaction and could cleave the Boc protecting group. A combination of the elevated 
temperatures and the acid produced by the reaction could contribute to the removal of 
the protecting group. 
To determine if the N-Boc protecting group was thermally stable, peptide 22 was heated 
to 130 °C in t-amyl-OH, in an NMR tube, Scheme 60. After 24 hours, analysis of the 
crude 1H NMR spectrum, showed the decomposition of peptide 22 to Ac-Gly-Trp-OMe 
(20). Running the reaction at 100 °C, afforded the protected peptide 22 only. Likewise, 
adding in Pd(OAc)2 to the reaction at 100 °C, gave peptide 22 exclusively, despite the 
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generation of acetic acid as the catalyst was heated. Operating the olefination reaction 
(Scheme 59) at lower temperatures may yield the olefinated peptide 21 with the Boc 
protecting group intact. 
 
Scheme 60: Decomposition study of peptide 22. 
 
Following the successful retention of the Boc protecting group at 100 °C (Scheme 60), 
the C-H olefination of tryptophan residues was attempted Scheme 61. Peptide 22 was 
olefinated at 100 °C to give the mono-olefinated peptide 23a in a 60% yield. Modified 
peptide 23a was recovered with the Boc protecting group, along with the protected 
starting material 22. The unprotected peptide 21 was not observed in the crude 1H NMR 
spectrum, making the conditions in Scheme 61, a suitable starting point to investigate 
the olefination reaction further.  
 
Scheme 61: Olefination of Ac-Gly-Trp(Boc)-OMe (22) at 100 °C. 
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Protection of the indole side chain appears to be crucial for the olefination of tryptophan 
residues. In Scheme 61, modified peptide 23a was recovered with the indole protecting 
group intact. If the protecting group could be easily removed, then the C-H 
functionalization can lead to the synthesis of a diverse library of modified tryptophan 
residues. The Boc protecting group was successfully removed by treating peptide 23a 
with TFA at room temperature to afford the deprotected modified peptide 21, Scheme 
62. 
 
Scheme 62: Removal of the Boc protecting group. 
 
2.3.3 Reaction optimisation  
The successful olefination of peptide 22, provided the basis for future investigations into 
reaction optimisation, Table 3. Running the reaction at 70 °C and 50 °C gave reduced 
yield (48% and 37%, entry 2 and 3), compared to 100 °C (60%, entry 1). Increasing the 
duration of the reaction (entry 5) to 96 hours at 100 °C gave very little change in the 
yield (61%). Next, a series of different solvents that are commonly used in C-H 
functionalization were screened. In the olefination of phenylalanine containing peptides 
Section 2.1.2, the initial results were obtained using a mixed solvent system of 
DCE/DMF. As with the olefination of Ac-Gly-Phe-OMe (1a) the DCE/DMF solvent 
system gave the olefin 2a in a 44% yield, much less than the t-amyl-OH solvent system 
(60%). Running the olefination reaction in toluene was found to give the highest yield of 
modified peptide 23a at 100 °C after 48 hours (85%). Reducing the reaction time form 
48 hours was shown to have a significant effect on the yield of peptide 23a, yielding 
82% of the modified material in as little as 2 hours (entry 17). Surprisingly, running the 
reaction for just 15 minutes gave a yield of 49% of the mono-olefinated peptide.  
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Table 3: Optimisation of the olefination of Ac-Gly-Trp(Boc)-OMe (22). 
 
Entry Solvent 
Temp 
/ °C 
Time  
/ h 
Yield / % 
1 t-amyl-OH 100 48 60 
2 t-amyl-OH 70 48 48 
3 t-amyl-OH 50 48 37 
4 t-amyl-OH 70 96 50 
5 t-amyl-OH 100 96 61 
6 HFIP 100 48 0 
7 MeCN 100 48 42 
8 Dioxane 100 48 40 
9 DCE 100 48 60 
10 DMF 100 48 0 
11 DCE/DMF 100 48 44 
12 THF 100 48 36 
13 Toluene 100 48 85 
14 Toluene 100 24 88a 
15 Toluene 100 12 87a 
16 Toluene 100 6 86 a 
17 Toluene 100 2 82a  
18 Toluene 100 1 78 a 
19 Toluene 100 0.75 74 a 
20 Toluene 100 0.50 69 a 
21 Toluene 100 0.25 49 a 
a yields were determined from the crude 1H NMR spectrum of 23a 
 
 
Some of the yields in Table 3 are taken from interpretation of the crude 1H NMR 
spectrum after filtering the reaction mixture through Celite (entries 14-21). The integrals 
from the methylene (CH2) protons of the tryptophan residue were compared from the 
crude 1H NMR spectra, as there was very little evidence of any other protons that 
correspond to other artefacts present in this area. The 1H NMR for the pure modified 
peptide, shows the methylene protons from the tryptophan side chain, as a set of 
 62 
 
doublet of doublets at 3.38 ppm and 3.47 ppm, whereas the methylene protons from the 
peptide starting material appears at 3.19 ppm and 3.27 ppm. The ratio of modified 
peptide to starting material from the integrals gave 3.75:1, giving a yield of 78% of 
olefinated peptide. An example of the crude 1H NMR after 1 hour is shown in Figure 2.  
  
Figure 13: Crude 1H NMR from a 400 MHz spectrometer, of the olefination of Ac-Gly-Trp(Boc)-OMe after 1 
hour. 
 
Plotting the data from Table 3 into Figure 14, shows there is very little change in the 
yields produced between the hours of 2 to 24. Figure 14 displays a large initial surge in 
the production of olefinated peptide 23a, however, the rate of production of 23a slows 
down after 45 minutes and eventually plateaus as the reaction approaches 6 hours. 
Consequent olefinations of tryptophan containing peptides were then run for a period of 
2 hours. 
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Figure 14: Conversion of olefinated Ac-Gly-Trp(Boc)-OMe produced over time, determined by integration of 
methylene protons in the crude 1H NMR spectrum. 
 
The model dipeptide 20 was then olefinated using the optimised reaction conditions and 
the products isolated after purification by column chromatography,  
 
Scheme 63: Olefination of A-Gly-Trp(N-Boc)-OMe to give the mono-, and di-olefinated tryptophan 
containing peptides. 
 
The di-olefinated tryptophan containing peptide 23a’, was observed and isolated from 
the olefination reaction. The yield recovered was incredibly small (1% yield) and is the 
minor product from the reaction.  
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2.3.4 Scope of the alkene 
The diversity of the alkene installed can increase the desirability of the reaction allowing 
the generation of a series of structurally related chemical libraries, using the same 
methodology each time. Investigations then focused on the olefination of the model 
dipeptide with a variety of substituted styrene analogues, Scheme 64. 
 
Scheme 64: Investigating the scope of the alkene used in the olefination of tryptophan residues. 
 
The olefination reaction was found to tolerate a variety of styrene-based olefins. 
Similarly, to the reactions conducted in Section 2.1.3, olefins bearing electron donating 
groups (CH3 and OMe, 23b and 23c) were well tolerated (78% and 59% respectively). 
Whilst olefins bearing electron donating groups (CF3 and CN, 23e and 23f) were also 
recovered (71% and 81%). 
 
2.3.5 Changing the neighbouring amino acid 
With the optimised conditions in hand, the next stage of the investigation involved 
screening the reaction against a series of different amino acids within a peptide 
sequence. The investigation changed the N-terminal amino acids and subjected 
peptides 21a and 25a-d to the olefination conditions, Scheme 65.  
  
 65 
 
 
Scheme 65: Screening of different amino acids at the N-terminus in tryptophan containing dipeptides. 
 
The C-H olefination reaction tolerated peptides containing alkyl chains upon 
neighbouring amino acids such as alanine 26a and leucine 26b, to afford modified 
peptides in good yields (68% and 62%). The addition of methionine at the N-terminus 
afford the corresponding modified peptide in an excellent yield (26d, 74%). The 
incorporation of phenylalanine at the N-terminus gave rise to olefination at the 
tryptophan residue exclusively (26c). Just as the previous study into the olefination of 
phenylalanine in Section 2.1, the N-terminal phenylalanine residue is unmodified by the 
reaction conditions.  
The peptides investigated in Scheme 65 each contain tryptophan residues at the C-
terminus only. The next stage involved investigating the olefination of N-terminal 
tryptophan residues in a series of dipeptides, Scheme 66. 
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Scheme 66: Olefination of N-terminal tryptophan residues. 
 
In contrast to the olefination of C-terminal phenylalanine residues Section 2.1.6, N-
terminal tryptophan resides were modified by the olefination reaction. Modified peptide 
29a and 29b were recovered in good yields (47% and 45%), lower than recovered yield 
of the complimentary the complimentary modified dipeptides 26b and 26d (68% and 
74%).  Nevertheless, the olefination of N-terminal tryptophan residues is significant 
compared to phenylalanine residues, which were unaffected by the olefination 
conditions.   
 
2.3.6 Olefination of tryptophan containing tripeptides 
With the olefination of a variety of dipeptides accomplished, the next stage involved the 
modification of tryptophan within longer chain peptides. The model tripeptides were 
synthesised as shown in Scheme 67. 
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Scheme 67: Preparation of tryptophan containing tripeptides. 
 
The four model tripeptides in Scheme 67 were synthesised in solution, building from the 
corresponding dipeptides. The C-terminal protecting group was cleaved under mild 
conditions using LiOH in a mixture of THF: MeOH: H2O to afford the corresponding 
dipeptide acid. The appropriate C-protected amino acid was then coupled to the peptide 
acid using HBTU and DIPEA. The sequential building of the peptide allowed for easy 
purification of the material as the tripeptide could be triturated from Et2O. The final stage 
involved the protection of the tryptophan side chain using Boc anhydride in the presence 
of NEt3. The protected material was then purified by column chromatography to afford 
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the desired tripeptide. The amino acids glycine, leucine and methionine were chosen as 
neighbouring residues as they had shown in Scheme 65, that tryptophan residues in 
dipeptides with these neighbouring amino acids were olefinated in the reaction 
conditions.    
 
Scheme 68: Olefination of tryptophan containing tripeptides. 
 
The olefination of tripeptide 32a with an N-terminal tryptophan residue afforded the 
corresponding modified tripeptide in a good yield (59%). Likewise, tripeptides bearing 
tryptophan residues in the middle of the peptide sequence (32b, 32c), were successfully 
olefinated by the reaction conditions, achieving yields of 69% and 55% respectively. 
 69 
 
Moving the tryptophan residue to the C-terminus of the peptide afforded the modified 
peptide in a good yield (68%); analogous to all of the examples in Scheme 68. 
 
2.4 Investigating the reaction mechanism for the olefination of tryptophan 
residues 
2.4.1 Olefination of N-terminal tryptophan residues 
Modified tripeptide 33a and dipeptides 29a-c were isolated with modified N-terminal 
tryptophan residues. However, in Section 2.1.6, the olefination of N-terminal 
phenylalanine residues was not observed by C-H functionalization. As discussed in 
Section 2.2.1, bidentate chelation of the metal catalyst to the peptide backbone appears 
crucial for C-H activation, yet olefination of monodentate species is still observed when 
targeting tryptophan residues. The modification of tryptophan containing peptides does 
not rely upon bidentate coordination to the peptide backbone. Instead, the Boc 
protecting group may be directing C-H functionalization in the tryptophan system by 
chelation to the carbamate functional group. Chelation to the peptide backbone does not 
appear to be crucial for functionalization. There are two proposed coordination sites: the 
formation of a metal-peptide species through chelation at the Boc protecting group, or 
chelation through the amide backbone, Figure 15. 
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Figure 15: Proposed chelation of tryptophan residues. 
 
In Figure 15, pathway A shows coordination of the metal through the carbamate amide, 
forming a 5 membered metallocycle. Pathway B depicts the chelation of the metal to the 
amide backbone, forming a six-membered ring. Coordination by pathway B is 
presumably higher in energy than coordination in pathway A. Chelation through a single 
amide residue was suggested as unfavourable due to the high energy pathway, under 
the reaction conditions in the olefination of N-terminal phenylalanine residues, (Section 
2.2.3). This is most likely also the case with Boc protected N-terminal tryptophan 
residues. It is therefore more likely that the C-H olefination of N-terminal tryptophan 
proceeds as shown in Scheme 69. 
 71 
 
 
Scheme 69: Proposed chelation of N-terminal tryptophan residues through the Boc protecting group. 
 
Scheme 69 displays the proposed C-H activation pathway, to give the monodentate 
metal-peptide complex. The protons upon the benzene ring of phenylalanine are less 
acidic than the proton present at the C-2 position of tryptophan. This presumably means 
there is less energy required to remove the C-2 proton, allowing the reaction to be 
carried out at lower temperatures, via a monodentate directing group. Activation of the 
C-2 position of the indole moiety is easily achieved in this example. The C-2 proton is 
removed by the acetate ligand in an AMLA mechanism, resulting in the formation of a 
new metal-carbon bond and a 5-membered ring. The resulting metal complex is 
presumably lower in energy than the complex depicted in pathway B (Figure 15). 
 
2.4.2 Modification of the amino acid tryptophan 
It appears that bidentate coordination is not necessary for the C-H functionalization of 
tryptophan residues as the Boc group is directing C-H activation. To test this theory, the 
C-H olefination of the native Boc protected amino acid would be observed if this is the 
case. Work began upon the synthesis of a di-protected tryptophan fragment, Scheme 
70. 
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Scheme 70: [a] Acylation of Trp-OMe to give compound 34, and [b] Boc protection of the indole to give 
amino acid 35. 
 
Starting from commercially available tryptophan methyl ester hydrochloride, the amine 
was protected using acetic anhydride to afford acetyl tryptophan methyl ester (34) in an 
excellent yield (90%). The protection was confirmed by the presence of a singlet at 1.95 
ppm in the 1H NMR spectrum, corresponding to the acetate group. The protected amino 
acid was then reacted with Boc anhydride to give the indole protected compound 35 as 
a white solid.  
Compound 35 was then subjected to the olefination reaction conditions for 2 hours, 
Scheme 71.  After purification by column chromatography, the mono olefinated amino 
acid was obtained in a 49% yield and identified by a characteristic doublet at 6.79 ppm 
with a coupling constant of 16.6 Hz, which corresponds to the formation of the trans 
alkene.  
 
Scheme 71: Olefination of Ac-Trp(Boc)-OMe (34) to afford modified amino acid 35a. 
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The olefination of the protected amino acid 35 further demonstrates that bidentate 
coordination is not necessary for the C-H functionalization of tryptophan, as the metal 
catalyst can only coordinate to a single directing group. To confirm the necessary indole 
protection, the free indole containing amino acid 34 was exposed to the C-H olefination 
conditions, Scheme 72.   
 
Scheme 72: Attempted olefination of Ac-Trp-OMe (34). 
 
Subjecting compound 34 to the C-H olefination conditions did not give modified amino 
acid 34a, Scheme 72. The Boc-protecting group appears crucial for C-H olefination of 
tryptophan residues. 
 
2.4.3 Olefination of silyl protected tryptophan residues  
Next, investigations looked at changing the indole protecting group on the tryptophan 
residue. Silyl protecting groups are used to protect not only amines, but also alcohols, 
thiols and indole to name but a few. A number of different silyl protecting groups were 
installed onto peptide 20, as shown in Scheme 73. 
 
Scheme 73: Installation of a silyl protecting group on model dipeptide 20. 
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Model peptide 20 was deprotonated using a 1M solution of LiHDMS under an inert 
environment before the addition of the silyl electrophile. After an aqueous work up and 
isolation by column chromatography, the silyl protected peptide was recovered in decent 
yields, Scheme 73. 
The sterically bulky tert-butyl dimethyl silyl (TBDMS) and isopropyl silyl (TIPS) groups 
were installed successfully to give the corresponding peptides 36a and 36b. However, 
the much more labile trimethyl silyl (TMS) protected peptide 36c was not recovered. The 
TMS group is much more susceptible to hydrolysis by acidic or basic media than the 
other silyl protecting groups and could have been removed during the workup of the 
crude material.  The silyl protected tryptophan residues were then subjected to the 
olefination reaction, Scheme 74. 
 
Scheme 74: The olefination of silyl protected tryptophan containing peptides 37a and 37b. 
 
The olefination of the TIPS protected peptide 36a was monitored by TLC. After 12 
hours, a new spot was observed on the TLC plate, however, there was little evidence in 
the crude 1H NMR to suggest that any the alkene had added. After purification by 
column chromatography, a trace amount (approximately 0.6%) of a colourless oil was 
recovered. The 1H NMR spectrum of the oil showed the compound contained a pair of 
doublets at 7.08 ppm and 7.85 ppm with J values of 15.8 and 16.0 Hz respectively, 
which are characteristic of trans alkene. The proton at the C-2 position of the indole was 
observed due to the presence of a singlet at 7.07 ppm; likewise, the presence of a 
doublet at 7.58 ppm, corresponds to a proton at C-7, confirms the olefin has not been 
added at either of these potions. Olefination has occurred at the C-4 position and has 
been determined by 1H NMR spectroscopy. The olefination of the TBDMS protected 
peptide 36a was not observed however.  
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Scheme 75: C-H olefination of TIPS protected tryptophan containing dipeptide to afford olefination at the C-
4 position. 
 
The TIPS protecting group contains a bulky silicon atom, compared to that of the Boc 
protected peptide 22. The silicon atom is hindering the coordination the incoming metal, 
and C-H activation at the C-2 position is not formed due to the steric repulsion, Scheme 
76. Palladium can however, chelate to the amide backbone, forming a five-, seven-
metallacycle by covalently bonding to the C-4 carbon of the indole. The five, seven- 
system is not very stable as reflected in the low yield observed.  
 
 
Scheme 76: Coordination of palladium to the TIPS protected peptide 37a. 
 
2.4.4 Installation of a pyrimidine directing group to tryptophan residues 
Next, attention turned to incorporating purpose built directing groups onto the peptide 
side chain. The pyrimidine-protecting group is used in literature as a directing group for 
indoles in C-H functionalisation reactions.126–128 The installation of a pyrimidine directing 
group onto a dipeptide started with peptide 20, Scheme 77. 
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Under an inert atmosphere, the aromatic N-H was deprotonated using sodium hydride at 
0 ˚C, before the electrophile was added to the reaction. After an aqueous workup, the 
crude mixture was analysed by 1H NMR spectroscopy, however there was no evidence 
to suggest the pyrimidine group had been installed upon the indole. Instead, there 
appeared to be fragmentation of the peptide itself from the reaction. Installing the 
protecting group onto a peptide post synthetically was not suitable in this transformation.  
 
Scheme 77: Attempted installation of pyrimidine onto peptide (1a) post synthetically. 
 
Efforts then changed to install the pyrimidine onto the tryptophan amino acid (34). 
Unnatural amino acid 39 was synthesised using the same conditions that had caused 
degradation of peptide 20, Scheme 78. The crude material was purified by column 
chromatography, to give the desired product in a 50% yield. 1H NMR spectroscopy was 
used to confirm the presence of the pyrimidine group.  
 
Scheme 78: Installation of the pyrimidine directing group onto amino acid 33. 
 
The unnatural amino acid 39, was then subjected to the olefination conditions, that had 
given rise to the modified tryptophan residues. Initially the reaction was heated to 100 ˚C 
for 2 hours, however, there was no sign of the olefinated peptide, instead only the 
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unreacted amino acid was recovered. The reaction was then repeated, increasing the 
duration to 48 hours, but this again yielded only the amino acid starting material, 
Scheme 79. 
 
Scheme 79: Attempted olefination of unnatural amino acid 40. 
 
The desired modified amino acid 41, was not observed in Scheme 79. The installed 
pyrimidine directing group appears to halt the olefination reaction all together. In this 
case, the installed directing group is not sterically bulky as was the case with the silyl 
protected tryptophan residues. The pyrimidine group may be poisoning the metal 
catalyst by irreversibly binding to the catalyst. The pyrimidine instead is not a suitable 
directing group for the olefination of tryptophan residues.  
 
2.4.5 Installation of sulfonyl directing groups to tryptophan residues 
Next, the investigation into tryptophan directing groups turned towards sulfonyl directing 
groups. As described by García-Rubia and co-workes, the olefination of the 
phenylalanine amino acid residues has been shown using a sulfonyl directing group. 80 
 
Scheme 80: The olefination of phenylalanine using a pre-installed pyridyl sulfone directing group.80 
 
The first step of the reaction involved generating the electrophile, pyridine sulphonyl 
chloride by reacting mercaptopyridine with a hypochlorite solution. The electrophile is 
unstable at room temperature and decomposes to give the less reactive sulfonic acid 
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derivative. Due to the rapid decomposition of the electrophile, the bright yellow mobile oil 
that was formed was quickly added to peptide 20, which had been dissolved in dry DMF 
and deprotonated using sodium hydride. After stirring for 16 hours at room temperature, 
the solution was worked up to afford a slimy brown oil. Analysis of the oil by 1H NMR 
spectroscopy afforded a fragmented peptide and a pyridine-based derivative only. The 
peptide has been destroyed in the reaction.  
 
Scheme 81: Attempted synthesis of a pyridyl sulphonyl peptide. 
 
A new strategy was employed for the addition of the sulphonyl directing group. Instead 
of attempting to functionalise the peptide post synthetically, a second approach sought 
to functionalize the tryptophan amino acid first, before incorporating the modified 
tryptophan based amino acid into a peptide sequence. The sulphonyl chloride 
electrophile was generated as using the procedure outlined in Scheme 81, and used 
without further purification with the di-protected amino acid 34, Scheme 82. 
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Scheme 82: Attempted generation of a tryptophan-based sulphonyl pyridine compound. 
 
The installation of the sulfone directing group onto the protected amino acid was 
unsuccessful, affording the amino acid only, Scheme 82. A reason for the failure of the 
reaction could be during the preparation of the sulphonyl chloride. If the sulphonyl 
chloride is not generated before its addition to the amino acid mixture, the reaction 
would not produce the intended unnatural amino acid. During the synthesis of the 
electrophile, a small sample was taken for analysis by 1H NMR spectroscopy. The 
spectrum produced clearly showed a transformation had taken place when compared to 
the pyridine-based starting material. However, the presence of the chloride or acid could 
not be confirmed by the 1H NMR spectrum. The in-situ formation of the pyridyl sulfone 
was not clearly observed. 
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2.5 Olefination of peptides containing multiple aromatic amino acids  
2.5.1 Introduction 
Site-selective modification of amino acid side chains is a problem in many C-H 
functionalization reactions. The work undertaken in this study has developed a method 
for the C-H olefination of both phenylalanine and tryptophan residues in small peptides. 
The methodology developed for the modification of these aromatic amino acids is 
similar, making site-selective C-H olefination difficult. The aim was to investigate the C-H 
olefination reaction on peptides containing both tryptophan and phenylalanine residues.   
 
2.5.2 Olefination of Ac-Trp(Boc)-Phe-OMe  
As documented in Section 2.1.6, the C-H functionailzation of N-terminal phenylalanine 
residues is not observed under the developed methodology. With this in mind, the 
dipeptide Ac-Phe-Trp(Boc)-OMe, with an N-terminal phenylalanine was synthesised, 
and the subsequent olefination studied, Scheme 83. 
 
Scheme 83: Olefination of Ac-Phe-Trp(Boc)-OMe (25c). 
 
As expected, the C-H olefination of peptide 25c afforded the corresponding mono-
olefinated tryptophan residue. The N-terminal phenylalanine residue was unaffected by 
the reaction. Site-selectivity had been exploited by positioning the phenylalanine residue 
at the N-terminus.  
Next, the peptide sequence was altered so that the tryptophan residue was located at 
the N-terminus with phenylalanine at the C-terminus. It has already been established 
that N-terminal tryptophan residues are modified under the olefination conditions 
(Section 2.4.1). The dipeptide Ac-Trp(Boc)-Phe-OMe (45), was subjected to the 
olefination conditions developed for the C-H olefination of tryptophan residues, Scheme 
84. 
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Scheme 84: Olefination of Ac-Trp(Boc)-Phe-OMe under the optimised conditions for the C-H olefination of 
tryptophan residues. 
 
Analysis of the crude material from the olefination of Ac-Trp(Boc)-Phe-OMe was difficult 
as the crude 1H NMR spectrum was extremely complicated at first glance. The crude 
compound was then purified by column chromatography to afford the 6 compounds as 
shown in Scheme 84, including the unmodified peptide 43. 
The olefination of dipeptide 43, gave a mixture of modified products, with olefinations 
occurring on both tryptophan and phenylalanine residues. The olefination of dipeptide 42 
was repeated to see if site-selective modification could be obtained by changing the 
solvent and duration of the reaction, Table 4. 
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Table 4: Investigating the solvent used for the olefination of peptide 43.
 
Entry Time/h Solvent 
Peptide 
45 46a 46b 46c 46d 46e 
1 6 Toluene 36 16 22 7 13 6 
2 24 Toluene 32 17 24 7 13 7 
3 6 DCE 40 20 24 7 9 0 
4 24 DCE 41 20 21 7 11 0 
5 6 t-amyl-OH 42 20 11 14 6 7 
6 24 t-amyl-OH 40 22 12 14 6 6 
7 6 Toluene 36 18 19 10 13 4 
8 6 Toluene 42 25 18 7 8 0 
9 1 Toluene 30 20 21 7 15 7 
 
Table 4, displays very little variation in the distribution of the olefinated products when 
changing the reaction solvent and duration of the reaction. When changing the solvent 
to t-amyl-OH which had been shown to be effective at the olefination of phenylalanine 
containing peptides, there was a small increase in the yield of peptides 43a, and 43c in 
which only the phenylalanine residue had been modified (entries 5 and 6). Overall 
however, the selective olefination of peptide 42 was not observed.  
 
2.5.3 Selective phenylalanine modification in the presence of tryptophan 
residues 
In Section 2.4.3, the modification of tryptophan residues bearing silyl protecting groups 
was not observed. It was theorised that to achieve selective phenylalanine modification 
in tryptophan containing peptides, that the tryptophan residue must be silyl protected. 
The TIPS protected peptide 44 was synthesised using the conditions in Scheme 73, 
Section 2.4.3. The silyl protected peptide was then subjected to the olefination 
conditions as shown in Scheme 85. 
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Scheme 85: C-H olefination of Ac-Trp(TIPS)-Phe-OMe 44. 
 
The reaction of Ac-Trp(TIPS)-Phe-OMe was performed using the optimised conditions 
for the C-H olefination of phenylalanine residues using t-amyl-OH as the reaction 
solvent. As expected, the olefination of peptide 45 afforded the corresponding 
phenylalanine modified peptide 48 only. The olefination of tryptophan was not observed.  
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 Conclusion 
Peptides are playing an ever-increasing role in the pharmaceutical industry; with 
applications as therapeutics and in the imaging of diseases for example. Peptide 
modification leads to the generation of more varied libraries of peptides, which have 
different physical and chemical proprieties compared to their unmodified counterparts. 
C-H functionalization is an attractive method for the modification of peptides, as this 
methodology does not necessarily rely on the use of pre-functionalized materials for 
transformations. Natural amino acids can be transformed using C-H functionalization to 
produce complex peptides in a single step.  
The aim of this investigation was to develop new methodology for the C-H 
functionalization of peptides, and therefore increase the number of modification 
strategies for chemists. The work documented in this thesis describes the development 
of a new C-H functionalization method for the direct modification of phenylalanine and 
tryptophan residues within peptides. 
 
3.1 Olefination of phenylalanine and tryptophan residues in peptides 
The aromatic amino acids phenylalanine and tryptophan were identified as potential 
targets for modification. As described in Section 1.4.2, the direct modification of 
phenylalanine residues by C-H functionalization has been under explored, despite the 
relative abundance of phenylalanine residues in natural peptides. The modification of 
tryptophan residues has been explored in the literature, but the study is still in its 
infancy. Developing new methodologies for the direct modification of amino acids within 
peptides sequences remains an area of great importance to maximise the options for 
peptide modification.  
Chapter 2 described the C-H olefination of the aromatic amino acids phenylalanine and 
tryptophan within a peptide sequence. Investigations started with the olefination of the 
model peptide Ac-Gly-Phe-OMe 1a, which gave the mono-, and di-olefinated modified 
peptides 2a and 2a’, Scheme 86.  
 
Scheme 86: Palladium catalysed C-H olefination of model dipeptide 1a. 
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Optimising the olefination reaction conditions afford the di-olefinated product 2a as the 
major species every time, with dwindling returns of the mono-olefinated peptide 2a’. 
Crucially it was found that changing the solvent to t-amyl-OH gave the di-olefinated 
product 2a in a yield of 81%. The methodology developed for the C-H olefination of 
phenylalanine residues was extended to peptides of greater chain lengths, different 
neighbouring amino acids and different styrenes, Figure 16. 
 
Figure 16: Summary of the C-H olefination of phenylalanine containing peptides. 
 
Section 2.3 detailed the application of the methodology for the C-H olefination of 
phenylalanine to peptides bearing tryptophan side chains. Initial attempts to olefinate 
tryptophan containing peptides were problematic due to the indole N-H present in 
tryptophan. The C-H olefination of tryptophan was achieved by first Boc protecting the 
indole and then applying the olefination methodology developed of the modification of 
phenylalanine residues. The model dipeptide Ac-Gly-Trp(Boc)-OMe was olefinated to 
give the mono-olefinated peptide in a 60% yield. In contrast to the studies conducted on 
the phenylalanine containing model peptide where t-amyl-OH had given the biggest 
 86 
 
yield of olefinated material, toluene was found to be a more suitable solvent, giving an 
82% yield.  
The methodology developed for the C-H olefination of tryptophan residues was 
extended to di- and tripeptides containing a number of different neighbouring amino 
acids and different styrenes, Figure 17. The Boc protecting group appears crucial for C-
H functionalization.  
 
Figure 17: Summary of the C-H olefination of tryptophan containing peptides. 
 
Greater differences between the two developed C-H olefination strategies were 
observed when the position of the aromatic amino acid was changed within a peptide 
sequence. N-terminal modifications were not observed when a phenylalanine residue 
was located at the N-terminus, yet tryptophan residues when located at the N-terminus, 
were modified using the appropriate reaction conditions. The observed differences in 
site reactivity could be explained due to the coordination of the peptide to the metal, 
Figure 18. 
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Figure 18: a) Bidentate coordination of Phe residues in the middle and at the C-terminus of peptide, b) 
Monodentate coordination of Phe residues at the N-terminus and c) monodentate coordination of Trp 
residues to the Boc directing group. 
 
Bidentate coordination of the peptide backbone to the metal centre appears crucial for 
the C-H activation of phenylalanine residues within peptides. The olefination of 
phenylalanine containing peptides relies upon bidentate coordination of the metal for the 
reaction to proceed. N-terminal phenylalanine residues are unaffected by the olefination 
methodology (Pathway B, Figure 18). In contrast, the modification of N-terminal 
tryptophan residues suggests that bidentate coordination is no longer crucial. Instead, 
the Boc protecting group is acting as a directing group, and allows for monodentate 
coordination to the metal centre. 
The final investigations looked at applying the olefination conditions to peptides 
containing both phenylalanine and tryptophan residues. When the olefination reaction 
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was applied to the model peptide 45, the reaction gave a mixture of olefinated products 
with no apparent selectivity, Scheme 87. 
  
Scheme 87: Olefination of di-aromatic peptide 45. 
 
Selective modification of the phenylalanine residue was achieved by removing the Boc 
group from the tryptophan residue and replacing it with a silyl protecting group. Likewise, 
positioning the phenylalanine residue to the N-terminus of the sequence afforded 
modification of the tryptophan residue exclusively, Scheme 88. 
 
Scheme 88: Selective olefination of a) phenylalanine and b) tryptophan residues in model dipeptides 47 and 
25c. 
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In summary, the C-H olefination of the aromatic residues phenylalanine and tryptophan 
were successfully modified within a peptide sequence. The methodology developed for 
the modification of each aromatic residue was found to tolerate peptides bearing 
different neighbouring amino acids, peptide chain lengths and olefins. Coordination of 
the metal to the peptide backbone in the olefination phenylalanine appears to be crucial 
for the success of the reaction. However, the use of a proximal directing group upon the 
indole nitrogen allows tryptophan residues to be modified through monodentate 
coordination. Finally, the modification of peptides bearing multiple aromatic residues 
were investigated. Selective olefination of tryptophan was achieved when placing the 
phenylalanine residue at the N-terminus, and selective tryptophan olefination was 
achieved by installing a bulky silyl protecting group upon the indole nitrogen.  
 
3.2 Current literature  
During the writing of this thesis, the first reported direct modification of phenylalanine 
residues was described by Wang et al.129 In this study, Wang reported the olefination of 
phenylalanine on di-, and tripeptides, to give the corresponding mono-olefinated 
peptides, Scheme 89. 
 
Scheme 89: The olefination of phenylalanine containing peptides by a) Wang et al.129 and b) this work. 
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The methodology developed in this thesis, affords the di-olefinated peptide in higher 
yields than the mono-olefinated peptide. As described in Section 1.2.3, Wang also 
proposed that coordination of the metal to the peptide backbone is crucial for the C-H 
activation of phenylalanine residues. Similarly, Wang also found that changing the 
position of the phenylalanine residue was crucial to the reaction success. C-terminal 
phenylalanine residues were modified by the reported functionalization methodology and 
N-terminal phenylalanine residues remained unmodified. In contrast to this report, 
Wang’s methodology when applied to peptides bearing mid sequence phenylalanine 
residues were unmodified by the reaction conditions. The findings in this thesis provide 
a route to the modification of phenylalanine residues within the middle of a peptide 
sequence. Wang reported that the mono-olefinated peptides were the major product of 
the olefination reaction, which contrasts with the findings of this thesis where the di-
olefinated phenylalanine was obtained as the major product each time, Scheme 90.  
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Scheme 90: The contrasting olefination of phenylalanine residues at the N- and C-termini and in the middle 
of a peptide sequence by Wang et al., and this work. 
 
The reactions conditions in Scheme 89 and Scheme 90 are similar to the methodology 
in this report, yet the major products differ. Wang’s method and the work presented here 
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offer two unique methods for the direct modification of phenylalanine residues in 
peptides. The work undertaken in this thesis is a complementary method for the 
modification of phenylalanine residues to afford the major product as the corresponding 
di-olefinated peptide.  
 
3.3 Future work 
3.3.1 Olefination of tyrosine and histidine containing peptides 
The next steps in this investigation comprise of developing a strategy for the olefination 
of the aromatic amino acids tyrosine and histidine. Tyrosine is a phenolic derivative of 
phenylalanine. The methodology developed on the olefination of phenylalanine could 
then be directly applied to protected tyrosine analogues. As discussed in Section 2.1.5, 
the olefination of phenylalanine residues in the presence of the tyrosine OH did not 
occur. Protection of the phenol with a suitable protecting group such as benzyl or tert-
butyl protecting groups may be crucial for C-H olefination, Scheme 91. When 
developing methodology for the olefination of histidine residues, the imidazole side chain 
may also need to be protected. Common protecting groups for histidine residues are 
shown in Scheme 91.  
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Scheme 91: Olefination of a) tyrosine and b) histidine containing peptides. 
 
In conjunction with the work described in this thesis, the development of the olefination 
of tyrosine and histidine residues, would generate more methods for peptide 
modification. The application of this new methodology could lead to the functionalization 
of more complex peptide sequences, containing a greater variety of aromatic amino 
acids such as those displayed in Figure 19.  
The methodology developed thus far in this thesis has been applied on peptides up to 4 
amino acids in length. There are few examples in nature of natural peptides with small 
chain lengths. Chemotactic peptide is an example of a phenylalanine containing 
therapeutic tripeptide.5 Pasireotide is a cyclic peptide prescribed for the treatment of 
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Cushing’s disease.130 The peptide Pasireotide contains 4 aromatic residues; tryptophan 
phenylalanine, phenylglycine and tyrosine. Each of the aromatic side chains could be 
modified using the C-H olefination procedure, apart from the phenylglycine unit (as 
described in Section 2.2.4). The modification of peptide therapeutics could lead to the 
development of more potent drugs for disease.  
 
Figure 19: Natural therapeutic peptides that could be modified by C-H olefination. 
 
The therapeutics chemotactic peptide and Pasireotide131 (Figure 19), could be modified 
using the olefination procedures described in this thesis. The modification of these “real 
world” peptides is an example of how the C-H olefination methodology gives chemists 
more tools for peptide modification to introduce varied amino acid side chains.   
 
3.3.2 Generating conformational constraints in peptides by C-H olefination 
reactions 
The intramolecular modification of peptide side chains leads to a change in peptide 
conformation and shape.99,100 The development of methods to alter peptide conformation 
are of great importance to chemists in areas such as therapeutics. These changes could 
also induce changes to the photochemical properties of the peptide too.69 
Conformational changes could be installed by using the C-H functionalization 
methodology in two ways. Peptides with non-natural vinylic side chains could be coupled 
to natural amino acids through C-H olefination. The olefin in question could be attached 
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to another peptide chain and when coupled by C-H olefination to an aromatic side chain, 
would form a new C-C bond between two peptide strands, Scheme 92. 
 
Scheme 92: Proposed C-C cross linking between two peptides by C-H olefination of a vinylic amino acid 
side chain and a tryptophan residue. 
 
Another transformation could use the C-H olefination procedure to install and olefin 
containing a secondary handle which would facilitate a second C-H functionalized 
transformation i.e. C-H arylation reaction.100 The methods described here would produce 
new links between peptide sequences without the need for pre-functionalization. These 
cross linked peptides have been shown to exhibit an increase in biological activity 
making them suitable for applications such as therapeutics.99,25 
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 Experimental 
4.1 General Experimental Information 
All manipulations were performed in oven-dried glassware in an atmosphere of air 
unless stated. Ag2CO3 and AgOPiv were prepared according to literature 
procedures.132,133 All other reagents and solvents were purchased from either Alfa 
Aesar, Fisher Scientific or Sigma Aldrich and used as supplied. Flash column 
chromatography was performed on silica gel (Fluorochem, silica gel 60 Å, particle size 
40-63 µm). Thin layer chromatography was performed on glass-backed silica gel plates 
(2.5 x 7.5 cm; Merck, TLC silica gel 60 Å); compounds were visualised by exposure to 
UV light (254 nm) or using a permanganate stain. NMR spectra were recorded on a 
JEOL Eclipse 400 spectrometer at 298 K; chemical shifts are reported in parts per 
million and coupling constants are reported in Hz. For some compounds, assignments 
for 1H and 13C NMR peaks were aided by 1H-1H COSY, 1H-1H NOESY and 1H-13C 
HMQC 2D NMR experiments. FTIR spectra were recorded in a diamond ATR cell using 
Perkin-Elmer Spectrum 2 instrument or an Aligent Technologies Cary 630 instrument. 
Melting points were recorded on a Stuart SMP10 melting point apparatus and are 
uncorrected. High-resolution mass spectrometry was obtained from the EPSRC UK 
National Mass Spectrometry Facility at Swansea University on an LTQ Orbitrap XL 1, 
using positive electrospray ionisation (ESI+).  
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4.2 Synthesis of phenylalanine containing peptides 
4.2.1 General procedure for the preparation of phenylalanine containing 
dipeptides 
 
The L-(amino acid) methyl ester hydrochloride (2.50 mmol) and K2CO3 (0.498 g, 3.60 
mmol) were dissolved in distilled water (30 mL) and stirred for 10 min at room 
temperature. The free amine was extracted with Et2O (3 x 20 mL), dried (MgSO4) and 
concentrated by rotary evaporation. The resulting colourless oil was dissolved in DCM 
(20 mL); the N-protected amino acid (1.00 mmol), HBTU (0.379 g, 1.00 mmol) and 
DIPEA (0.174 mL, 1.00 mmol) were then added to the reaction mixture, which was 
stirred for 12 h. The resulting suspension was filtered and washed with 1M HCl (20 mL), 
sat. NaHCO3 (3 x 20 mL) and H2O (20 mL). The organic layers were then dried (MgSO4) 
and concentrated to dryness in vacuo. The resulting oil was recrystallised from DCM / 
hexanes. 
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4.2.2 Ac-Gly-Phe-OMe (1a) 
 
Peptide 1a was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetylglycine (0.117 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 1a as a 
white solid (0.218 g, 78%); m.p. 95-97 °C. 
1H NMR (400 MHz, CDCl3) δ 2.00 (3H, s, Acetyl-CH3), 3.07 (1H, dd, J = 13.9, J = 6.0, 
Phe-CHH), 3.13 (1H, dd, J = 13.9, J = 6.0, Phe-CHH), 3.72 (3H, s, Ester-CH3), 3.88 (2H, 
app dd, J = 16.5, J = 5.0, Gly-CH2), 4.84 (1H, dt, J = 7.6, J = 6.0,  Phe-α-CH), 6.33 (1H, 
m, Gly-NH), 6.57 (1H, br d, J = 7.6, Phe-NH), 7.08 (2H, d, J = 6.4, Ar-H) 7.23-7.30 (3H, 
m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.0 (Acetyl-CH3), 37.9 (Phe-CH2), 43.2 (Gly-CH2), 
52.6 (Ester-CH3), 53.3 (Phe-α-CH), 127.3 (Ar-C), 128.7 (Ar-C), 129.3 (Ar-C), 135.7 (Ar-
C), 168.6 (C=O), 170.7 (C=O), 171.8 (C=O). 
IR Umax/cm-1 (solid) 3263 m (N-H), 3072 s (C-H), 2958 s (C-H), 1751 s (Ester C=O), 1709 
s (Amide C=O), 1657 m (C=C), 1445 m (C-H).  
HRMS (ESI) [M+H]+ m/z calcd. for C14H19N2O4: 279.1339, found: 279.1339. 
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4.3 General procedure for the olefination of phenylalanine containing 
peptides 
 
Peptide (0.359 mmol), Pd(OAc)2 (8 mg, 0.036 mmol, 10 mol%), AgOAc (0.300 g, 1.780 
mmol) and styrene (0.166 mL, 1.440 mmol) were stirred together in t-amyl-OH (3 mL) at 
130 °C for 12 h. The reaction mixture was then allowed to cool to room temperature and 
filtered through a plug of Celite. The filtrate was then concentrated to dryness. The 
resulting residue was purified by flash column chromatography and recrystallised from 
DCM / hexanes. 
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4.3.1 C-H olefination of model dipeptide 1a; synthesis of modified peptides 2a 
and 2a’ 
 
Following the general procedure in Section 4.3, the reaction of Ac-Gly-Phe-OMe (1a) 
(0.100 g, 0.359 mmol), styrene (0.166 mL, 1.440 mmol), Pd(OAc)2 (8 mg, 0.036 mmol, 
10 mol%) and AgOAc gave a crude product that was a mixture of the di-olefinated 
peptide 2a and the mono-olefinated peptide 2aʹ in a ratio of 8:1, as judged by 1H NMR 
spectroscopy. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 2a as an off-white solid (0.140 g, 81%); m.p. 
198-199 °C, Rf 0.33 (EtOAc), and 2aʹ as an off-white solid (0.011 g, 8%); m.p. 129-132 
°C, Rf 0.15 (EtOAc). 
Data for 2a: 
1H NMR (400 MHz, CDCl3) δ 1.83 (3H, s, Acetyl-CH3), 3.49 (2H, d, J = 7.0, Phe-CH2), 
3.55 (3H, s, Ester-CH3), 3.70 (1H, dd, J = 16.9, J = 5.0, Gly-CHH), 3.79 (1H, dd, J = 
16.9, J = 5.0, Gly-CHH), 4.78 (1H, dt, J = 7.4, J = 6.9, Phe-α-CH), 5.82 (1H, m, Gly-NH), 
6.40 (1H, br d, J = 7.7, Phe-NH), 7.01 (2H, d, J = 16.0, Alkene-CH), 7.27-7.33 (3H, m, 
Ar-H), 7.39 (4H, t, J = 7.8, Ar-H), 7.47 (2H, d, J = 16.0, Alkene-CH), 7.58 (6H, d, J = 7.8, 
Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 31.0 (Phe-CH2), 42.8 (Gly-CH2), 
52.7 (Ester-CH3), 53.0 (Phe-α-CH), 125.8 (Ar-C), 126.2 (Alkene-C=C), 126.7 (Ar-C), 
127.7 (Ar-C), 128.0 (Ar-C), 128.8 (Ar-C), 131.6 (Ar-C), 131.8 (Alkene-C=C), 137.1 (Ar-
C), 137.8 (Ar-C), 168.2 (C=O), 170.2 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3300 m (N-H), 3057 s (C-H), 2954 s (C-H), 1727 s (Ester C=O), 
1632 s (Amide C=O), 1535 m (C=C), 1436 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C30H31N2O4: 483.2278 found: 483.2275.  
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Data for 2aʹ: 
1H NMR (400 MHz, CDCl3) δ 1.87 (3H, s, Acetyl-CH3), 3.18 (1H, dd, J = 14.2, J = 6.2, 
Phe-CHH), 3.41 (1H, dd, J = 14.2, J = 6.2, Phe-CHH), 3.65 (3H, s, Ester-CH3), 3.68 (1H, 
m, Gly-CHH), 3.85 (1H, dd, J = 16.9, J = 5.3, Gly-CHH), 4.81 (1H, dt, J = 7.3, J = 6.2, 
Phe-α-CH), 6.34 (1H, t, J = 5.3, Gly-NH), 6.94 (1H, d, J = 7.3, Phe-NH), 7.01 (1H, d, J = 
16.0, Alkene-CH), 7.07-7.11 (1H, m, Ar-H), 7.18 (1H, t, J = 7.3, Ar-H), 7.24-7.29 (2H, m, 
Ar-H), 7.35-7.40 (3H, m, Ar-H / Alkene-CH), 7.54 (2H, d, J = 7.3, Ar-H), 7.63 (1H, d, J = 
7.3, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.7 (Acetyl-CH3), 34.8 (Phe-CH2), 42.9 (Gly-CH2), 
52.4 (Ester-CH3), 53.3 (Phe-α-CH), 125.4 (Ar-C),125.8 (Ar-C), 126.6 (Alkene-C=C), 
127.1 (Ar-C), 127.6 (Ar-C), 127.8 (Ar-C), 128.5 (Ar-C), 128.7 (Ar-C), 130.5 (Ar-C), 133.7 
(Alkene-C=C), 136.7 (Ar-C), 137.1 (Ar-C), 168.2 (C=O), 170.2 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3302 m (N-H), 3027 s (C-H), 2950 s (C-H), 1733 s (Ester C=O), 
1636 s (Amide C=O), 1511 m (C=C), 1215 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C22H25N2O4: 381.1814, found: 381.1810. 
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4.3.2 Synthesis of modified peptide 3a 
 
Modified peptide 3a was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 4-methylstyrene (0.190 mL, 1.440 mmol), using the general procedure in Section 
4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3a and the mono-olefinated peptide in a ratio of 5:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3a as 
an off-white solid (0.141 g, 77%); m.p. 239-242 °C, Rf 0.39 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.83 (3H, s, Acetyl-CH3), 2.37 (6H, s, Ar-CH3), 3.45-3.53 
(2H, m, Phe-CH2), 3.55 (3H, s, Ester-CH3), 3.68 (1H, dd, J = 16.9, J = 5.1, Gly-CHH), 
3.77 (1H, dd, J = 16.9, J = 5.1, Gly-CHH), 4.75 (1H, dt, J = 7.5, J = 6.9, Phe-α-CH), 5.71 
(1H, m, Gly-NH), 6.24 (1H, br d, J = 7.5, Phe-NH), 6.98 (2H, d, J = 15.9, Alkene-CH), 
7.20 (4H, d, J = 7.9, Ar-H), 7.30 (1H, t, J = 7.9, Ar-H), 7.40 (2H, d, J = 15.9, Alkene-CH), 
7.47 (4H, d, J = 7.9, Ar-H), 7.55 (2H, d, J = 7.9, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.3 (Ar-CH3), 22.7 (Acetyl-CH3), 30.8 (Phe-CH2), 
42.8 (Gly-CH2), 52.7 (Ester-CH3), 53.1 (Phe-α-CH), 125.2 (Ar-C), 125.3 (Ar-C), 126.6 
(Alkene C=C), 127.6 (Ar-C), 129.5 (Ar-C), 131.4 (Ar-C), 131.6 (Alkene C=C), 134.4 (Ar-
C), 137.9 (Ar-C), 137.9 (Ar-C), 168.3 (C=O), 170.3 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3264 m (N-H), 3056 w (C-H), 2917 w (C-H), 1740 s (Ester C=O), 
1696 s (Amide C=O), 1652 m (C=C), 1510 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C32H35N2O4: 511.2591, found: 511.2582. 
  
 103 
 
4.3.3 Synthesis of modified peptide 3b 
 
Modified peptide 3b was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 4-methoxystyrene (0.194 mL, 1.440 mmol), using the general procedure in Section 
4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3b and the mono-olefinated peptide in a ratio of 3:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3b as 
an off-white solid (0.097 g, 50%); m.p. 260-262 °C, Rf 0.34 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.85 (3H, s, Acetyl-CH3), 3.48 (2H, br d, J = 7.1, Phe-CH2), 
3.54 (3H, s, Ester-CH3), 3.69 (1H, dd, J = 16.9, J = 4.9, Gly-CHH), 3.76 (1H, dd, J = 
16.9, J = 4.9, Gly-CHH), 3.83 (6H, s, OCH3), 4.77 (1H, dt, J = 7.4, J = 7.0, Phe-α-CH), 
5.76 (1H, m, Gly-NH), 6.25 (1H, br d, J = 7.4, Phe-NH), 6.92-6.98 (6H, m, Alkene-CH / 
Ar-H), 7.28-7.33 (4H, m, Alkene-CH / Ar-H), 7.50-7.54 (5H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 30.9 (Phe-CH2), 42.8 (Gly-CH2), 
52.7 (Ester-CH3), 53.1 (Phe-α-CH), 55.3 (OCH3), 114.2 (Ar-C), 124.1 (Ar-C), 125.3 
(Alkene-C=C), 127.6 (Ar-C), 128.0 (Ar-C), 130.0 (Ar-C), 131.0 (Ar-C), 131.3 (Alkene-
C=C), 138.1 (Ar-C), 159.5 (Ar-C), 168.3 (C=O), 170.2 (C=O), 171.7(C=O). 
IR Umax /cm-1 (solid) 3265 m (N-H), 3062 w (C-H), 2943 w (C-H), 1738 s (Ester C=O), 
1694 s (Amide C=O), 1651 m (C=C), 1538 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C32H35N2O6: 543.2490, found: 543.2486. 
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4.3.4 Synthesis of modified peptide 3c 
 
Modified peptide 3c was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 4-trifluoromethylstyrene (0.213 mL, 1.440 mmol), using the general procedure in 
Section 4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 3c and the mono-olefinated peptide in a ratio of 5:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 3c as a white solid (0.162 g, 73%); m.p. 218-220 °C, Rf 0.40 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.94 (3H, s, Acetyl-CH3), 3.43 (1H, dd, J = 14.2, J = 7.8, 
Phe-CHH),  3.50-3.56 (4H, m, Phe-CHH / Ester-CH3), 3.78 (1H, dd, J = 16.5, J = 5.0, 
Gly-CHH), 3.87 (1H, dd, J = 16.5, J = 5.0, Gly-CHH), 4.78 (1H, dt, J = 7.3, J = 6.9, Phe-
α-CH), 5.92-5.95 (1H, m, Gly-NH), 6.51 (1H, br d, J = 7.3, Phe-NH), 7.05 (2H, J = 16.0, 
Alkene-CH), 7.35 (1H, t, J = 7.8, Ar-H), 7.58-7.71 (12H, m, Ar-H / Alkene-CH).   
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 31.6 (Phe-CH2), 43.0 (Gly-CH2), 
52.8 (Ester-CH3), 53.1 (Phe-α-CH), 125.7 (Ar-C), 126.3 (Ar-C), 126.9 (Ar-C), 127.8 (Ar-
C), 128.4 (Ar-C), 129.4 (Ar-C), 129.7 (Alkene-C=C), 130.2 (Alkene-C=C), 132.2 (Ar-C), 
137.3 (Ar-C), 140.5 (Ar-C), 168.3 (C=O), 170.4 (C=O), 171.6 (C=O).  
IR Umax /cm-1 (solid) 3318 m (N-H), 3055 w (C-H), 2956 w (C-H), 1720 s (Ester C=O), 
1612 m (C=C), 1507 m (C=C), 1321 s (C-F), 1109 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C32H30F6N2O4: 619.2026, found 619.2028.   
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4.3.5 Synthesis of modified peptide 3d 
 
Modified peptide 3d was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 3-nitrostyrene (0.201 mL, 1.440 mmol), using the general procedure in Section 4.3. 
The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3d and the mono-olefinated peptide in a ratio of 8:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3d as a 
white solid (0.123 g, 60%); m.p. 172-174 °C, Rf 0.31 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 2.04 (3H, s, Acetyl-CH3), 3.36 (1H, dd, J = 14.2, J = 9.2, 
Phe-CHH), 3.50-3.55 (4H, m, Ester-CH3 / Phe-CHH), 3.91-4.02 (2H, m, Gly-CH2), 4.75 
(1H, m, Phe-α-CH), 6.63 (1H, m, Gly-NH), 7.05 (2H, d, J = 16.0, Alkene-CH), 7.14 (1H, 
d, J = 7.3, Phe-NH), 7.33 (1H, t, J = 7.8, Ar-H), 7.53 (2H, t, J = 8.2, Ar-H), 7.62 (2H, d, J 
= 7.8, Ar-H), 7.74 (2H, d, J = 16.0, Alkene-CH), 7.82 (2H, d, J = 7.8, Ar-H), 8.09 (2H, d, J 
= 8.2, Ar-H) 8.61 (2H, s, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 32.4 (Phe-CH2), 43.1 (Gly-CH2), 
52.9 (Ester-CH3), 53.8 (Phe-α-CH), 121.2 (Ar-C), 122.4 (Ar-C), 126.3 (Ar-C), 127.9 (Ar-
C), 128.9 (Ar-C), 129.4 (Alkene-C=C), 129.8 (Alkene-C=C), 132.7 (Ar-C), 133.1 (Ar-C), 
137.0 (Ar-C), 139.1 (Ar-C), 149.0 (Ar-C), 168.7 9 (C=O), 171.0 (C=O), 171.9 (C=O). 
IR Umax /cm-1 (solid) 3301 m (N-H), 3070 w (C-H), 2957 w (C-H), 2222 m (C≡N), 1727 s 
(Ester C=O), 1653 m (C=C), 1519 m (C=C), 1349 s (N=O). 
HRMS (ESI) [M+H]+ m/z calcd. for C30H30N4O8: 573.1980, found 573.1984. 
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4.3.6 Synthesis of modified peptide 3e 
 
Modified peptide 3e was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 4-cyanostyrene (0.173 mL, 1.440 mmol), using the general procedure in Section 
4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3e and the mono-olefinated peptide in a ratio of 5:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3e as a 
yellow solid (0.145 g, 76%); m.p. 209-211 °C, Rf 0.40 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 2.00 (3H, s, Acetyl-CH3), 3.36 (1H, dd, J = 14.4, J = 8.3, 
Phe-CHH), 3.48-3.54 (4H, m, Phe-CHH / Ester-CH3), 3.82 (1H, dd, J = 16.6, J = 5.3, 
Gly-CHH), 3.90 (1H, dd, J = 16.6, J = 5.3, Gly-CHH), 4.75 (1H, dt, J = 8.0, J = 6.5, Phe-
α-CH), 6.08 (1H, br t, J = 5.3, Gly-NH), 6.75 (1H, d, J = 8.0, Phe-NH), 7.02 (2H, d, J = 
15.9, Alkene-CH), 7.35 (1H, t, J = 7.8, Ar-H),  7.62-7.64 (3H, m, Ar-H), 7.66-7.71 (9H, m, 
Ar-H / Alkene-CH).   
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 31.9 (Phe-CH2), 43.2 (Gly-CH2), 
52.8 (Ester-CH3), 53.2 (Phe-α-CH), 110.9 (Ar-C), 119.0 (Ar-C), 126.5 (Ar-C), 127.2 (Ar-
C), 127.9 (Ar-C), 129.4 (Alkene-C=C), 130.0 (Alkene-C=C), 132.5 (Ar-C), 132.6 (Ar-C), 
137.0 (Ar-C), 141.5 (Ar-C), 168.5 (C=O), 170.6 (C=O), 171.7 (C=O). 
IR Umax /cm-1 (solid) 3301 m (N-H), 3090 w (C-H), 2958 w (C-H), 1728 s (Ester C=O), 
1653 m (C=C), 1518 m (C=C), 1262 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C32H29N4O4: 533.2183, found 533.2181. 
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4.3.7 Synthesis of modified peptide 3f 
 
Modified peptide 3f was prepared from Ac-Gly-Phe-OMe (0.100 g, 0.359 mmol) and 4-
vinylbiphenyl (0.260 g, 1.440 mmol), using the general procedure in Section 4.3. The 1H 
NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 3f 
and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3f as 
an off-white solid (0.075 g, 33%); m.p. 246-249 °C, Rf 0.52 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.83 (3H, s, Acetyl-CH3), 3.55 (2H, d, J = 6.9, Phe-CH2), 
3.57 (3H, s, Ester-CH3), 3.75 (1H, dd, J = 16.8, J = 5.0, Gly-CHH), 3.82 (1H, dd, J = 
16.8, J = 5.0, Gly-CHH), 4.82 (1H, dt, J = 7.5, J = 6.9, Phe-α-CH), 5.81 (1H, br t, J = 5.0, 
Gly-NH), 6.34 (1H, br d, J = 7.5, Phe-NH), 7.07 (2H, d, J = 15.9, Alkene-CH), 7.32-7.39 
(4H, m, Ar-H), 7.45-7.48 (4H, m, Ar-H), 7.52 (2H, d, J = 15.9, Alkene-CH), 7.60-7.68 
(13H, m, Ar-H). 
13C{1H} NMR (100 MHz, DMSO-d6) δ 22.4 (Acetyl-CH3), 30.7 (Phe-CH2), 41.7 (Gly-CH2), 
52.1 (Ester-CH3), 53.2 (Phe-α-CH), 126.0 (Ar-C), 126.5 (Ar-C), 126.6 (Ar-C), 126.9 
(Alkene-C=C), 127.0 (Ar-C), 127.4 (Ar-C), 127.5 (Ar-C), 129.0 (Ar-C), 129.1 (Ar-C), 
130.0 (Ar-C), 130.6 (Ar-C), 132.9 (Alkene-C=C), 136.5 (Ar-C), 139.3 (Ar-C), 139.7 (Ar-
C), 169.2 (C=O), 169.5 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3266 m (N-H), 3029 w (C-H), 2924 w (C-H), 1725 s (Ester C=O), 
1633 s (Amide C=O), 1601 m (C=C), 1518 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C42H39N2O4: 635.2904 found: 635.2895. 
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4.3.8 Synthesis of modified peptide 3g 
 
Modified peptide 3g was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 2-vinylnapthalene (0.222 g, 1.440 mmol), using the general procedure in Section 
4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3g and the mono-olefinated peptide in a ratio of 3:1. Purification by flash column 
chromatography (50% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 3g as an off-white solid (0.079 g, 38%); m.p. 224-227 °C, Rf 0.54 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, DMSO-d6) δ 1.77 (3H, s, Acetyl-CH3), 3.48-3.52 (5H, m, Ester-CH3 / 
Phe-CH2), 3.61 (1H, dd, J = 16.5, J = 5.7, Gly-CHH), 3.65 (1H, dd, J = 16.5, J = 5.7, Gly-
CHH), 4.57 (1H, dt, J = 7.9, J = 6.5, Phe-α-CH), 7.28 (2H, d, J = 16.0, Alkene-CH2), 7.33 
(1H, t, J = 7.8, Ar-H), 7.45-7.52 (4H, m, Ar-H), 7.69 (2H, d, J = 7.8, Ar-H), 7.72 (2H, d, J 
= 16.0, Alkene-CH), 7.88-7.90 (4H, m, Ar-H), 7.92-7.96 (4H, m, Ar-H), 7.99 (1H, br t, J = 
6.5, Phe-NH), 8.05 (2H, s, Ar-H), 8.64 (1H, br d, J = 8.2, Ar-H). 
13C{1H} NMR (100 MHz, DMSO-d6) δ 22.9 (Acetyl-CH3), 31.4 (Phe-CH2), 42.4 (Gly-CH2), 
52.7 (Ester-CH3), 53.7 (Phe-α-CH), 124.0 (Ar-C), 125.5 (Ar-C), 126.1 (Ar-C), 126.5 (Ar-
C), 126.7 (Alkene-C=C), 127.4 (Ar-C), 127.6 (Ar-C), 128.0 (Ar-C), 128.2 (Ar-C), 131.2 
(Alkene-C=C), 132.7 (Ar-C), 133.0 (Ar-C), 133.3 (Ar-C), 134.9 (Ar-C), 137.4 (Ar-C), 
169.2 (C=O), 169.5 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3289 m (N-H), 2958 w (C-H), 1726 s (Ester C=O), 1636 m (C=C), 
1508 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C38H35N2O4: 583.2591 found 583.2579. 
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4.3.9 Synthesis of modified peptide 3h 
 
Modified peptide 3h was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) 
and 4-fluorostyrene (0.172 mL, 1.440 mmol), using the general procedure in Section 
4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3h and the mono-olefinated peptide in a ratio of 5:1. Purification by flash column 
chromatography (50% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 3h as an off-white solid (0.128 g, 69%); m.p. 190-193 °C, Rf 0.25 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.90 (3H, s, Acetyl-CH3), 3.42 (1H, dd, J = 14.5, J = 7.3, 
Phe-CHH), 3.45 (1H, dd, J = 14.5, J = 6.4, Phe-CHH), 3.53 (3H, s, Ester-CH3), 3.72-3.76 
(1H, m, Gly-CHH), 3.82 (1H, dd, J = 16.5, J = 5.0, Gly-CHH), 4.77 (1H, dt, J = 7.5, J = 
7.3, Phe-α-CH), 6.03 (1H, br t, J = 5.0, Gly-NH), 6.59 (1H, br d, J = 7.5, Phe-NH), 6.96 
(2H, d, J = 16.0, Alkene-CH3), 7.07 (4H, t, J = 8.7, Ar-H), 7.30 (1H, t, J = 7.8, Ar-H), 7.38 
(2H, d, J = 16.0, Alkene-CH3), 7.54-7.57 (6H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 31.3 (Phe-CH2), 42.9 (Gly-CH2), 
52.7 (Ester-CH3), 53.1 (Phe-α-C), 115.6 (Ar-C), 115.8 (Ar-C), 125.7 (Ar-C), 125.8 
(Alkene-C=C), 127.7 (Ar-C), 128.3 (Ar-C), 128.3 (Ar-C), 130.5 (Alkene-C=C), 131.6 (Ar-
C), 133.4 (Ar-C), 137.7 (Ar-C), 161.2 (Ar-C-F), 163.7 (Ar-C-F), 168.3 (C=O), 170.4 
(C=O), 171.7 (C=O). 
IR Umax /cm-1 (solid) 3298 m (N-H), 3066 w (C-H), 2930 w (C-H), 1726 s (Ester C=O), 
1630 m (Amide C=O), 1507 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C30H29F2N2O4: 519.2090 found: 519.2086.  
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4.3.10 Synthesis of modified peptide 3i 
 
Modified peptide 3i was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) and 
4-chlorostyrene (0.173 mL, 1.440 mmol), using the general procedure in Section 4.3. 
The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3i and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 3i as a 
yellow solid (0.121 g, 61%); m.p. 234-238 °C, Rf 0.53 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.93 (3H, s, Acetyl-CH3), 3.41-3.51 (2H, m, Phe-CH2), 3.52 
(3H, s, Ester-CH3), 3.74 (1H, dd, J = 16.8, J = 5.0, Gly-CHH), 3.82 (1H, dd, J = 16.8, J = 
5.0, Gly-CHH), 4.76 (1H, dt, J = 7.4, J = 7.1, Phe-α-CH), 5.87 (1H, m, Gly-NH), 6.39 
(1H, br d, J = 7.4, Phe-NH), 6.96 (2H, d, J = 16.0, Alkene-CH), 7.31 (1H, t, J = 8.2, Ar-
H), 7.36 (4H, d, J = 8.5, Ar-H), 7.45 (2H, d, J = 16.0, Alkene-CH), 7.52 (4H, d, J = 8.2, 
Ar-H), 7.57 (2H, d, J = 8.2, Ar-H). 
13C{1H} NMR (100 MHz, DMSO-d6) δ 22.4 (Acetyl-CH3), 30.6 (Phe-CH2), 41.6 (Gly-CH2), 
52.1 (Ester-CH3), 53.1 (Phe-α-CH), 125.6 (Ar-C), 126.8 (Alkene-C=C), 127.3 (Ar-C), 
128.4 (Ar-C), 128.7 (Ar-C), 129.8 (Ar-C), 132.1 (Alkene-C=C), 133.2 (Ar-C), 136.2 (Ar-
C), 137.0 (Ar-C), 169.2 (C=O), 169.5 (C=O), 171.7 (C=O). 
IR Umax /cm-1 (solid) 3344 m (N-H), 3063 w (C-H), 2949 w (C-H), 1725 s (Ester C=O), 
1659 s (C=C), 1630 s (Amide C=O), 1514 m (C=C), 1437 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C30H29Cl2N2O4: 551.1499, found: 551.1492. 
  
 111 
 
4.3.11 Synthesis of modified peptide 3j 
 
Modified peptide 3j was prepared from Ac-Gly-Phe-OMe (1a) (0.100 g, 0.359 mmol) and 
4-bromostyrene (0.188 mL, 1.440 mmol), using the general procedure in Section 4.3. 
The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 3j and the mono-olefinated peptide in a ratio of 5:1. Purification by flash column 
chromatography (65% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 3j as a yellow solid (0.113 g, 49%); m.p. 177-180 °C, Rf 0.31 (65% EtOAc 
/ pet. ether). 
1H NMR (400 MHz, DMSO-d6) δ  1.76 (3H, s, Acetyl-CH3), 3.24-3.26 (1H, m, Phe-CHH), 
3.36-3.42 (1H, m, Phe-CHH), 3.45 (3H, s, Ester-CH3), 3.54-3.59 (1H, m, Gly-CHH), 
3.64-3.70 (1H, m, Gly-CHH), 4.41-4.47 (1H, m, Phe-α-CH), 7.07 (2H, d, J = 16.0, 
Alkene-CH3), 7.25-7.29 (2H, m, Ar-H), 7.53-7.62 (11H, m, Alkene-CH / Ar-H), 7.94-7.96 
(1H, m, Gly-NH), 8.55-8.57 (1H, m, Phe-NH). 
13C{1H} NMR (100 MHz, DMSO-d6) δ 22.4 (Acetyl-CH3), 30.6 (Phe-CH2), 41.6 (Gly-CH2), 
52.1 (Ester-CH3), 53.1 (Phe-α-CH), 120.7 (Ar-C), 125.6 (Ar-C), 126.9 (Alkene-C=C), 
127.3 (Ar-C), 128.8 (Ar-C), 129.9 (Ar-C), 131.6 (Alkene-C=C), 133.2 (Ar-C), 136.5 (Ar-
C), 137.0 (Ar-C), 169.2 (C=O), 169.5 (C=O), 171.7 (C=O). 
IR Umax /cm-1 (solid) 3309 m (N-H), 2924 w (C-H), 1725 s (Ester C=O), 1639 m (C=C), 
1488 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C30H29Br2N2O4: 641.0471, found: 641.0465. 
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4.4 Scope of the N-protecting group 
4.4.1 Synthesis of N-Phthaloyl glycine (Phth-Gly-OH) (4) 
 
Phthalic anhydride (2.000 g, 13.50 mmol) and glycine (0.780 g, 10.39 mmol) were 
slurried in toluene before the addition of triethylamine (1.88 mL, 13.50 mmol). The 
resulting suspension was refluxed under Dean-Stark conditions for 10 h. After allowing 
the mixture to cool to room temperature, the toluene was removed by rotary evaporation 
to give a crude oil. The oil was suspended in water and acidified using conc. HCl(aq.) (3 
mL) to give a white solid that was isolated by filtration and dried on the filter pad to afford 
off-white needles of Phth-Gly-OH (4) (2.005 g, 94%), m.p. 190-192 °C. 
1H NMR (400 MHz, CDCl3) δ 4.49 (2H, s, Gly-CH3), 7.76 (2H, dd, J = 5.5, J = 3.1, Ar-H), 
7.90 (2H, dd, J = 5.5, J = 3.1, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 38.5 (Gly-CH2), 123.7 (Phth-CH), 131.9 (Phth-C), 
134.3 (Phth-CH), 167.4 (C=O), 171.6 (C=O). 
IR Umax/cm-1 (solid) 3559 m (O-H), 3051 w (C-H), 2988 w (C-H), 2937 w (C-H), 1773 s 
(Phth C=O), 1710 s (carboxylic acid C=O), 1610 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C10H8NO2: 206.0448, found: 206.0448. 
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4.4.2 Phth-Gly-Phe-OMe (5) 
 
Peptide 5 was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and Phth-glycine (4) (0.205 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 5 as a 
white solid (0.231 g, 63%); m.p. 172-173 °C. 
1H NMR (400 MHz, CDCl3) δ 3.09 (1H, dd, J = 13.7, J = 5.5, Phe-CHH), 3.16 (1H, dd, J 
= 13.7, J = 5.5, Phe-CHH), 3.73 (3H, s, Ester-CH3) 4.35 (2H, dt, J = 17.4, J = 16.5, Gly-
CH2), 4.87 (1H, dt, J = 7.3, J = 5.5, Phe-α-CH), 6.36 (1H, m, Phe-NH), 7.07-7.09 (2H, m, 
Ar-H), 7.17-7.27 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 37.5 (Phe-CH2), 40.5 (Gly-CH2), 52.5 (Ester-CH3), 
53.3 (Phe-α-CH), 123.6 (Ar-C), 127.1 (Ar-C), 128.5 (Ar-C), 129.3 (Ar-C), 131.9 (Ar-C), 
134.2 (Ar-C), 135.4 (Ar-C), 165.6 (C=O), 167.6 (C=O), 171.5 (C=O). 
IR Umax /cm-1 (solid) 3308 m (N-H), 3032 s (C-H), 2950 s (C-H), 1776 s (Ester C=O), 
1714 s (C=O), 1659 s (Amide C=O), 1543 m (C=C), 1417 m (C=C), 1206 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C20H19N2O5: 367.1288, found: 367.1289. 
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4.4.3 Fmoc-Gly-Phe-OMe (6a) 
 
Peptide 6a was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and Fmoc-glycine (0.297 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 6a as a 
white solid (0.307 g, 67%); m.p. 127-128 °C. 
1H NMR (400 MHz, CDCl3) δ 3.08-3.18 (2H, m, Phe-CH2), 3.74 (3H, s, Ester-CH3), 3.82-
3.94 (2H, m, Gly-CH2), 4.22 (1H, br dd, J = 7.2, J = 7.0, Fmoc-CH), 4.41 (2H, br d, J = 
7.2, Fmoc-CH3), 4.90 (1H, dt, J = 7.6, J = 6.0, Phe-α-CH), 5.34-5.36 (1H, m, Gly-NH), 
6.31 (1H, br d, J = 7.6, Phe-NH), 7.07 (2H, br d, J = 6.4, Ar-H), 7.21-7.28 (3H, m, Ar-H), 
7.32 (2H, t, J = 7.3, Fmoc-Ar-H), 7.41 (2H, t, J = 7.3, Fmoc-Ar-H), 7.59 (2H, br d, J = 7.3, 
Fmoc-Ar-H), 7.78 (2H, d, J = 7.3, Fmoc-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 37.8 (Phe-CH2), 44.3 (Gly-CH2), 47.0 (Fmoc-CH), 
52.4 (Ester-CH3), 53.1 (Phe-α-CH), 67.3 (Fmoc-CH2), 120.0 (Ar-C), 125.0 (Ar-C), 127.1 
(Ar-C), 127.2 (Ar-C), 127.7 (Ar-C), 128.6 (Ar-C), 129.2 (Ar-C), 135.5 (Ar-C), 141.2 (Ar-
C), 143.7 (Ar-C), 156.4 (C=O), 168.5 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3302 m (N-H), 3029 s (C-H), 2950 s (C-H), 1724 s (Ester C=O), 
1665 s (Amide C=O), 1515 m (C=C), 1479 m (C=C). 
HRMS (ESI) [M+H+] m/z calcd. for C27H27N2O5: 459.1914, found: 459.1908. 
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4.4.4 Boc-Gly-Phe-OMe (6b) 
 
Peptide 6b was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and Boc-glycine (0.175 g, 1.00 mmol), using the procedure in Section 
4.2.1., to afford 6b as a colourless oil (0.205 g, 61%). 
1H NMR (400 MHz, CDCl3) δ 1.44 (9H, s, Boc-(CH3)3), 3.08 (1H, dd, J = 13.8, J = 6.0, 
Phe-CHH), 3.13 (1H, dd, J = 13.8, J = 6.0, Phe-CHH), 3.70-3.84 (5H, m, Ester-CH3 / 
Gly-CH2), 4.87 (1H, dt, J = 7.5, J = 6.0, Phe-α-CH), 5.29 (1H, m, Gly-NH), 6.74 (1H, br d, 
J = 7.5, Phe-NH), 7.09-7.11 (2H, m, Ar-H) 7.22-7.30 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 28.2 (Boc-(CH3)3), 37.8 (Phe-CH2), 44.0 (Gly-CH2), 
52.3 (Ester-CH3), 53.0 (Phe-α-CH), 80.0 (Boc-C), 127.0 (Ar-C), 128.5 (Ar-C), 129.1 (Ar-
C), 135.6 (Ar-C), 155.9 (C=O), 169.2 (C=O), 171.7 (C=O). 
IR Umax /cm-1 (oil) 3251 m (N-H), 3071 s (C-H), 2979 s (C-H), 1753 s (Ester C=O), 1741 s 
(Carbamate C=O), 1536 s (C=C), 1497 m (C=C), 1436 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C17H24N2O5:  337.1758, found: 337.1756. 
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4.4.5 Cbz-Gly-Phe-OMe (6c) 
 
Peptide 6c was synthesised from L-Phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and Cbz-glycine (0.209 g, 1.00 mmol), using the procedure in Section 
4.2.1., to afford 6c as a colourless oil (0.193 g, 52%). 
1H NMR (400 MHz, CDCl3) δ 3.03 (1H, dd, J = 13.7, J = 6.0, Phe-CHH), 3.10 (1H, dd, J 
= 13.7, J = 6.0, Phe-CHH), 3.67 (3H, s, Ester-CH3), 3.75-3.87 (2H, m, Gly-CH2), 4.86 
(1H, dt, J = 7.8, J = 6.0, Phe-α-CH), 5.08 (2H, s, Cbz-CH2) 5.71 (1H, m, Gly-NH), 6.82 
(1H, m, Phe-NH), 7.07 (2H, br d, J = 6.4, Ar-H) 7.18-7.26 (3H, m, Ar-H), 7.29- 7.33 (5H, 
m, Cbz-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 37.7 (Phe-CH2), 44.2 (Gly-CH2), 52.3 (Ester-CH3), 
53.0 (Phe-α-CH), 67.0 (Z-CH2), 127.0 (Ar-C), 127.9 (Ar-C), 128.1 (Ar-C), 128.4 (Ar-C), 
128.9 (Ar-C), 129.1 (Ar-C), 135.5 (Ar-C), 136.0 (Ar-C), 156.5 (C=O), 168.8 (C=O), 171.7 
(C=O). 
IR Umax /cm-1 (oil) 3317 m (N-H), 3030 s (C-H), 2952 s (C-H), 1723 s (Carbamate C=O), 
1656 s (Amide C=O), 1604 m (C=C), 1518 m (C=C), 1215 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C20H23N2O5: 371.1601, found: 371.1602. 
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4.4.6 Synthesis of modified peptide 8a 
 
Modified peptide 8a was prepared from Fmoc-Gly-Phe-OMe (6a) (0.165 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
8a and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 8a as an off-white solid (0.124 g, 52%); m.p. 145-148 °C, Rf 0.34 (25% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 3.48 (2H, br d, J = 6.9, Phe-CH2), 3.53 (3H, s, Ester-CH3), 
3.70-3.74 (2H, m, Gly-CH2), 4.16-4.19 (1H, m, Fmoc-CH), 4.31-4.33 (2H, m, Fmoc-CH2), 
4.81 (1H, dt, J = 7.3, J = 6.9, Phe-α-CH), 5.10 (1H, m, Gly-NH), 6.51 (1H, br d, J = 7.3 
Phe-NH),  7.00 (2H, d, J = 15.8, Alkene-CH), 7.26-7.32 (6H, m, Ar-H), 7.35-7.42 (6H, m, 
Ar-H), 7.48 (2H, d, J = 15.8, Alkene-CH), 7.55-7.58 (7H, m, Ar-H), 7.75-7.77 (2H, m, Ar-
H). 
13C{1H} NMR (100 MHz, CDCl3) δ 31.4 (Phe-CH2), 44.3 (Gly-CH2),  47.1 (Fmoc-CH), 
52.8 Ester-CH3), 53.2 (Phe-α-CH), 67.2 (Fmoc-CH2), 120.1 (Ar-C), 124.8 (Ar-C), 125.2 
(Ar-C), 125.9 (Ar-C), 126.3 (Alkene-C=C), 126.8 (Ar-C), 127.2 (Ar-C), 127.8 (Ar-C), 
128.1 (Ar-C), 128.9 (Ar-C), 131.8 (Alkene-C=C), 131.9 (Ar-C), 137.3 (Ar-C), 137.9 (Ar-
C), 141.4 (Ar-C), 143.9 (Ar-C), 156.4 (C=O), 168.4 (C=O), 171.9 (C=O). 
IR Umax /cm-1 (solid) 3300 m (N-H), 3057 s (C-H), 2949 s (C-H), 1725 s (Ester C=O), 
1691 s (C=O), 1645 s (Amide C=O), 1530 m (C=C), 1448 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C43H39N2O5: 663.2853 found: 663.2851. 
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4.4.7 Synthesis of modified peptide 8b 
 
Modified peptide 8b was prepared from Boc-Gly-Phe-OMe (6b) (0.121 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
8b and the mono-olefinated peptide in a ratio of 8:1. Purification by flash column 
chromatography (50% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 8b as an off-white solid (0.138 g, 71%); m.p. 164-166 °C, Rf 0.45 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.41 (9H, s, Boc-(CH3)3), 3.39 (1H, dd, J = 14.4, J = 7.1, 
Phe-CHH), 3.48 (1H, d, J = 14.4, J = 7.1, Phe-CHH), 3.51 (3H, s, Ester-CH3), 3.62-3.70 
(2H, m, Gly-CH2), 4.80 (1H, app q, J = 7.1, Phe-α-CH), 4.88-4.93 (1H, m, Gly-NH), 6.68 
(1H, br d, J = 7.1, Phe-NH), 7.01 (2H, d, J = 16.0, Alkene-CH), 7.26-7.31 (3H, m, Ar-H), 
7.38 (4H, t, J = 7.4, Ar-H), 7.49 (2H, d, J = 16.0, Alkene-CH), 7.56-7.59 (6H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 28.2 (Boc-(CH3)3), 31.5 (Phe-CH2), 44.0 (Gly-CH2), 
52.6 (Ester-CH3), 53.0 (Phe-α-CH), 80.1 (Boc-C), 125.7 (Ar-C), 126.1 (Ar-C), 126.7 
(Alkene-C=C), 127.6 (Ar-C), 127.9 (Ar-C), 128.8 (Ar-C), 131.6 (Alkene-C=C), 131.8 (Ar-
C), 137.2 (Ar-C), 137.2 (Ar-C), 137.7 (Ar-C), 155.8 (C=O), 169.8(C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3324 m (N-H), 2977 s (C-H), 1725 s (Ester C=O), 1647 s (Amide 
C=O), 1598 m (C=C), 1449 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C33H37N2O5: 541.2697, found: 541.2692.  
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4.4.8 Synthesis of modified peptide 8c 
 
Modified peptide 8c was prepared from Cbz-Gly-Phe-OMe (6c) (0.133 g, 0.359 mmol) 
styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 1H 
NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 8c 
and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 8c as an off-white solid (0.144 g, 70%); m.p. 177-179 °C, Rf 0.55 (25% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 3.41-3.45 (2H, m, Phe-CH2), 3.51 (3H, s, Ester-CH3), 3.65-
3.76 (2H, m, Gly-CH2), 4.80 (1H, app q, J = 7.3, Phe-α-CH), 5.03 (2H, s, Cbz-CH2), 5.71 
(1H, m, Gly-NH), 6.60 (1H, br d, J = 7.3, Phe-NH), 6.99 (2H, d, J = 16.0, Alkene-CH), 
7.24-7.31 (7H, m, Ar-H), 7.36 (5H, t, J = 7.6, Ar-H), 7.47 (2H, d, J = 16.0, Alkene-CH), 
7.54-7.57 (6H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 31.3 (Phe-CH2), 44.2 (Gly-CH2), 52.7 (Ester-CH3), 
53.0 (Phe-α-CH), 67.1 (Cbz-CH2), 125.7 (Ar-C), 126.1 (Ar-C), 126.7 (Alkene-C=C), 
127.7 (Ar-C), 128.0 (Ar-C), 128.0 (Ar-C), 128.2 (Ar-C), 125.5 (Ar-C), 128.8 (Ar-C), 131.7 
(Alkene-C=C), 131.7 (Ar-C), 136.1 (Ar-C), 137.1 (Ar-C), 137.8 (Ar-C), 156.2 (C=O), 
168.3 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3317 m (N-H), 3029 s (C-H), 2954 s (C-H), 1726 s (Ester C=O), 
1688 s (Amide C=O), 1644 m (C=C), 1533 m (C=C), 1441 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C36H35N2O5: 575.2540 found: 575.2534. 
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4.5 Synthesis of dipeptides 9a-k 
4.5.1 Ac-Ala-Phe-OMe (9a) 
 
Peptide 9a was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-alanine (0.131 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9a as a 
white solid (0.261 g, 89%); m.p. 125-126 °C. 
1H NMR (400 MHz, CDCl3) δ 1.30 (3H, d, J = 7.0, Ala-CH3), 1.93 (3H, s, Acetyl-CH3), 
3.03 (1H, dd, J = 13.7, J = 6.4, Phe-CHH), 3.13 (1H, dd, J = 13.7, J = 6.4, Phe-CHH), 
3.70 (3H, s, Ester-CH3),  4.48 (1H, dq, J = 7.4, J = 6.9, Ala-α-CH), 4.80-4.85 (1H, m, 
Phe-α-CH), 6.33 (1H,  br d, J = 7.4, Ala-NH), 6.81 (1H, br d, J = 7.9, Phe-NH), 7.08-7.10 
(2H, m, Ar-H), 7.18-7.27 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 18.5 (Ala-CH3), 23.1 (Acetyl-CH3), 38.3 (Phe-CH2), 
48.1 (Ala-α-CH), 52.7 (Ester-CH3), 53.8 (Phe-α-CH), 127.1 (Ar-C), 128.5 (Ar-C), 129.2 
(Ar-C), 135.7 (Ar-C), 169.9 (C=O), 171.1 (C=O), 172.1 (C=O). 
IR Umax /cm-1 (solid) 3252 m (N-H), 3075 w (C-H), 2988 w (C-H), 2938 w (C-H), 1753 s 
(Ester C=O), 1637 s (Amide C=O), 1537 m (C=C), 1436 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C15H21N2O4: 293.1496, found: 293.1492. 
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4.5.2 Ac-Val-Phe-OMe (9b) 
 
Peptide 9b was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-valine (0.159 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9b as a 
white solid (0.224 g, 70%); m.p 176-177 °C. 
1H NMR (400 MHz, CDCl3) δ 0.92 (3H, app t, J = 6.4, Val-CH3), 2.00-2.07 (4H, m, 
Acetyl-CH3 / Val-CH3CHCH3) 3.07 (1H, dd, J = 14.0, J = 6.2, Phe-CHH), 3.12 (1H, dd, J 
= 14.0, J = 6.2, Phe-CHH), 3.72 (3H, s, Ester-CH3), 4.28 (1H, dd, J = 9.2, J = 6.9, Val-α-
CH), 4.85 (1H, dd, J = 7.8, J = 6.2, Phe-α-CH), 6.19 (1H, br d, J = 9.2, Val-NH), 6.49 
(1H, br d, J = 7.8, Phe-NH), 7.10-7.12 (2H, m, Ar-H), 7.22-7.30 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 18.1 (Val-CH3), 19.0 (Val-CH3), 23.2 (Acetyl-CH3), 
31.2 (Val-CH), 37.8 (Phe-CH2), 52.3 (Ester-CH3), 53.1 (Phe-α-CH), 58.2 (Val-α-CH), 
127.2 (Ar-C), 128.6 (Ar-C), 129.2 (Ar-C), 135.5 (Ar-C), 170.0 (C=O), 170.9 (C=O), 171.6 
(C=O). 
IR Umax /cm-1 (solid) 3288 m (N-H), 3030 w (C-H), 2954 w (C-H), 1743 s (Ester C=O), 
1643 s (Amide C=O), 1538 m (C=C), 1383 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C17H25N2O4: 321.1809, found: 321.1810. 
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4.5.3 Ac-Ile-Phe-OMe (9c) 
 
Peptide 9c was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-isoleucine (0.173 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9c 
as a white solid (0.234 g, 70%); m.p. 194-195 °C. 
1H NMR (400 MHz, CDCl3) δ 0.85-0.88 (6H, m, Ile-(CH3)2), 1.04-1.14 (1H, m, Ile-
CHHCH3), 1.41-1.51 (1H, m, Ile-CHHCH3), 1.72-1.82 (1H, m, Ile-CH2CHCH3), 1.98 (3H, 
s, Acetyl-CH3), 3.07 (1H, dd, J = 13.7, J = 6.0, Phe-CHH) 3.12 (1H, dd, J = 13.7, J = 6.0, 
Phe-CHH), 3.71 (3H, s, Ester-CH3), 4.26 (1H, dd, J = 8.7, J = 6.5, Ile-α-CH), 4.85 (1H, 
dt, J = 7.8, J = 6.0, Phe-α-CH), 6.07 (1H, br d, J = 6.5, Ile-NH), 6.29 (1H, br d, J = 7.8, 
Phe-NH), 7.08-7.10 (2H, m, Ar-H), 7.21-7.30 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 11.3 (Ile-CH2CH3), 15.2 (Ile-CHCH3), 23.3 (Acetyl-
CH3), 24.9 (Ile-CH), 37.4 (Ile-CH2), 37.8 (Phe-CH2), 52.4 (Ester-CH3), 53.1 (Phe-α-CH), 
57.5 (Ile-α-CH), 127.2 (Ar-C), 128.7 (Ar-C), 129.2 (Ar-C), 135.5 (Ar-C), 169.8 (C=O), 
170.8 (Ar-C), 171.5 (C=O).  
IR Umax /cm-1 (solid) 3296 m (N-H), 2971 w (C-H), 1741 w (Ester C=O), 1663 s (Amide 
C=O), 1647 m (C=C), 1541 m (C=C), 1384 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C18H27N2O4: 335.1965, found: 335.1965. 
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4.5.4 Ac-Leu-Phe-OMe (9d) 
 
Peptide 9d was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-leucine (0.173 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9d as a 
white solid (0.261 g, 78%); m.p. 110-111 °C. 
1H NMR (400 MHz, CDCl3) δ 0.88 (6H, d, J = 5.5, Leu-(CH3)2), 1.43-1.50 (1H, m, Leu-
CH2CH(CH3)2), 1.55-1.64 (2H, m, Leu-CH2), 1.91 (3H, s, Acetyl-CH3), 3.03 (1H, dd, J = 
13.9, J = 6.4, Phe-CHH), 3.10 (1H, dd, J = 13.9, J = 6.4, Phe-CHH), 3.68 (3H, s, Ester-
CH3), 4.45-4.50 (1H, m, Leu-α-CH), 4.79 (1H, dt, J = 7.8, J = 6.4, Phe-α-CH), 6.34 (1H, 
br d, J = 8.2, Leu-NH), 6.83 (1H, br d, J = 7.8, Phe-NH), 7.09-7.11 (2H, m, Ar-H) 7.18-
7.27 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.3 (Leu-CH3), 22.9 (Leu-CH3), 23.1 (Acetyl-CH3), 
24.8 (Leu-CH), 38.0 (Phe-CH2), 41.2 (Leu-CH2), 51.6 (Leu-α-CH), 52.4 (Ester-CH3), 53.4 
(Phe-α-CH), 127.0 (Ar-C), 128.5 (Ar-C), 129.2 (Ar-C), 135.9 (Ar-C), 170.3 (C=O), 171.9 
(C=O), 172.3 (C=O). 
IR Umax /cm-1 (solid) 3265 m (N-H), 3055 w (C-H), 2896 w (C-H), 1753 s (Ester C=O), 
1687 s (Amide C=O), 1601 m (C=C), 1566 m (C=C). 
HRMS (ESI) [M+H]+ m/z calcd. for C18H27N2O4: 335.1965, found: 335.1963. 
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4.5.5 Ac-Pro-Phe-OMe (9e) 
 
Peptide 9e was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-proline (0.157 g, 1.00 mmol), using the procedure in Section 
4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9e as a 
white solid (0.213 g, 67%); m.p. 106-108 °C. 
1H NMR (400 MHz, CD3OD) δ 1.72-1.80 (1H, m, Pro-CHCHHCH2), 1.88-1.95 (2H, m, 
Pro-CH2CH2CH2), 2.01 (3H, s, Acetyl-CH3), 2.34-2.40 (1H, m, Pro-CHCHHCH2), 2.98 
(1H, dd, J = 14.0, J = 7.8, Phe-CHH), 3.21 (1H, dd, J = 14.0, J = 5.5, Phe-CHH), 3.33 
(2H, t, J = 7.0, Pro-NHCH2CH2), 3.73 (3H, s, Ester-CH3), 4.56 (1H, dd, J = 8.0, J = 7.0, 
Pro-α-CH), 4.83 (1H, dt, J = 7.8, J = 5.5, Phe-α-CH), 7.10-7.15 (2H, m, Ar-H), 7.20-7.30 
(3H, m, Ar-H), 7.54 (1H, br d, J = 5.5, Phe-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.4 (Acetyl-CH3), 24.8 (Pro-CH2), 26.9 (Pro-CH2), 
37.9 (Phe-CH2), 48.0 (Pro-CH2), 52.3 (Ester-CH3), 53.1 (Phe-α-CH), 59.3 (Pro-α-CH3), 
126.8 (Ar-C), 128.2 (Ar-C), 129.3 (Ar-C), 136.3 (Ar-C), 170.8 (C=O), 170.8 (C=O), 171.8 
(C=O). 
IR Umax /cm-1 (solid) 3524 m (N-H), 3065 w (C-H), 2900 w (C-H), 1732 s (Ester C=O), 
1644 s (Amide C=O), 1497 m (C=C), 1292 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C17H23N2O4: 319.1652, found: 319.1652. 
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4.5.6 Ac-Phe-Phe-OMe (9f) 
 
Peptide 9f was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-phenylalanine (0.207 g, 1.00 mmol), using the procedure in 
Section 4.2.1, and isolated as a white solid (0.195 g, 53%); m.p. 170-171 °C. 
1H NMR (400 MHz, CDCl3) δ 1.90 (3H, s, Acetyl-CH3), 2.94-3.12 (4H, m, Phe-CH2), 3.65 
(3H, s, Ester-CH3), 4.74 (2H, m, Phe-α-CH (x2)), 6.57 (1H, br d, J = 8.2, Phe-NH), 6.72 
(1H, d, J = 7.8, Phe-NH), 7.02-7.04 (2H, m, Ar-H) 7.15-7.26 (8H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 37.8 (Phe-CH2), 38.1 (Phe-CH2), 
52.2 (Ester-CH3), 53.4 (Phe-α-CH), 54.2 (Phe-α-CH), 126.8 (Ar-C), 127.0 (Ar-C), 128.4 
(Ar-C), 129.1 (Ar-C), 129.2 (Ar-C), 135.6 (Ar-C), 136.3 (Ar-C), 170.1 (C=O), 170.8 
(C=O), 171.2 (C=O). 
IR Umax /cm-1 (solid) 3308 m (N-H), 3066 w (C-H), 2973 w (C-H), 1733 s (Ester C=O), 
1646 s (Amide C=O), 1538 m (C=C), 1435 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C21H25N2O4: 369.1809, found: 369.1813. 
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4.5.7 Ac-Tyr-Phe-OMe (9g) 
 
Peptide 9g was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-tyrosine (0.223 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9g 
as a cream solid (0.311 g, 81%); m.p. 57-59 °C. 
1H NMR (400 MHz, CDCl3) δ 1.92 (3H, s, Acetyl-CH3), 2.79-2.81 (1H, m, Tyr-CHH), 
2.89-2.93 (1H, m, Tyr-CHH), 2.95-3.00 (1H, m, Phe-CHH), 3.06-3.11 (1H, m, Phe-CHH), 
3.67 (3H, s, Ester-CH3), 4.58-4.64 (1H, m, Tyr-α-CH), 4.73-4.48 (1H, m, Phe-α-CH), 
6.30 (1H, d, J = 8.0, Tyr-NH), 6.45 (1H, d, J = 7.8, Phe-NH), 6.70 (2H, d, J = 8.9, Phe-
Ar-H), 6.98-7.04 (4H, m, Tyr-Ar-H), 7.21-7.26 (3H, m, Phe-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 23.0 (Acetyl-CH3), 37.5 (Tyr-CH2), 37.8 (Phe-CH2), 
52.4 (Ester-CH3), 53.5 (Phe-α-CH), 54.5 (Tyr-α-CH), 115.6 (Ar-C), 127.1 (Ar-C), 127.5 
(Ar-C), 128.6 (Ar-C), 129.2 (Ar-C), 130.3 (Ar-C), 135.5 (Ar-C), 155.4 (Ar-C), 170.4 
(C=O), 170.8 (C=O), 171.4 (C=O).  
IR Umax /cm-1 (solid) 3274 m (N-H), 2947 s (C-H), 1726 s (Ester C=O), 1647 m (C=C), 
1515 m (C=C), 1435 m (C-H), 1220 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C21H25N2O5: 385.1763, found: 385.1762.  
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4.5.8 Ac-Trp-Phe-OMe (9h) 
 
Peptide 9h was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-tryptophan (0.246 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9h 
as a cream solid (0.371 g, 91%); m.p. 73-76 °C. 
1H NMR (400 MHz, CDCl3) δ 1.93 (Acetyl-CH3), 2.89 (1H, dd, J = 13.7, J = 6.2, Phe-
CHH), 2.99 (1H, dd, J = 13.7, J = 6.2, Phe-CHH), 3.10 (1H, dd, J = 14.4, J = 7.8, Trp-
CHH), 3.27 (1H, dd, J = 14.4, J = 5.0, Trp-CHH), 3.61 (3H, s, Ester-CH3), 4.65-4.74 (2H, 
m, Trp-α-CH, Phe-α-CH), 6.23 (1H, br d, J = 7.3, Trp-NH), 6.33 (1H, br d, J = 7.8, Phe-
NH), 6.85-6.87(2H, m, Phe-Ar-H), 7.01 (1H, d, J = 2.3, Trp-Ar-H), 7.08-7.19 (5H, m, 
Phe-Ar-H / Trp-Ar-H), 7.33 (1H, d, J = 8.0, Trp-Ar-H), 7.67 (1H, d, Trp-Ar-H), 8.30 (1H, 
br s, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.2 (Acetyl-CH3), 28.2 (Trp-CH2), 37.1 (Phe-CH2), 
52.2 (Ester-CH3), 53.3 (Phe-α-CH), 53.7 (Trp-α-CH), 110.4 (Ar-C), 111.2 (Ar-C), 118.7 
(Ar-C), 119.7 (Ar-C), 122.1 (Ar-C), 123.4 (Ar-C), 127.0 (Ar-C), 128.5 (Ar-C), 129.1 (Ar-
C), 135.5 (Ar-C), 136.1 (Ar-C), 170.0 (C=O), 170.9 (C=O), 171.3 (C=O). 
IR Umax /cm-1 (solid) 3291 m (O-H), 3064 s (C-H), 2969 s (C-H), 1737 s (Ester C=O), 
1637 m (C=C), 1541 m (C=C), 1445 m (C-H), 1216 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C23H26N3O4: 408.1918, found: 408.1923. 
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4.5.9 Ac-Thr-Phe-OMe (9i) 
 
Peptide 9i was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-threonine (0.162 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9i 
as a cream solid (0.259 g, 78%); m.p. 127-129 °C. 
1H NMR (400 MHz, CDCl3) δ 1.13 (3H, d, J = 6.5, Thr-CH3), 1.98 (3H, Acetyl-CH3), 3.00 
(1H, dd, J = 14.0, J = 7.8, Phe-CHH), 3.18 (1H, dd, J = 14.0, J = 5.4, Phe-CHH), 3.74 
(3H, s, Ester-CH3), 4.29 (1H, ddd, J = 13.0, J = 6.5, J = 2.5, Thr-CH), 4.36 (1H, dd, J = 
7.7, J = 2.5, Thr-α-CH), 4.81 (1H, dt, J = 7.9, J = 5.4, Phe-α-CH), 6.49 (1H, br d, J = 7.7, 
Thr-NH), 7.12-7.14 (2H, m, Phe-Ar-H), 7.21-7.30 (4H, m, Phe-Ar-H /Phe-NH).  
13C{1H} NMR (100 MHz, CDCl3) δ 17.8 (Thr-CH3), 23.0 (Acetyl-CH3), 37.6 (Phe-CH2), 
52.5 (Ester-CH3), 53.3 (Phe-α-CH), 56.3 (Thr-α-CH), 66.3 (Thr-CH), 127.1 (Ar-C), 128.6 
(Ar-C), 129.1 (Ar-C), 135.7 (Ar-C), 171.0 (C=O), 171.0 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3273 m (N-H), 3062 s (C-H), 2928 s (C-H), 1737 s (Ester C=O), 
1640 m (C=C), 1517 m (C=C), 1435 m (C-H), 1214 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C16H23N2O5: 323.1607, found: 323.1605.  
  
 129 
 
4.5.10 Ac-Cys-Phe-OMe (9j) 
 
Peptide 9j was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-cysteine (0.163 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9j 
as a cream solid (0.272 g, 84%); m.p. 121-123 °C. 
1H NMR (400 MHz, CDCl3) δ 1.66 (1H, dd, J = 10.1, J = 7.8, Cys-SH), 2.00 (3H, s, 
Acetyl-CH3), 2.66 (1H, ddd, J = 14.2, J = 10.1, J = 6.9, Cys-CHH), 2.97-3.07 (2H, m, 
Cys-CHH / Phe-CHH), 3.19 (1H, dd, J = 13.7, J = 5.5, Phe-CHH), 3.76 (Ester-CH3), 
4.55-4.59 (1H, m, Cys-α-CH), 4.81-4.86 (1H, m, Phe-α-CH), 6.37 (1H, d, J = 7.8, Cys-
NH), 6.69 (1H, d, J = 7.8, Phe-NH), 7.11-7.13 (2H, m, Phe-Ar-H), 7.23-7.32 (3H, m, Phe-
Ar-H).   
13C{1H} NMR (100 MHz, CDCl3) δ 23.1 (Acetyl-CH3), 26.4 (Cys-CH2), 37.6 (Phe-CH2), 
52.5 (Ester-CH3), 53.4 (Phe-α-CH), 53.9 (Cys-α-CH), 127.3 (Ar-C), 128.7 (Ar-C), 129.2 
(Ar-C), 135.5 (Ar-C), 169.4 (C=O), 170.1 (C=O), 171.5 (C=O).  
IR Umax /cm-1 (solid) 3266 m (N-H), 3069 s (C-H), 2939 s (C-H), 1736 s (Ester C=O), 
1635 m (C=C), 1541 m (C=C), 1481 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C15H21N2O4S: 325.1222, found: 325.1218. 
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4.5.11 Ac-Met-Phe-OMe (9k) 
 
Peptide 9k was synthesised from L-phenylalanine methyl ester hydrochloride (0.539 g, 
2.50 mmol) and N-acetyl-L-methionine (0.191 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 9k 
as a white solid (0.268 g, 76%); m.p. 110-111 °C. 
1H NMR (400 MHz, CDCl3) δ 1.89-2.03 (5H, m, Met-SCH3 / Met-CH2CH2S), 2.04 (3H, s, 
Acetyl-CH3), 2.47-2.60 (2H, m, Met-CHCH2CH2), 3.06 (1H, dd, J = 13.7, J = 6.0, Phe-
CHH), 3.13 (1H, dd, J = 13.7, J = 6.0, Phe-CHH), 3.72 (3H, s, Ester-CH3), 4.58 (1H, dt, J 
= 7.8, J = 6.9, Met-α-CH), 4.80-4.85 (1H, m, Phe-α-CH), 6.26 (1H, br d, J = 7.8, Met-
NH), 6.68 (1H, br d, J = 8.2, Phe-NH), 7.10-7.12 (2H, m, Ar-H), 7.22-7.31 (3H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 14.9 (Met-CH3), 23.2 (Acetyl-CH3), 29.9 (Met-SCH2), 
31.3 (Met-CH2), 37.7 (Phe-CH2), 51.8 (Met-α-CH), 52.4 (Ester-CH3), 53.2 (Phe-α-CH), 
127.2 (Ar-C), 128.7 (Ar-C), 129.2 (Ar-C), 135.5 (Ar-C), 169.9 (C=O), 170.8 (C=O), 171.5 
(C=O). 
IR Umax /cm-1 (solid) 3287 m (N-H), 3061 w (C-H), 2952 w (C-H), 2914 w (C-H), 1750 s 
(Ester C=O), 1641 s (Amide C=O). 1537 m (C=C), 1367 m (C=C), 1158 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C17H25N2O4S: 353.1530, found: 353.1529. 
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4.6 Modification of Phe dipeptides 9a-f, 9k 
4.6.1 Synthesis of modified peptide10a 
 
Modified peptide 10a was prepared from Ac-Ala-Phe-OMe (9a) (0.105 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
10a and the mono-olefinated peptide in a ratio of 8:1. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 10a as 
an off-white solid (0.135 g, 76%); m.p. 193-194 °C, Rf 0.48 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.22 (3H, d, J = 7.3, Ala-CH3), 1.83 (3H, s, Acetyl-CH3), 
3.44 (2H, d, J = 7.3, Phe-CH2), 3.56 (3H, s, CO2CH3), 4.38 (1H, dq, J = 7.3, J = 6.8, Ala-
α-CH), 4.76 (1H, dq, J = 7.8, J = 7.3, Phe-α-CH), 6.07 (1H, br d, J = 7.3, Ala-NH), 6.65 
(1H, br d, J = 7.8, Phe-NH), 7.01 (2H, d, J = 15.8, Alkene-CH), 7.26 - 7.31 (3H, m, Ar- 
H), 7.38 (4H, dt, J = 7.8, J = 7.3, Ar-H), 7.47 (2H, d, J = 15.8, Alkene-CH), 7.56 (2H, d, J 
= 7.8, Ar-H), 7.58 (4H, br d, J = 7.3, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 18.4 (Ala-CH3), 22.9 (Acetyl-CH3), 31.3 (Phe-CH2), 
48.6 (Ala-α-CH), 52.6 (Ester-CH3), 53.1 (Phe-α-CH), 125.8 (Ar-C), 126.1 (Alkene-C=C), 
126.7 (Ar-C), 127.6 (Ar-C), 127.9 (Ar-C), 128.7 (Ar-C), 131.8 (Ar-C), 131.9 (Alkene-
C=C), 137.1 (Ar-C), 137.8 (Ar-C), 169.7 (C=O), 171.8 (C=O), 171.8 (C=O);  
IR Umax /cm-1 (solid) 3290 m (N-H), 3057 w (C-H), 2979 w (C-H), 1732 s (Ester C=O), 
1632 m (C=C), 1532 m (C=C), 1260 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C31H33N2O4: 497.2435 found: 497.2428. 
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4.6.2 Synthesis of modified peptide 10b 
 
Modified peptide 10b was prepared from Ac-Val-Phe-OMe (9b) (0.115 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
10b and the mono-olefinated peptide in a ratio of 5:1. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10b as an off-white solid (0.121 g, 64%); m.p. 210-213 °C; Rf 0.36 (25% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.78 (6H, dd, J = 6.8, J = 6.3, Val-(CH3)2), 1.88-1.96 (4H, 
m, Acetyl-CH3 / Val-CH3CHCH3), 3.37 (1H, dd, J = 14.3, J = 8.5, Phe-CHH), 3.45 (1H, 
dd, J = 14.3, J = 6.5, Phe-CHH), 3.63 (3H, s, Ester-CH3), 4.15 (1H, dd, J = 8.5, J = 6.5, 
Val-α-CH), 4.72 (1H, dt, J = 8.5, J = 6.5, Phe-α-CH), 5.99 (1H, br d, J = 6.5, Val-NH), 
6.34 (1H, br d, J = 6.5, Phe-NH), 7.04 (2H, d, J = 15.9, Alkene-CH), 7.28-7.33 (3H, m, 
Ar-H), 7.39 (4H, t, J = 7.8, Ar-H), 7.49 (2H, d, J = 15.9, Alkene-CH), 7.55 (2H, d, J = 7.8, 
Ar-H), 7.61 (4H, d, J = 7.8, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 18.2 (Val-CH3), 19.0 (Val-CH3), 23.2 (Acetyl-CH3), 
31.4 (Val-CH), 35.4 (Phe-CH2), 52.6 (Ester-CH3), 53.3 (Phe-α-CH), 58.2 (Val-α-CH), 
125.4 (Ar-C), 126.2 (Alkene-C=C), 126.6 (Ar-C), 127.8 (Ar-C), 128.0 (Ar-C), 128.9 (Ar-
C), 130.6 (Ar-C), 131.3 (Alkene-C=C), 133.7 (Ar-C), 136.8 (Ar-C), 137.4 (Ar-C), 170.0 
(C=O), 171.1 (C=O), 171.9 (C=O);  
IR Umax /cm-1 (solid) 3268 m (N-H), 3060 w (C-H), 2926 w (C-H), 1736 s (Ester C=O), 
1629 m (C=C), 1538 m (C=C), 1256 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C33H37N2O4: 525.2743, found: 525.2743. 
 133 
 
4.6.3 Synthesis of modified peptide 10c 
 
Modified peptide 10c was prepared from Ac-Ile-Phe-OMe (9c) (0.120 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
10c and the mono-olefinated peptide in a ratio of 10:3. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10c as an off-white solid (0.116 g, 60%); m.p. 198-200 °C, Rf = 0.34 (25% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.73-0.77 (6H, m, Ile-(CH3)2), 0.96-1.04 (1H, m, Ile-
CHHCH3), 1.27-1.35 (1H, m, Ile-CHHCH3), 1.63-1.70 (1H, m, Ile-CH2CHCH3), 1.87 (3H, 
s, Acetyl-CH3), 3.37 (1H, dd, J = 14.5, J = 8.6, Phe-CHH), 3.45 (1H, dd, J = 14.5, J = 
6.8, Phe-CHH), 3.63 (3H, s, Ester-CH3), 4.16 (1H, dd, J = 8.6 Ile-α-CH), 4.70-4.75 (1H, 
m, Phe-α-CH), 5.95 (1H, br d, J = 8.6, Ile-NH), 6.28 (1H, br d, J = 6.8, Phe-NH), 7.05 
(2H, d, J = 16.0, Alkene-CH), 7.28-7.33 (3H, m, Ar-H), 7.38-7.41 (4H, m, Ar-H), 7.49 
(2H, d, J = 16.0, Alkene-CH), 7.56 (2H, d, J = 7.7, Ar-H), 7.61 (4H, br d, J = 7.7, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 11.4 (Ile-CH3), 14.8 (Ile-CHCH3), 23.2 (Acetyl-CH3), 
24.9 (Ile-CH2), 31.3 (Phe-CH2), 37.9 (Ile-CH), 52.6 (Ester-CH3), 53.4 (Phe-α-CH), 57.4 
(Ile-α-CH), 126.0 (Ar-C), 126.1 (Alkene-C=C), 126.8 (Ar-C), 127.8 (Ar-C), 128.0 (Ar-C), 
128.8 (Ar-C), 131.7 (Alkene-C=C), 132.5 (Ar-H), 137.1 (Ar-C), 137.8 (Ar-C), 169.6 
(C=O), 170.7 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3278 m (N-H), 3061 w (C-H), 2923 w (C-H), 1736 s (Ester C=O), 
1632 m (C=C), 1538 m (C=C), 1256 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C34H39N2O4: 539.2904, found: 539.2900. 
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4.6.4 Synthesis of modified peptide 10d 
 
Modified peptide 10d was prepared from Ac-Leu-Phe-OMe (9d) (0.120 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
9d and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (50% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10d as an off-white solid (0.128 g, 66%); m.p. 198-202 °C, Rf = 0.30 
(50% EtOAc / pet. ether).  
1H NMR (400 MHz, CDCl3) δ 0.79 (6H, dd, J = 6.1, J = 5.7, Leu-(CH3)2), 1.36-1.43 (1H, 
m, Leu-CH2CH(CH3)2), 1.46-1.52 (2H, m, Leu-CH2CH), 1.87 (3H, s, Acetyl-CH3), 3.41 
(1H, dd, J = 14.4, J = 7.6, Phe-CHH), 3.46 (1H, dd, J = 14.4, J = 7.6, Phe-CHH), 3.60 
(3H, s, Ester-CH3), 4.36 (1H, dt, J = 8.2, J = 5.4, Leu-α-CH), 4.76 (1H, dt, J = 7.7, J = 
7.5, Phe-α-CH), 6.30 (1H, br d, J = 8.2, Leu-NH), 6.57 (1H, br d, J = 7.6, Phe-NH), 7.03 
(2H, d, J = 16.0, Alkene-CH), 7.27-7.32 (3H, m, Ar-H), 7.39 (4H, t, J = 7.8, J = 7.3, Ar-
H), 7.48 (2H, d, J = 16.0, Alkene-CH), 7.56 (2H, d, J = 7.8, Ar-H), 7.59 (4H, d,  J = 7.3, 
Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Acetyl-CH3), 22.7 (Leu-CH3), 22.8 (Leu-CH3), 
24.5 (Leu-CH), 31.4 (Phe-CH2), 41.4 (Leu-CH2), 51.6 (Leu-α-CH3), 52.7 (Ester-CH3), 
53.3 (Phe-α-CH), 125.9 (Ar-C), 126.0 (Ar-C), 126.8 (Alkene-C=C), 127.7 (Ar-C), 128.0 
(Ar-C), 128.8 (Ar-C), 131.7 (Alkene-C=C), 132.2 (Ar-C), 137.1 (Ar-C), 137.8 (Ar-C), 
170.7 (C=O), 171.7 (C=O), 171.8 (C=O);  
IR Umax /cm-1 (solid) 3260 m (N-H), 3021 w (C-H), 2964 w (C-H), 1728 s (Ester C=O), 
1671 s (Amide C=O), 1650 m (C=C), 1555 m (C=C), 1207 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C34H39N2O4: 539.2904, found: 539.2897. 
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4.6.5 Synthesis of modified peptide 10e 
 
Modified peptide 10e was prepared from Ac-Pro-Phe-OMe (9e) (0.114 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
10e and the mono-olefinated peptide in a ratio of 5:4. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10e as an off-white solid (0.045 g, 24%); m.p. 194-197 °C, Rf 0.21 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.63-1.68 (1H, m, Pro-CHCHHCH2), 1.81-1.86 (2H, m, 
Pro-CH2CH2CH2), 1.95 (3H, s, Acetyl-CH3), 2.29-2.32 (1H, m, Pro-CHCHHCH2), 3.24-
3.36 (2H, m, Pro-NHCH2CH2), 3.42 (2H, d, J = 7.5, Phe-CH2), 3.59 (3H, s, Ester-CH3), 
4.49-4.51 (1H, m, Pro-α-CH), 4.77 (1H, app q, J = 7.8, Phe-α-CH), 6.98 (2H, d, J = 15.8, 
Alkene-CH), 7.27-7.29 (3H, m, Ar-H), 7.35-7.39 (4H, m, Ar-H), 7.50 (2H, d, J = 15.8, 
Alkene-CH); 7.54-7.66 (6H, m, Ar-H), 7.71 (1H,d, J = 7.8, Phe-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.4 (Acetyl-CH3), 24.9 (Pro-CH2), 27.2 (Pro-CH2), 
31.7 (Phe-CH2), 48.3 (Pro-CH2), 52.7 (Ester-CH3), 53.2 (Phe-α-CH), 59.6 (Pro-α-CH3), 
125.6 (Ar-C), 126.4 (Ar-C), 127.0 (Alkene-C=C), 127.5 (Ar-C), 127.9 (Ar-C), 128.8 (Ar-
C), 131.8 (Ar-C), 132.4 (Ar-C), 137.5 (Alkene-C=C), 138.0 (Ar-C), 171.1 (C=O), 171.2 
(C=O), 172.1 (C=O). 
IR Umax /cm-1 (solid) 3275 m (N-H), 2921 w (C-H), 1735 s (Ester C=O), 1630 m (C=C), 
1536 m (C=C), 1255 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C33H35N2O4: 523.2591, found: 523.2589. 
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4.6.6 Synthesis of modified peptide 10f 
 
Modified peptide 10f was prepared from Ac-Phe-Phe-OMe (9f) (0.132 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
9f and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (50% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10f as an off-white solid (0.107 g, 52%); m.p. 202-204 °C; Rf 0.52 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) (* denotes the modified phenylalanine residue) δ 1.78 (3H, s, 
Acetyl-CH3), 2.89 (1H, dd, J = 13.7, J = 7.3, Phe-CHH), 2.97 (1H, dd, J = 13.7, J = 6.0, 
Phe-CHH), 3.38* (2H, d, J = 7.3, Phe-CH2), 3.52 (3H, s, Ester-CH3), 4.54 (1H, dt, J = 
7.7, J = 7.3, Phe-α-CH), 4.71* (1H, dt, J = 7.8, J = 7.3, Phe-α-CH), 5.88 (1H, br d, J = 
7.7, Phe-NH), 6.18* (1H, br d, J = 7.8, Phe-NH), 6.99 (2H, d, J = 16.0, Alkene-CH), 7.03-
7.05 (2H, m, Phe-Ar-H), 7.15-7.20 (3H, m, Phe-Ar-H), 7.27-7.32* (3H, m, Ar-H), 7.40* 
(4H, t, J = 7.8, Ar-H), 7.46 (2H, d, J = 16.0, Alkene-CH), 7.55* (2H, d, J = 7.8, Ar-H), 
7.59* ( 4H, d, J = 7.8, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 23.0 (Acteyl-CH3), 31.5 (Phe-CH2), 38.3 (Phe-CH2), 
52.6 (Ester-CH3), 53.1 (Phe-α-CH), 54.2 (Phe-α-CH), 125.8 (Ar-C), 126.1 (Alkene-C=C), 
126.8 (Ar-C), 126.9 (Ar), 127.6 (Ar-C), 127.9 (Ar-C), 128.6 (Ar-C), 128.8 (Ar-C), 129.2 
(Ar-C), 131.7 (Ar-C), 131.9 (Alkene-C=C), 136.6 (Ar-C), 137.2 (Ar-C), 137.8 (Ar-C), 
169.7 (C=O), 170.3 (C=O), 171.4 (C=O);  
IR Umax /cm-1 (solid) 3221 m (N-H), 3058 w (C-H), 2927 w (C-H), 1736 s (Ester C=O), 
1636 m (C=C), 1537 m (C=C), 1214 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C37H37N2O4: 573.2748, found: 573.2744. 
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4.6.7 Synthesis of modified peptide 10k 
 
Modified peptide 10k was prepared from Ac-Met-Phe-OMe (9k) (0.127 g, 0.359 mmol) 
and styrene (0.166 mL, 1.440 mmol), using the general procedure in Section 4.3. The 
1H NMR spectrum for the crude product contained a mixture of the di-olefinated peptide 
10k and the mono-olefinated peptide in a ratio of 4:1. Purification by flash column 
chromatography (25% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 10k as an off-white solid (0.120 g, 60%); m.p. 186-190 °C; Rf 0.38 (50% 
EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.81-1.90 (5H, m, Met-SCH3 / Met-CH2CH2S), 1.93 (3H, s, 
Acetyl-CH3), 2.38-2.48 (2H, m, Met-CHCH2CH2), 3.39 (1H, dd, J = 14.4, J = 8.2, Phe-
CHH), 3.47 (1H, dd, J = 14.4, J = 6.6, Phe-CHH), 3.61 (3H, s, Ester-CH3), 4.47 (1H, dt, J 
= 7.7, J = 6.9, Met-α-CH), 4.77 (1H, dt, J = 7.8, J = 6.6, Phe-α-CH), 6.13 (1H, br d, J = 
7.7, Met-NH), 6.73 (1H, br d, J = 7.8, Phe-NH), 7.03 (2H, d, J = 16.0, Alkene-CH), 7.27-
7.32 (3H, m, Ar-H), 7.39 (4H, app t, J = 7.8, J = 7.4, Ar-H), 7.48 (2H, d, J = 16.0, Alkene-
CH), 7.56 (2H, d, J = 7.8, Ar-H), 7.60 (4H, br d, J = 7.4, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 14.7 (Met-SCH3), 23.0 (Acetyl-CH3), 29.6 (Met-CH2S), 
31.3 (Met-CH2), 31.5 (Phe-CH2), 51.7 (Met-α-CH), 52.7 (Ester-CH3), 53.2 (Phe-α-CH), 
126.0 (Ar-C), 126.0 (Alkene-C=C), 126.8 (Ar-C), 127.7 (Ar-C), 128.8 (Ar-C), 131.7 (Ar-
C), 132.2 (Alkene-C=C), 137.1 (Ar-C), 137.8 (Ar-C), 169.9 (C=O), 170.6 (C=O), 171.7 
(C=O). 
IR Umax /cm-1 (solid) 3286 s (N-H), 3027 w (C-H), 2924 w (C-H), 1738 s (Ester C=O), 
1679 s (Amide C=O), 1649 m (C=C), 1511 m (C=C), 1200 s (C-O). 
HRMS (ESI) [M+H]+ m/z calcd. for C33H37N2O4S: 557.2469, found: 557.2464. 
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4.7 Synthesis of peptides bearing C-terminal glycine residues 
4.7.1 Ac-Phe-Gly-OMe (11) 
 
Glycine methyl ester hydrochloride (0.314 g, 2.50 mmol) was dissolved in H2O (20 mL) 
before the addition of Amberlyst A21 ion exchange resin (3.140 g, 10.0 w/w). The 
suspension was stirred for 20 min at room temperature before filtration and 
concentration to dryness in vacuo. The resulting residue was slurried in DCM (30 mL), 
along with N-acetyl-L-phenylalanine (0.207 g, 1.00 mmol), HBTU (0.379 g, 1.00 mmol) 
and DIPEA (0.174 mL, 1.00 mmol) and stirred for 12 h. The resulting suspension was 
filtered and washed with 1M HCl (20 mL), sat. NaHCO3 (3 x 20 mL) and H2O (20 mL). 
The organic layers were then dried (MgSO4) and concentration to dryness in vacuo. The 
resulting oil was recrystallised from DCM / hexanes to afford 4h as a white solid (0.078 
g, 28%); m.p. 129-130 °C. 
1H NMR (400 MHz, CDCl3) δ 1.96 (3H, s Acetyl-CH3), 3.03-3.13 (2H, m, Phe-CH2), 3.72 
(3H, s, Ester-CH3), 3.91 (1H, dd, J = 18.0, J = 5.3, Gly-CHH), 4.00 (1H, dd, J = 18.0, J = 
5.3 Gly-CHH), 4.77 (1H, dt, J = 8.0, J = 7.3, Phe-α-CH), 6.49 (1H, br d, J = 8.0,  Phe-
NH), 6.80 (1H, br t, J = 5.3, Gly-NH), 7.20-7.31 (5H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.0 (Acetyl-CH3), 38.1 (Phe-CH2), 41.1 (Gly-CH2), 
52.3 (Ester-CH3), 54.2 (Phe-α-CH), 126.9 (Ar-C), 128.6 (Ar-C), 129.2 (Ar-C), 136.4 (Ar-
C), 169.8 (C=O), 170.3 (C=O), 171.4 (C=O). 
IR Umax /cm-1 (solid) 3278 m (N-H), 3070 w (C-C), 2976 w (C-C), 2923 s (C-C), 1748 s 
(Ester C=O), 1657 s (Amide C=O), 1548 m (C=C), 1498 m (C=C), 1433 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C14H19N2O4: 279.1339 found: 279.1334.  
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4.8 General procedure for the synthesis of phenylalanine containing 
tripeptides 
 
Sodium carbonate (0.206 g, 1.940 mmol) was dissolved in H2O (15 mL) and added to a 
solution of the appropriate dipeptide ester (0.970 mmol) in MeOH (15 mL). The resulting 
suspension was stirred at room temperature for 4 h before acidification by the dropwise 
addition of 1M HCl (~3 mL). The aqueous solvent was then removed and the resulting 
solid washed with ethanol (3 x 10 mL), before the filtrate was evaporated to dryness. 
The crude dipeptide acid was then used without further purification. L-(amino acid) 
methyl ester hydrochloride (2.280 mmol) and K2CO3 (0.454 g, 3.283 mmol) were 
dissolved in distilled water (30 mL) and stirred for 10 min at room temperature. The free 
amine was extracted with Et2O (3 x 20 mL), dried (MgSO4) and concentrated to dryness. 
The resulting residue was slurried in DCM (20 mL) before the N-protected dipeptide 
(0.912 mmol), HBTU (0.346 g, 0.912 mmol) and DIPEA (0.158 mL, 0.912 mmol) were 
added. The suspension was then stirred for 16 h at room temperature. The suspension 
was then filtered and washed with 1M HCl (20 mL), sat. NaHCO3 (3 x 20 mL) and water 
(20 mL). The organic layers were then dried (MgSO4) and concentration to dryness in 
vacuo. The resulting residue was purified by column chromatography using EtOAc as 
eluent, before being recrystallised using DCM / hexanes. 
 140 
 
4.8.1 Ac-Gly-Leu-OMe (12) 
 
Peptide 12 was synthesised from L-leucine methyl ester hydrochloride (0.454 g, 2.50 
mmol) and N-acetylglycine (0.117 g, 1.00 mmol), using the procedure in Section 4.2.1, 
to afford 12 as a yellow oil (0.171 g, 70%);  
1H NMR (400 MHz, CDCl3) δ 0.86 (6H, app t, J = 6.2, Leu-(CH3)3), 1.47-1.63 (3H, m, 
Leu-CHCH2), 1.95 (3H, s, Acetyl-CH3), 3.64 (3H, s, Ester-CH3), 3.89-3.99 (2H, m, Gly-
CH2), 4.44-4.49 (1H, m, Leu-α-CH), 7.36 (1H, br t, J = 5.3, Gly-NH), 7.67 (1H, d, J = 7.8, 
Leu-NH);  
13C{1H} NMR (100 MHz, CDCl3) δ 21.4 (Leu-(CH3)3), 22.5 (Ester-CH3), 24.5 (Leu-CH), 
40.5 (Leu-CH2), 42.7 (Gly-CH2), 50.7 (Leu-α-CH), 52.1 (Ester-CH3), 169.4 (C=O), 171.1 
(C=O), 173.2 (C=O);  
IR Umax /cm-1 (oil) 3283 m (N-H), 3073 w (C-H), 2957 w (C-H), 2871 w (C-H), 1739 s 
(Ester C=O), 1646 s (Amide C=O), 1533 m (C=C), 1438 m (C-H), 1206 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C11H21N2O4: 245.1496, found: 245.1496. 
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4.8.2 Ac-Gly-Phe-Leu-OMe (13a) 
 
Peptide 13a was synthesised from Ac-Gly-Phe-OMe (1a) (0.270 g, 0.970 mmol) and L-
leucine methyl ester hydrochloride (0.414 g, 2.280 mmol), using the procedure in 
Section 4.8. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 13a as a white solid (0.186 g, 52% over 2 
steps); m.p. 180-181 °C, Rf 0.11 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.85-0.90 (6H, m, Leu-(CH3)2), 1.49-1.56 (3H, m, Leu-
CH2CHCH3)2), 2.01 (3H, s, Acetyl-CH3), 3.03-3.14 (2H, m, Phe-CH2), 3.71 (3H, s, Ester-
CH3), 3.89 (2H, d, J = 5.5, Gly-CH2), 4.49-4.55 (1H, m, Phe-α-CH), 4.68-4.74 (1H, dt, J = 
7.8, J = 6.9, Leu-α-CH), 6.30 (1H, m, Gly-NH), 6.37 (1H, br d, J = 7.8, Phe-NH), 6.70 
(1H, br d, J = 7.8, Leu-NH), 7.20-7.22 (2H, m, Ar-H), 7.24-7.31 (3H, m, Ar-H);  
13C{1H} NMR (100 MHz, CD3OD) δ 21.8 (Leu-CH3), 22.4 (Leu-CH3), 23.3 (Acetyl-CH3), 
25.8 (Leu-CH), 38.8 (Phe-CH2), 41.4 (Leu-CH2), 43.5 (Gly-CH2), 52.2 (Ester-CH3), 52.7 
(Phe-α-CH), 55.6 (Leu-α-CH), 127.8 (Ar-C), 129.4 (Ar-C), 130.4 (Ar-C), 138.2 (Ar-C), 
171.4 (C=O), 173.5 (C=O), 173.8 (C=O), 174.3 (C=O);  
IR Umax /cm-1 (solid) 3278 m (N-H), 2975 w (C-H), 1748 s (Ester C=O), 1694 s (Amide 
C=O), 1530 m (C=C), 1435 m (C-H), 1224 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C20H30N3O5: 392.2180, found: 392.2178. 
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4.8.3 Ac-Gly-Leu-Phe-OMe (13b) 
 
Peptide 13b was synthesised from Ac-Gly-Leu-OMe (12) (0.237 g, 0.970 mmol) and L-
phenylalanine methyl ester hydrochloride (0.499 g, 2.280 mmol), using the procedure in 
Section 4.8. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 13b as a white solid (0.164 g, 46% over 2 
steps); m.p. 125-128 °C, Rf 0.11 (EtOAc). 
1H NMR (400 MHz, CD3OD) δ 0.89 (3H, d, J = 6.4, Leu-CH3), 0.93 (3H, d, J = 6.4, Leu-
CH3), 1.47-1.51 (2H, m, Leu-CH2), 1.59-1.63 (1H, m, Leu-CH2CH(CH3)2), 2.00 (3H, s, 
Acetyl-CH3), 2.97-3.03 (1H, m, Phe-CHH), 3.14 (1H, dd, J = 14.2, J = 6.0, Phe-CHH), 
3.67 (3H, s, Ester-CH3), 3.82 (2H, s, Gly-CH2), 4.42 (1H, dd, J = 8.7, J = 6.4, Leu-α-CH), 
4.62 (1H, dd, J = 8.7, J = 6.0, Phe-α-CH), 7.18-7.21 (2H,m, Ar-H), 7.25-7.29 (3H, m, Ar-
H);  
13C{1H} NMR (100 MHz, CD3OD) δ 22.0 (Leu-CH3), 22.4 (Leu-CH3), 23.4 (Acetyl-CH3), 
25.8 (Leu-CH), 38.2 (Phe-CH2), 41.9 (Leu-CH2), 43.5 (Gly-CH2), 52.7 (Phe-α-CH), 52.9 
(Ester-CH3), 55.2 (Leu-α-CH), 127.9 (Ar-C), 129.5 (Ar-C), 130.3 (Ar-C), 138.1 (Ar-C), 
171.5 (C=O), 173.2 (C=O), 173.9 (C=O), 174.6 (C=O);  
IR Umax /cm-1 (solid) 3285 m (N-H), 2956 w (C-H), 1745 s (Ester C=O), 1694 s (Amide 
C=O), 1659 s (Amide C=O), 1531 m (C=C), 1435 m (C-H), 1210 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C20H30N3O5: 392.2180, found: 392.2181. 
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4.8.4 Ac-Phe-Gly-Leu-OMe (13c) 
 
Peptide 13c was synthesised from Ac-Phe-Gly-OMe (11) (0.270 g, 0.970 mmol) and L-
leucine methyl ester hydrochloride (0.414 g, 2.280 mmol), using the procedure in 
Section 4.8.  Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 13c as a white solid (0.157 g, 44% over 2 
steps); m.p. 144-145 °C, Rf 0.14 (EtOAc). 
1H NMR (400 MHz, CD3OD) δ 0.90 (3H, d, J = 6.2, Leu-CH3), 0.94 (3H, d, J = 6.2, Leu-
CH3), 1.56-1.67 (3H, m, Leu-CH2CH(CH3)2), 1.91 (3H, s, Ester-CH3), 2.92 (1H, dd, J = 
13.7, J = 8.9, Phe-CHH), 3.13 (1H, dd, J = 13.7, J = 6.2, Phe-CHH), 3.65-3.70 (4H, m, 
Ester-CH3 / Gly CHH), 3.93 (1H, d, J = 16.9, Gly-CHH), 4.44-4.50 (1H, m, Phe-α-CH), 
7.19-7.30 (5H, m, Ar-H);  
13C{1H} NMR (100 MHz, CD3OD) δ 21.6 (Acetyl-CH3), 22.4 (Leu-CH3), 23.4 (Leu-CH3), 
25.8 (Leu-CH), 38.2 (Phe-CH2), 41.2 (Gly-CH2), 43.3 (Leu-CH2), 52.1 (Ester-CH3), 52.7 
(Leu-α-CH), 57.0 (Phe-α-CH), 127.8 (Ar-C), 129.5 (Ar-C), 130.2 (Ar-C), 138.4 (Ar-C), 
171.6 (C=O), 173.6 (C=O), 174.4 (C=O), 174.6 (C=O);  
IR Umax /cm-1 (solid) 3285 m (N-H), 2959 w (C-H), 1750 s (Ester C=O), 1692 s (Amide 
C=O), 1631 s (Amide C=O), 1436 m (C-H), 1228 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C20H29N3O5: 392.2180, found: 392.2181. 
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4.8.5 Ac-Gly-Leu-Leu-OMe (13d) 
 
Peptide 13d was synthesised from Ac-Gly-Leu-OMe (12) (0.237 g, 0.970 mmol) and L-
leucine methyl ester hydrochloride (0.414 g, 2.280 mmol), using the procedure in 
Section 4.8. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 13d as a white solid (0.235 g, 72% over 2 
steps); m.p. 125-128 °C; Rf 0.19 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.91-0.95 (12H, m, (Leu-(CH3)2) x2), 1.52-1.69 (6H, m, 
(Leu-CH2CH(CH3)2) x2), 2.04 (3H, s, Acetyl-CH3), 3.73 (3H, s, Ester-CH3), 3.93-4.03 
(2H, m, Gly-CH2), 4.52-4.58 (2H, m, (Leu-α-CH) x2), 6.62 (1H, br t, J = 5.0, Gly-NH), 
6.72 (1H, br d, J = 8.2, Leu-NH), 6.86 (1H, br d, J = 8.7, Leu-NH);  
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Acetyl-CH3), 22.2 (Leu-CH3), 22.7 (Leu-CH3), 
22.7 (Leu-CH3), 22.8 (Leu-CH3), 22.8 (Leu-CH3), 24.6 (Leu-CH, 24.8 (Leu-CH), 40.9 
(Leu-CH2), 41.7 (Leu-CH2), 43.2 (Gly-CH2), 50.9 (Leu-α-CH), 51.7 (Leu-α-CH), 52.2 
(Ester-CH3), 169.0 (C=O), 170.9 (C=O), 172.1 (C=O), 173.2 (C=O);  
IR Umax /cm-1 (solid) 3275 m (N-H), 3075 w (C-H), 2957 w (C-H), 1750 s (Ester C=O), 
1691 s (Amide C=O), 1630 s (Amide C=O), 1532 m (C=C), 1438 m (C-H), 1202 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C26H41N4O6: 505.3021 found: 505.3020.  
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4.9 General procedure for the synthesis of phenylalanine containing 
tetrapeptides 
 
Sodium carbonate (0.068 g, 0.646 mmol) was dissolved in H2O (10 mL) and added to a 
solution of the appropriate tripeptide ester (0.323 mmol) in MeOH (10 mL). The resulting 
suspension was stirred at room temperature for 4 h before acidification by the dropwise 
addition of 1M HCl (~3 mL). The aqueous solvent was then removed and the resulting 
solid washed with ethanol (3 x 10 mL), before the filtrate was evaporated to dryness. 
The crude tripeptide acid was carried through without further purification. The 
appropriate L-(amino acid) methyl ester hydrochloride (0.808 mmol) and K2CO3 (0.161 g, 
1.162 mmol) were dissolved in distilled water (30 mL) and stirred for 10 mins at room 
temperature. The free amine was extracted with Et2O (3 x 20 mL), dried (MgSO4) and 
concentrated to dryness. The resulting residue was slurried in DCM (20 mL), before N-
protected dipeptide (0.323 mmol), HBTU (0.122 g, 0.323 mmol) and DIPEA (0.056 mL, 
0.323 mmol) were added. The suspension was then stirred for 16 h at room 
temperature. The suspension was then filtered and washed with 1M HCl (20 mL), sat. 
NaHCO3 (3 x 20 mL) and water (20 mL). The organic layers were then dried (MgSO4) 
and concentrated to dryness in vacuo. The resulting residue was purified by column 
chromatography using EtOAc as eluent, before being recrystallised using DCM / 
hexanes. 
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4.9.1 Ac-Gly-Phe-Leu-Leu-OMe (14a) 
 
Peptide 14a was synthesised from Ac-Gly-Phe-Leu-OMe (13a) (0.126 g, 0.323 mmol) 
and L-leucine methyl ester hydrochloride (0.147 g, 0.808 mmol), using the general 
procedure in Section 4.9. Purification by flash column chromatography (10% MeOH / 
DCM) followed by recrystallisation from DCM / hexanes gave 14a as a white solid (0.104 
g, 64%); m.p. 179-181 °C, Rf 0.13 (10% MeOH / DCM). 
1H NMR (400 MHz, CD3CN) δ 0.80-0.87 (12H, m, Leu-(CH3)2 (x2)), 1.42-1.61 (6H, m, Leu-
CH2 / Leu-CH2CH(CH3)2 (x2)), 1.81 (3H, s, Acetyl-CH3), 2.96 (1H, dd, J = 14.2, J = 8.2, 
Phe-CHH), 3.10 (1H, dd, J = 14.2, J = 5.0, Phe-CHH), 3.56 (1H, dd, J = 5.3, J = 2.6, Gly-
CHH), 3.59 (4H, m, Ester-CH3 / Gly-CHH), 4.19-4.29 (1H, m, Phe-α-CH / Leu-α-CH), 4.38-
4.43 (1H, m, Leu-α-CH), 6.78 (1H, br d, J = 6.0, NH), 6.88 (2H, m, NH), 7.02 (1H, d, J = 
8.7, NH), 7.16-7.28 (5H, m, Phe-Ar-H).  
13C{1H} NMR (100 MHz, CD3OD) δ 21.8 (Leu-CH3), 22.0 (Leu-CH3), 22.4 (Acetyl-CH3), 
23.4 (Leu-CH3), 23.5 (Leu-CH3), 25.7 (Leu-CH), 25.8 (Leu-CH), 38.3 (Phe-CH2), 41.4 
(Leu-CH2), 41.8 (Leu-CH2), 43.6 (Gly-CH2), 52.6 (Ester-CH3), 53.0 (Leu-α-CH),  53.2 
(Leu-α-CH), 55.2 (Phe-α-CH), 127.9 (Ar-C), 129.5 (Ar-C), 130.3 (Ar-C), 138.0 (Ar-C), 
171.9 (C=O), 173.2 (C=O), 173.9 (C=O), 174.6 (C=O), 174.8 (C=O). 
IR Umax /cm-1 (solid) 3279 m (N-H), 3067 w (C-H), 2956 w (C-H), 1748 s (Ester C=O), 
1692 s (Amide C=O), 1630 m (C=C), 1526 m (C=C), 1439 m (C-H), 1203 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C26H41N4O6: 505.3021 found: 505.3013. 
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4.9.2 Ac-Gly-Leu-Phe-Leu-OMe (14b) 
 
Peptide 14b was synthesised from Ac-Gly-Leu-Phe-OMe (13a) (0.126 g, 0.323 mmol) 
and L-leucine methyl ester hydrochloride (0.147 g, 0.808 mmol), using the general 
procedure in Section 4.9. Purification by flash column chromatography (10% MeOH / 
DCM) followed by recrystallisation from DCM / hexanes gave 14b as a white solid 
(0.112 g, 69%); m.p. 190-193 °C, Rf 0.10 (10% MeOH / DCM). 
1H NMR (400 MHz, CDCl3) δ 0.86-0.98 (12H, m, Leu-(CH3)2 (x2)), 1.54-1.65 (6H, m, 
Leu-CH2 / Leu-CH2CH(CH3)2 (x2)), 1.99 (3H, s, Acetyl-CH3), 3.02-3.11 (2H, m, Phe-
CH2), 3.71 (3H, s, Ester-CH3), 3.89-3.94 (1H, m, Gly-CHH), 4.06-4.13 (1H, m, Gly-CHH), 
4.47-4.54 (1H, α-CH), 4.77-4.78 (1H, m, α-CH), 4.96-5.01 (1H, m, α-CH),  7.16-7.28 
(7H, m, Phe-Ar-H / NH / NH ), 7.54-7.59 (2H, m, NH (x2)).  
13C{1H} NMR (100 MHz, CD3OD) δ 21.8 (Leu-CH3), 21.9 (Leu-CH3), 22.5 (Acetyl-CH3), 
23.1 (Leu-CH3), 23.4 (Leu-CH3),  25.5 (Leu-CH), 25.8 (Leu-CH), 38.4 (Phe-CH2), 41.4 
(Leu-CH2), 41.7 (Leu-CH2), 43.7 (Gly-CH2), 52.2 (α-CH), 52.7 (Ester-CH3), 53.3 (α-CH), 
55.8 (α-CH), 127.7 (Ar-C), 129.4 (Ar-C), 130.4 (Ar-C), 138.5 (Ar-C), 171.9 (C=O), 173.4 
(C=O), 174.2 (C=O), 174.4 (C=O), 174.8 (C=O). 
IR Umax /cm-1 (solid) 3277 m (N-H), 3073 w (C-H), 2956 w (C-H), 1745 s (Ester C=O), 
1694 s (Amide C=O), 1630 m (C=C), 1526 m (C=C), 1438 m (C-H), 1205 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C26H41N4O6: 505.3021 found: 505.3017. 
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4.9.3 Ac-Gly-Leu-Leu-Phe-OMe (14c) 
 
Peptide 14c was synthesised from Ac-Gly-Leu-Leu-OMe (13d) (0.155 g, 0.323 mmol) 
and L-phenylalanine methyl ester hydrochloride (0.174 g, 0.808 mmol), using the 
procedure in Section 4.9. Purification by flash column chromatography (10% MeOH / 
DCM) followed by recrystallisation from DCM / hexanes gave 14c as a white solid (0.072 
g, 44%); m.p. 181-184 °C, Rf 0.09 (10% MeOH / DCM). 
1H NMR (400 MHz, CD3OD) δ 0.88-0.97 (12H, m, Leu-CH3 (x2)), 1.46-1.65 (6H, m, Leu-
CH2 / Leu-CH2CH(CH3)2 (x2)), 1.98 (3H, s, Acetyl-CH3), 2.98-3.03 (1H, m, Phe-CHH), 
3.11-3.19 (1H, m, Phe-CHH), 3.66 (3H, s, Ester-CH3), 3.83-3.86 (2H, m, Gly-CH2), 4.29-
4.40 (3H, m, Leu-α-CH / Leu-α-CH), 4.60-4.65 (1H, m, Phe-α-CH) 7.18-7.28 (5H, m, 
Phe-Ar-H). 
13C{1H} NMR (100 MHz, CD3OD) δ 21.8 (Leu-CH3), 22.0 (Leu-CH3), 22.4 (Acetyl-CH3), 
23.4 (Leu-CH3), 23.5 (Leu-CH3),  25.8 (Leu-CH), 25.8 (Leu-CH), 38.3 (Phe-CH2), 41.4 
(Leu-CH2), 41.7 (Leu-CH2), 43.7 (Gly-CH2), 52.6 (Ester-CH3), 53.2 (α-CH), 53.8 (α-CH), 
55.2 (α-CH), 127.9 (Ar-C), 129.5 (Ar-C), 130.3 (Ar-C), 138.0 (Ar-C), 171.9 (C=O), 173.2 
(C=O), 173.9 (C=O), 174.5 (C=O), 174.8 (C=O). 
IR Umax /cm-1 (solid) 3270 m (N-H), 3070 w (C-H), 2955 w (C-H), 1744 s (Ester C=O), 
1692 s (Amide C=O), 1630 m (C=C), 1532 m (C=C), 1436 m (C-H), 1210 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C26H41N4O6: 505.3021 found: 505.3015 
.  
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4.9.4 Ac-Phe-Gly-Leu-Leu-OMe (14d) 
 
Peptide 14d was synthesised from Ac-Phe-Gly-Leu-OMe (13c) (0.126 g, 0.323 mmol) 
and L-leucine methyl ester hydrochloride (0.147 g, 0.808 mmol), using the procedure in 
Section 4.9. Purification by flash column chromatography (10% MeOH / DCM) followed 
by recrystallisation from DCM / hexanes gave 14d as a white solid (0.065 g, 40%); m.p. 
183-186 °C, Rf 0.09 (10% MeOH / DCM). 
1H NMR (400 MHz, CD3OD) δ 0.89-0.97 (12H, m, Leu-CH3 (x2)), 1.57-1.75 (6H, m, Leu-
CH2 / Leu-CH2CH(CH3)2 (x2)), 1.91 (3H, s, Acetyl-CH3), 2.92 (1H, dd, J = 13.7, J = 8.8, 
Phe-CHH), 3.14 (1H, dd, J = 13.7, J = 6.2, Phe-CHH), 3.64-3.68 (4H, m, Ester-CH3 / 
Gly-CHH), 3.91 (1H, d, J = 16.0, Gly-CHH), 4.37-4.48 (3H, m, Phe-α-CH / Leu-α-CH / 
Leu-α-CH), 7.19-7.32 (5H, m, Phe-Ar-H). 
13C {1H} NMR (100 MHz, CD3OD) δ 21.7 (Leu-CH3), 21.8 (Leu-CH3), 22.4 (Acetyl-CH3), 
23.4 (Leu-CH3), 23.5 (Leu-CH3), 25.7 (Leu-CH), 25.8 (Leu-CH), 38.3 (Phe-CH2), 41.4 
(Leu-CH2), 41.8 (Leu-CH2), 43.6 (Gly-CH2), 52.1 (Leu-α-CH), 52.6 (Ester-CH3), 53.0 
(Leu-α-CH), 57.0 (Phe-α-CH), 127.8 (Ar-C), 129.5 (Ar-C), 130.2 (Ar-C), 138.4 (Ar-C), 
171.4 (C=O), 173.4 (C=O), 174.5 (C=O), 174.9 (C=O), 175.2 (C=O). 
IR Umax /cm-1 (solid) 3280 m (N-H), 2956 w (C-H), 1747 s (Ester C=O), 1694 s (Amide 
C=O), 1630 m (C=C), 1532 m (C=C), 1436 m (C-H), 1222 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C26H41N4O6: 505.3021 found: 505.3015. 
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4.10 Modification of phenylalanine containing tri- and tetra-peptides 
4.10.1 Synthesis of modified peptide 15a 
 
Modified peptide 15a was prepared from Ac-Gly-Phe-Leu-OMe (13a) (0.100 g, 0.255 
mmol) and styrene (0.118 mL, 1.022 mmol), using the general procedure in Section 4.3. 
The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 15a and the mono-olefinated peptide in a ratio of 4:1. Purification by flash 
column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 
15a as an off-white solid (0.090 g, 59%); m.p. 206-207 °C, Rf 0.24 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.80 (3H, d, J = 6.2, Leu-CH3), 0.83 (3H, d, J = 6.2, Leu-
CH3), 1.32-1.37 (1H, m, Leu-CH2CH(CH3)3), 1.42-1.48 (2H, m, Leu-CH2), 1.91 (3H, s, 
Acetyl-CH3), 3.34-3.46 (2H, m, Phe-CH2), 3.76 (1H, dd, J = 16.8, J = 5.0, Gly-CHH), 
3.85 (1H, dd, J = 16.8, J = 5.0, Gly-CHH), 4.43 (1H, dt, J = 7.4, J = 5.5, Leu-α-CH), 4.60 
(1H, dt, J = 7.9, J = 7.4, Phe-α-CH), 6.05 (1H, br d, J = 7.9, Phe-NH), 6.13 (1H, br t, J = 
5.0, Gly-NH), 6.79 (1H, br d, J = 7.4, Leu-NH), 6.98 (2H, d, J = 16.0, Alkene-CH), 7.26-
7.32 (3H, m, Ar-H), 7.37-7.41 (4H, m, Ar-H), 7.54-7.59 (4H, m, Alkene-CH / Ar-H), 7.61 
(4H, d, J = 7.4, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 22.0 (Leu-CH3), 22.4 (Leu-CH2), 22.8 (Acetyl-CH3), 
24.6 (Leu-CH), 32.1 (Phe-CH2), 41.5 (Gly-CH2), 42.9 (Leu-CH2), 51.1 (Phe-α-CH), 52.2 
(Ester-CH3), 54.4 (Leu-α-CH) 125.9 (Ar-C), 126.3 (Alkene-C=C), 126.8 (Ar-C), 127.6 
(Ar-C), 128.0 (Ar-C), 128.8 (Ar-C), 131.9 (Alkene-C=C), 132.1 (Ar-C), 137.1 (Ar-C), 
137.9 (Ar-C), 168.2 (C=O), 170.0 (C=O), 170.4 (C=O), 127.3 (C=O);  
IR Umax /cm-1 (solid) 3276 m (N-H), 3062 w (C-H), 2928 w (C-H), 1741 s (Ester C=O), 
1632 m (C=C), 1533 m (C=C), 1448 m (C-H), 1150 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C36H42N3O5: 596.3119 found: 596.3113.  
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4.10.2 Synthesis of modified peptide 15b 
 
Modified peptide 15b was prepared from Ac-Gly-Leu-Phe-OMe (13b) (0.100 g, 0.255 
mmol) and styrene (0.118 mL, 1.022 mmol), using the general procedure in Section 4.3. 
The 1H NMR spectrum for the crude product contained a mixture of the di-olefinated 
peptide 15b and the mono-olefinated peptide in a ratio of 5:1. Purification by flash 
column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 
15b as an off-white solid (0.096 g, 63%); m.p. 204-207 °C, Rf 0.22 (EtOAc) 
1H NMR (400 MHz, CDCl3) δ 0.77 (3H, d, J = 6.2, Leu-CH3), 0.80 (3H, d, J = 6.2, Leu-
CH3), 1.34-1.40 (1H, m, Leu-CH2CH(CH3)3), 1.44-1.56 (2H, m, Leu-CH2), 1.91 (3H, s, 
Acetyl-CH3), 3.42 (2H, d, J = 7.7, Phe-CH2), 3.57 (3H, s, Ester-CH3), 3.63 (1H, dd, J = 
16.5, J = 5.0, Gly-CHH), 3.71 (1H, dd, J = 16.5, J = 5.0, Gly-CHH), 4.39 (1H, dt, J = 5.5, 
J = 4.6, Leu-α-CH), 4.76 (1H, app q, J = 7.7, Phe-α-CH), 6.43 (1H, br d, J = 8.3, Leu-
NH), 6.48 (1H, m, Gly-NH), 6.92 (1H, br d, J = 7.7, Phe-NH), 6.99 (2H, d, J = 16.0, 
Alkene-CH), 7.25-7.29 (3H, m, Ar-H), 7.35-7.39 (4H, m, Ar-H), 7.48-7.55 (4H, m, 
Alkene-CH / Ar-H), 7.58 (4H, d, J = 7.7, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 21.7 (Acetyl-CH3), 22.7 (Leu-CH3), 22.8 (Leu-CH3), 
24.6 (Leu-CH), 31.4 (Phe-CH2), 41.0 (Gly-CH2), 43.2 (Leu-CH2), 51.7 (Leu-α-CH), 52.6 
(Ester-CH3), 53.1 (Phe-α-CH), 125.8 (Ar-C), 126.3 (Alkene-C=C), 126.8 (Ar-C), 127.6 
(Ar-C), 127.9 (Ar-C), 128.8 (Ar-C), 131.8 (Alkene-C=C), 132.1 (Ar-C), 137.2 (Ar-C), 
137.7 (Ar-C), 168.8 (C=O), 170.8 (C=O), 171.4 (C=O), 171.9 (C=O);  
IR Umax /cm-1 (solid) 3275 s (N-H), 3062 w (C-H), 2954 w (C-H), 1743 s (Ester C=O), 
1634 m (C=C), 1527 m (C=C), 1207 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C36H42N3O5: 596.3119 found: 596.3114. 
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4.10.3 Synthesis of modified peptide 16a 
 
Modified peptide 16a was prepared from Ac-Gly-Phe-Leu-Leu-OMe (14a) (0.060 g, 
0.119 mmol) and styrene (0.055 mL, 0.476 mmol), using the general procedure in 
Section 4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 16a and the mono-olefinated peptide in a ratio of 5:1. Purification by 
flash column chromatography (10% MeOH / DCM) followed by recrystallisation from 
DCM / hexanes gave 16a as an off-white solid (0.025 g, 30%); m.p. 206-209 °C, Rf 0.15 
(10% MeOH / DCM) 
1H NMR (400 MHz, CDCl3) δ 0.76-0.83 (12H, m, Leu-(CH3)2 (x2)), 1.42-1.52 (6H, m, 
Leu-CH2 / Leu-CH2CH(CH3)2 (x2)), 1.91 (3H, s, Acetyl-CH3), 3.35-3.40 (1H, m, Phe-
CHH), 3.45-3.56 (2H, m, Phe-CHH / Gly-CHH), 3.59 (3H, s, Ester-CH3), 3.66 (1H, d, J = 
15.6, Gly-CHH), 4.37-4.46 (2H, m, α-CH (x2)), 4.73 (1H, m, α-CH), 6.94 (2H, d, J = 15.6, 
Alkene-CH), 7.22-7.25 (2H, m, Ar-H), 7.35 (5H, m, Ar-H), 7.50 (2H, d, J = 7.3, Ar-H), 
7.58-7.63 (6H, m, Alkene-CH / Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 22.0 (Leu-CH3), 22.6 (Acetyl-CH3), 
22.7 (Leu-CH3), 22.8 (Leu-CH3), 24.7 (Leu-CH), 24.7 (Leu-CH), 31.9 (Phe-CH2), 41.1 
(Leu-CH2), 41.6 (Leu-CH2), 43.3 (Gly-CH2), 51.1 (Ester-CH3), 52.0 (Leu-α-CH), 52.1 
(Leu-α-CH), 54.5 (Phe-α-CH), 125.9 (Ar-C), 126.8 (Ar-C), 126.9 (Ar-C), 127.5 (Ar-
C),127.9 (Ar-C), 128.8 (Ar-C), 131.8 (Ar-C), 132.7 (Ar-C), 137.2 (Ar-C), 138.0 (Ar-C), 
168.8 (C=O), 170.6 (C=O), 170.6 (C=O), 171.4 (C=O), 172.4 (C=O). 
IR Umax /cm-1 (solid) 3272 m (N-H), 3068 w (C-H), 2957 w (C-H), 1747 s (Ester C=O), 
1693 s (Amide C=O), 1626 m (amide C=O), 1521 m (C=C), 1438 m (C-H), 1203 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C42H53N4O6Na: 731.3779 found: 731.3782. 
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4.10.4 Synthesis of modified peptide 16b 
 
Modified peptide 16b was prepared from Ac-Gly-Leu-Phe-Leu-OMe (14b) (0.060 g, 
0.119 mmol) and styrene (0.055 mL, 0.476 mmol), using the general procedure in 
Section 4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 16b and the mono-olefinated peptide in a ratio of 5:1. Purification by 
flash column chromatography (10% MeOH / DCM) followed by recrystallisation from 
DCM / hexanes gave 16b as an off-white solid (0.036 g, 43%); m.p. 208-211 °C, Rf 0.15 
(10% MeOH / DCM) 
1H NMR (400 MHz, CDCl3) δ 0.77-0.85 (12H, m, Leu-(CH3)2 (x2)), 1.45-1.52 (6H, m, 
Leu-CH2 / Leu-CH2CH(CH3)2 (x2)), 1.92 (3H, s, Acetyl-CH3), 3.36-3.42 (1H, m, Phe-
CHH), 3.46-3.56 (2H, m, Phe-CHH / Gly-CHH), 3.60 (3H, s, Ester-CH3), 3.74-3.79 (1H, 
m, Gly-CHH), 4.37 (1H, m, α-CH), 4.43-4.47 (1H, m, α-CH) 4.74 (1H, m, α-CH), 6.95 
(2H, d, J = 15.9, Alkene-CH), 7.23-7.25 (2H, m, Ar-H), 7.35 (5H, t, J = 7.4, Ar-H), 7.51 
(2H, d, J = 7.8, Ar-H), 7.59-7.65 (6H, m, Alkene-CH / Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 22.0 (Leu-CH3), 22.6 (Acetyl-CH3), 
22.7 (Leu-CH3), 22.8 (Leu-CH3), 24.6 (Leu-CH), 24.7 (Leu-CH), 31.9 (Phe-CH2), 41.1 
(Leu-CH2), 41.5 (Leu-CH2), 43.3 (Gly-CH2), 51.1 (Ester-CH3), 52.0 (Leu-α-CH), 52.1 
(Leu-α-CH), 54.5 (Phe-α-CH), 125.9 (Ar-C), 126.7 (Ar-C), 126.9 (Ar-C), 127.5 (Ar-
C),127.9 (Ar-C), 128.8 (Ar-C), 131.8 (Ar-C), 132.7 (Ar-C), 137.2 (Ar-C), 137.9 (Ar-C), 
168.9 (C=O), 170.6 (C=O), 170.8 (C=O), 171.5 (C=O), 172.4 (C=O). 
IR Umax /cm-1 (solid) 3275 m (N-H), 3062 w (C-H), 2957 w (C-H), 2923 w (C-H), 1742 s 
(Ester C=O), 1628 m (amide C=O), 1532 m (C=C), 1449 m (C-H), 1259 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C42H53N4O6: 709.3965 found: 709.3964. 
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4.10.5 Synthesis of modified peptide 16c 
 
Modified peptide 16c was prepared from Ac-Gly-Leu-Leu-Phe-OMe (14c) (0.060 g, 
0.119 mmol) and styrene (0.055 mL, 0.476 mmol), using the general procedure in 
Section 4.3. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 16c and the mono-olefinated peptide in a ratio of 5:1. Purification by 
flash column chromatography (10% MeOH / DCM) followed by recrystallisation from 
DCM / hexanes gave 16c as an off-white solid (0.034 g, 40%); m.p. 205-209 °C, Rf 0.19 
(10% MeOH / DCM). 
1H NMR (400 MHz, CDCl3) δ 0.75-0.87 (12H, m, Leu-(CH3)2 (x2)), 1.42-1.54 (6H, m, 
Leu-CH2 / Leu-CH2CH(CH3)2 (x2)), 1.93 (3H, s, Acetyl-CH3), 3.34-3.41 (1H, m, Phe-
CHH), 3.43-3.49 (1H, m, Phe-CHH), 3.59 (3H, s, Ester-CH3), 3.64-3.68 (2H, m, Gly-
CH2), 4.36 (1H, m, α-CH), 4.43-4.44 (1H, m, α-CH), 4.69-4.71 (1H, m, α-CH), 6.94 (2H, 
d, J = 16.0, Alkene-CH), 7.09-7.06 (2H, m, Ar-H), 7.21-7.23 (2H, m, Ar-H), 7.34 (5H, t, J 
= 7.4, Ar-H), 7515 (2H, d, J = 7.8, Ar-H), 7.58-7.63 (6H, m, Alkene-CH / Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 21.9 (Leu-CH3), 22.6 (Acetyl-CH3), 
22.8 (Leu-CH3), 23.0 (Leu-CH3), 24.5 (Leu-CH), 24.6 (Leu-CH), 31.7 (Phe-CH2), 40.7 
(Leu-CH2), 41.3 (Leu-CH2), 43.3 (Gly-CH2), 50.9 (Ester-CH3), 51.8 (Leu-α-CH), 52.3 
(Leu-α-CH), 53.9 (Phe-α-CH), 125.7 (Ar-C), 126.4 (Ar-C), 126.9 (Ar-C), 127.4 (Ar-
C),127.9 (Ar-C), 128.7 (Ar-C), 131.9 (Ar-C), 132.3 (Ar-C), 137.2 (Ar-C), 137.9 (Ar-C), 
169.2 (C=O), 170.6 (C=O), 170.8 (C=O), 171.6 (C=O), 173.3 (C=O). 
IR Umax /cm-1 (solid) 3274 m (N-H), 3062 w (C-H), 2956 w (C-H), 2920 w (C-H), 1742 s 
(Ester C=O), 1630 m (amide C=O), 1533 m (C=C), 1450 m (C-H), 1203 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C42H53N4O6: 709.3965 found: 709.3958. 
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4.11 Preparation of unnatural phenylalanine derived peptides 
4.11.1 Ac-Gly-Phg-OMe (17) 
 
Peptide 17 was synthesised from (S)-(+)-2-phenylglycine methyl ester hydrochloride 
(0.504 g, 2.50 mmol) and N-acetylglycine (0.117 g, 1.00 mmol), using the procedure in 
Section 4.2.1. The crude compound was recrystallised from DCM / hexanes to afford 17 
as a yellow solid (0.159 g, 60%); m.p. 145-147 °C. 
1H NMR (400 MHz, CDCl3) δ 1.99 (3H, s, Acetyl-CH3), 3.72 (3H, s, Ester-CH3), 3.96 (1H, 
dd, J = 16.7, J = 5.2, Gly-CHH), 4.05 (1H, dd, J = 16.7, J = 5.2, Gly-CHH), 5.53 (1H, d, J 
= 6.9, Phg-α-CH), 6.56 (1H, m, Gly-NH), 7.32-7.36 (5H, m, Phg-Ar-H), 7.48 (1H, br d, J 
= 6.9, Phg-NH).  
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 43.0 (Gly-CH2), 52.8 (Ester-CH3), 
56.6 (Phg-α-CH), 127.3 (Ar-C), 128.6 (Ar-C), 128.9 (Ar-C), 135.8 (Ar-C), 168.6 (C=O), 
170.8 (C=O), 171.0 (C=O).  
IR Umax /cm-1 (solid) 3239 m (N-H), 3096 s (C-H), 2958 s (C-H), 1731 s (Ester C=O), 
1627 m (C=C), 1543 m (C=C), 1228 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C13H17N2O4: 265.1183, found: 265.1193. 
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4.11.2 N-methyl-l-phenylalanine methyl Ester hydrochloride (Me-Phe-OMe.HCl) 
(18) 
 
Under an atmosphere of dry nitrogen, LiOH.H2O (0.418 g, 9.967 mmol) and 4 Å 
molecular sieves were stirred in anhydrous DMF (15 mL) for 20 min. L-phenylalanine 
methyl ester hydrochloride (1.000 g, 4.636 mmol) was added to the solution and stirred 
for a further 45 min before the addition of iodomethane (0.317 mL, 5.100 mmol). The 
resulting suspension was left to stir at room temperature for 18 h. The brown suspension 
was then filtered and the filter cake washed with EtOAc (50 mL). The filtrate was then 
washed with water (3 x 30 mL), dried (MgSO4) and concentrated to dryness in vacuo. to 
give a yellow oil. The oil was purified by flash column chromatography using EtOAc as 
eluent to give Me-Phe-OMe.HCl (18) as a pale-yellow oil (0.682 g, 64%), Rf 0.33 
(EtOAc). 
1H NMR (400 MHz, CDCl3) δ 2.30 (3H, s, CH3), 2.90 (2H, d, J = 6.7, Phe-CH2) 3.39 (1H, 
t, J = 6.7, Phe-α-CH), 3.60 (3H, s, Ester-CH3), 7.11-7.13 (2H, m, Ar-H), 7.16-7.19 (1H, 
m, Ar-H), 7.21-7.25 (2H, m, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 34.4 (NCH3), 39.2 (Phe-CH2), 51.3 (ster-CH3), 64.4 
(Phe-α-CH), 126.4 (Ar-C), 128.2 (Ar-C), 128.8 (Ar-C), 136.9 (Ar-C), 174.5 (C=O). 
IR Umax/cm-1 (oil) 3028 s (C-H), 2949 s (C-H), 1732 s (Ester C=O), 1454 m (C-H). 
HRMS (ESI) [M+H]+[-HCl] m/z calcd. for C11H16NO2: 194.1176 found: 194.1174. 
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4.11.3 Ac-Gly-(N-Me)Phe-OMe (19) 
 
Peptide 19 was synthesised from N-methyl-L-phenylalanine methyl ester hydrochloride 
(0.574 g, 2.50 mmol) and N-acetylglycine (0.173 g, 1.00 mmol), using the procedure in 
Section 4.2.1. Purification by flash column chromatography (EtOAc) afforded peptide 19 
as a yellow oil (0.164 g, 56%), Rf 0.18 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 2.30 (3H, s, Acetyl-CH3), 2.80 (3H, s, NCH3), 3.04 (1H, dd, 
J = 14.4, J = 11.0, Phe-CHH), 3.35 (1H, dd, J = 14.4, J = 5.3, Phe-CHH), 3.75 (3H, s, 
Ester-CH3), 3.86 (1H, dd, J = 17.7, J = 4.0, Gly-CHH), 4.02 (1H, dd, J = 17.7, J = 4.0, 
Gly-CHH), 5.22 (1H, dd, J = 11.0, J = 5.3, Phe-α-CH), 6.55 (1H, m, Gly-NH), 7.16 (2H, 
br d, J = 7.3, Ar-H), 7.20-7.32 (3H, m, Ar-H);  
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 31.9 (NCH3), 34.4 (Phe-CH2), 41.4 
(Gly-CH2), 52.4 (Ester-CH3), 58.9 (Phe-α-CH), 126.9 (Ar-C), 128.5 (Ar-C), 128.6 (Ar-C), 
136.5 (Ar-C), 168.8 (C=O), 170.0 (C=O), 170.6 (C=O);  
IR Umax /cm-1 (oil) 3327 m (N-H), 2952 w (C-H), 1737 s (Ester C=O), 1636 s (Amide 
C=O), 1496 m (C=C), 1260 s (C-O);  
HRMS (ESI) [M+H]+ m/z calcd. for C15H21N2O4: 293.1496 found: 293.1496. 
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4.12 General procedure for the preparation of tryptophan containing 
peptides  
 
L-Tryptophan methyl ester hydrochloride (0.637 g, 2.50 mmol) and K2CO3 (0.498 g, 3.60 
mmol) were dissolved in distilled water (30 mL) and stirred for 10 min at room 
temperature. The free amine was extracted with DCM (3 x 20 mL), dried (MgSO4) and 
concentrated by rotary evaporation. The resulting oil was dissolved in DCM (20 mL); the 
appropriate N-protected amino acid (1.00 mmol), HBTU (0.379 g, 1.00 mmol) and 
DIPEA (0.174 mL, 1.00 mmol) were then added to the reaction mixture, which was 
stirred for 12 h. The resulting suspension was filtered and washed with 1M HCl (20 mL), 
sat. NaHCO3 (3 x 20 mL) and H2O (20 mL). The organic layers were then dried (MgSO4) 
and concentrated to dryness in vacuo. The resulting oil was recrystallized from DCM / 
hexanes.  
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4.12.1 Ac-Gly-Trp-OMe (20) 
 
Peptide 20 was synthesised from L-tryptophan methyl ester hydrochloride (0.637 g, 2.50 
mmol) and N-acetylglycine (0.117 g, 1.00 mmol), using the procedure in Section 4.12. 
The crude compound was recrystallised from DCM / hexanes to afford 20 as an orange 
solid (0.279 g, 88%); m.p. 177-180 °C. 
1H NMR (400 MHz, CD3OD) δ 1.93 (3H, s, Acetyl-CH3), 3.21 (1H, dd, J = 14.6, J = 7.4, 
Trp-CHH), 3.26-3.31 (1H, m, Trp-CHH), 3.65 (3H, s, Ester-CH3), 3.81 (2H, d, J = 4.1, 
Gly-CH2), 4.74 (1H, app q, J = 7.4, Trp-α-CH), 6.99-7.03 (1H, m, Trp-Ar-H), 7.06-7.10 
(2H, m, Trp-Ar-H), 7.30-7.33 (1H, m, Trp-Ar-H), 7.48-7.50 (1H, m, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CD3OD) δ 22.4 (Acetyl-CH3), 28.4 (Trp-CH2), 43.4 (Gly-CH2), 
52.7 (Ester-CH3), 54.8 (Trp-α-CH), 110.3 (Ar-C), 112.3 (Ar-CH), 119.1 (Ar-CH), 119.9 
(Ar-CH), 122.5 (Ar-CH), 124.6 (Ar-CH), 128.7 (Ar-C), 138.0 (Ar-C), 171.4 (C=O), 173.7 
(C=O), 173.8 (C=O).  
IR Umax /cm-1 (solid) 3235 m (N-H), 3060 w (C-H), 2951 w (C-H), 1749 s (Ester C=O), 
1642 m (amide C=O), 1436 m (C-H).  
HRMS (ESI) [M+H]+ m/z calcd. for C16H20N3O4: 318.1448, found: 318.1451.  
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4.13 General procedure for the Boc protection of tryptophan residues  
 
Tryptophan containing peptides (0.75 mmol) was dissolved in DCM (20 mL) and treated 
with NEt3 (0.105 mL, 0.75 mmol). A solution of Boc anhydride (0.327 g, 1.50 mmol) in 
DCM (5 mL) was added dropwise to the peptide solution, and heated under reflux for 16 
h. The solution was allowed to cool to room temperature, before concentration to 
dryness by rotary evaporation. The crude compound was purified by flash column 
chromatography and the resulting residue was recrystallised from DCM / hexanes to 
afford the Boc protected peptide. 
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4.13.1 Ac-Gly-Trp(Boc)-OMe (22) 
 
Peptide 22 was synthesised from Ac-Gly-Trp-OMe (20) (0.238 g, 0.75 mmol) using the 
procedure in Section 4.13. Purification by flash column chromatography (EtOAc) 
followed by recrystallisation from DCM / hexanes gave 20 as an off-white solid (0.276 g, 
88%); m.p. 92-95 °C, Rf 0.16 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.66 (9H, s, Boc-(CH3)3), 1.96 (3H, s, Acetyl-CH3), 3.19 
(1H, dd, J = 14.6, J = 6.0, Trp-CHH), 3.27 (1H, dd, J = 14.6, J = 6.0, Trp-CHH), 3.69 
(3H, s, Ester-CH3), 3.83-3.94 (2H, m, Gly-CH2), 4.90 (1H, dd, J = 7.8, J = 6.0, Trp-α-
CH), 6.48 (1H, br t, J = 5.0, Gly-NH), 6.94 (1H, br d, J = 7.8, Trp-NH), 7.22 (1H, t, J = 
7.7, Trp-Ar-H), 7.30 (1H, t, J = 6.9, Trp-Ar-H), 7.41 (1H, s, Trp-Ar-H), 7.47 (1H, d, J = 
7.7, Trp-Ar-H), 8.08 (1H, br d, J = 6.9, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 27.3 (Trp-CH2), 28.1 (Boc-(CH3)3), 
43.1 (Gly-CH2), 52.5 (Ester-CH3), 52.6 (Trp-α-CH), 83.8 (Boc-C), 114.7 (Ar-C), 115.3 
(Ar-C), 118.6 (Ar-C), 122.6 (Ar-C), 124.2 (Ar-C), 124.6 (Ar-C), 130.3 (Ar-C), 135.2 (Ar-
C), 149.5 (C=O), 168.8 (C=O), 170.6 (C=O). 
IR Umax /cm-1 (solid) 3273 m (N-H), 3058 w (C-H), 2933 w (C-H), 1740 s (Ester C=O), 
1658 m (amide C=O), 1428 m (C-H), 1246 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C21H28N3O6: 418.1973, found: 418.1973. 
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4.14 General procedure for the olefination of tryptophan containing 
peptides 
 
Tryptophan containing peptides (0.238 mmol), Pd(OAc)2 (5 mg, 0.024 mmol, 10 mol%), 
AgOAc (0.100 g, 0.599 mmol) and styrene (0.109 mL, 0.952 mmol) were stirred together 
in toluene (3 mL) at 100 °C for 2 h. The reaction was then allowed to cool to room 
temperature and filtered through a plug of Celite© before the filtrate was concentrated to 
dryness. The resulting residue was purified by column chromatography and 
recrystallized in DCM / hexanes. 
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4.14.1 Synthesis of modified peptide 23a 
 
Following the general procedure in Section 4.14, the reaction of Ac-Gly-Trp(Boc)-OMe 
(22) (0.100 g, 0.238 mmol), Pd(OAc)2 (5 mg, 0.024 mmol, 10 mol%), AgOAc (0.100 g, 
0.599 mmol) and styrene (0.109 mL, 0.952 mmol) gave a crude product that was a 
mixture of the mono-olefinated peptide 23a and the di-olefinated peptide 23a’ in a ratio 
of 20:1, as judged by 1H NMR spectroscopy. Purification by flash column 
chromatography (EtOAc) followed by recrystallisation from DCM / hexanes gave 23a as 
an off-white solid (0.101 g, 82); m.p. 116-118 °C, Rf 0.26 (EtOAc) and 23a’′ as an off-
white solid (0.002 g, 1%); m.p. 98-99 °C, Rf 0.42 (EtOAc). 
Data for 23a: 
1H NMR (400 MHz, CDCl3) δ 1.64 (9H, s, Boc-(CH3)3), 1.92 (3H, s, Acetyl-CH3), 3.38 
(1H, dd, J = 14.5, J = 6.6, Trp-CHH), 3.47 (1H, dd, J = 14.5, J = 6.6, Trp-CHH), 3.55 
(3H, s, Ester-CH3), 3.74 (1H, dd, J = 16.7, J = 5.0, Gly-CHH), 3.84 (1H, dd, J = 16.7, J = 
5.0, Gly-CH2), 4.89 (1H, dt, J = 7.6, J = 6.6, Trp-α-CH), 5.89 (1H, br t, J = 5.0, Gly-NH), 
6.41 (1H, br d, J = 7.6, Trp-NH), 6.78 (1H, d, J = 16.6, alkene-CH), 7.27-7.34 (4H, m, 
alkene-CH / Ar-H), 7.39 (2H, t, J = 7.6, Ar-H), 7.51-7.56 (3H, m, Ar-H), 8.13 (1H, d, J = 
8.1, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 27.3 (Trp-CH2), 28.3 (Boc-(CH3)3), 
42.9 (Gly-CH2), 52.6 (Ester-CH3), 52.6 (Trp-α-CH), 84.2 (Boc-C), 114.3 (Ar-C), 115.6 
(Ar-C), 118.5 (Ar-C), 119.9 (alkene-CH), 122.9 (Ar-C), 124.8 (Ar-C), 126.6 (Ar-C), 128.1 
(Ar-C), 128.8 (Ar-C), 129.9 (Ar-C), 132.5 (alkene-CH), 135.8 (Ar-C), 136.2 (Ar-C), 136.7 
(Ar-C), 150.4 (C=O), 168.3 (C=O), 170.3 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3281 m (N-H), 2955 w (C-H), 1726 s (Ester C=O), 1647 m (amide 
C=O), 1523 m (C=C), 1455 m (C-H), 1205 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C29H34N3O6: 520.2442, found: 520.2436. 
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Data for 23a’: 
1H NMR (400 MHz, CDCl3) δ 1.60 (9H, s, Boc-(CH3)3), 1.84 (3H, s, Acetyl-CH3), 3.43-
3.46 (1H, m, Trp-CHH), 3.50 (3H, s, Ester-CH3), 3.63-3.68 (3H, m, Gly-CH2 / Trp-CHH), 
4.78-4.84 (1H, m, Trp-α-CH), 5.92 (1H, br t, J = 4.6, Gly-NH), 6.26 (1H, br d, J = 7.7, 
Trp-NH), 6.67 (1H, d, J = 16.6, alkene-CH), 7.04 (1H, d, J = 16.6, alkene-CH), 7.21-7.34 
(5H, m, alkene-CH / Ar-H), 7.35-7.44 (5H, m, Ar-H), 7.53 (2H, d, J = 7.4, Ar-H), 7.57 
(2H, d, J = 7.4, Ar-H), 7.84 (1H, d, J = 16.2, alkene-CH), 8.15 (1H, d, J = 8.1, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.7 (Acetyl-CH3), 28.3 (Boc-(CH3)3), 28.5 (Trp-CH2),  
42.7 (Gly-CH2), 52.4 (Ester-CH3), 53.1 (Trp-α-CH), 84.2 (Boc-C), 114.7 (Ar-C),114.9 (Ar-
C), 119.6 (Ar-C), 121.8 (Ar-C), 124.8 (Ar-C), 126.6 (Ar-C), 126.6 (Ar-C), 126.8 (Ar-C), 
127.8 (Ar-C), 128.2 (Ar-C), 128.6 (Ar-C), 128.8 (Ar-C), 131.4 (Ar-C), 132.3 (Ar-C), 133.7 
(Ar-C), 136.4 (Ar-C), 136.9 (Ar-C), 137.1 (Ar-C), 137.2 (Ar-C), 150.1 (C=O), 168.4 
(C=O), 170.1 (C=O), 171.6 (C=O).  
IR Umax /cm-1 (solid) 3226 m (N-H), 2978 w (C-H), 1720 s (Ester C=O), 1638 m (amide 
C=O), 1424 m (C-H), 1250 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C37H40N3O6: 622.2912, found: 622.2910. 
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4.15 Removal of the Boc protecting group from tryptophan residues 
4.15.1 Synthesis of modified peptide 21 
 
Peptide 23a (0.060 g, 0.115 mmol) was dissolved in trifluoroacetic acid (3 mL, 39.2 
mmol) and left to stir at room temperature for 2 h. The resulting solution was then 
concentrated to by rotary evaporation to give peptide 21 as a dark brown solid (0.047 g, 
97%); m.p. 132-134 ˚C.  
1H NMR (400 MHz, CDCl3) δ 1.86 (3H, s, Acetyl-CH3), 3.43-3.54 (2H, m, Trp-CH2), 3.65 
(3H, s, Ester-CH3), 3.74 (1H, dd, J = 17.0, J = 5.0, Gly-CHH), 3.81 (1H, dd, J = 17.0, J = 
5.0, Gly-CHH), 4.90 (1H, dt, J = 7.5, J = 5.0, Trp-α-CH), 6.44 (1H, br t, J = 5.0, Gly-NH), 
6.58 (1H, br d, J = 7.5, Trp-NH), 6.87 (1H, d, J = 16.5, Alkene-CH), 7.04-7.10 (2H, m, 
Alkene-CH / Ar-H), 7.19 (1H, t, J = 6.9, Trp-Ar-H), 7.29 (2H, t, J = 8.2, Ar-H), 7.35-7.40 
(3H, m, Ar-H), 7.49 (2H, m, Ar-H),  8.41 (1H, br s, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.1 (Acetyl-CH3), 26.3 (Trp-CH2), 42.9 (Gly-CH2), 
52.9 (Ester-CH3), 53.4 (Trp-α-CH), 109.8 (Ar-C), 110.9 (Ar-C), 116.2 (Alkene-C=C), 
118.3 (Ar-C), 120.2 (Ar-C), 126.2 (Ar-C), 127.1 (Alkene-C=C), 128.1 (Ar-C),  128.8 (Ar-
C), 129.0 (Ar-C), 134.2 (Ar-C), 136.5 (Ar-C), 136.5 (Ar-C), 168.5 (C=O), 171.5 (C=O), 
172.5 (C=O). 
IR Umax /cm-1 (solid) 3312 m (N-H), 3058 s (C-H), 2952 s (C-H), 1728 s (Ester C=O), 
1654 m (C=C), 1541 m (C=C).  
HRMS (ESI) [M+H]+ m/z calcd. for C24H26N3O4: 420.1918, found: 420.1918. 
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4.16 Synthesis of modified peptide 23b-f 
4.16.1 Synthesis of modified peptide 23b 
 
Modified peptide 23b was prepared from Ac-Gly-Trp(Boc)-OMe (22) (0.100 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 23b and the di-olefinated peptide in a ratio of 24:1. Purification by 
flash column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes 
gave 23b as a yellow oil (0.099 g, 78%); Rf 0.25 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.63 (9H, s, Boc-(CH3)3), 1.91 (3H, s, Acetyl-CH3), 2.37 
(3H, s, Ar-CH3), 3.37 (1H, dd, J = 14.4, J = 6.4, Trp-CHH), 3.46 (1H, dd, J = 14.4, J = 
6.4, Trp-CHH), 3.55 (Ester-CH3), 3.72 (1H, dd, J = 16.8, J = 5.0, Gly-CHH), 3.83 (1H, 
dd, J = 16.8, J = 5.0, Gly-CHH), 4.88 (1H, dt, J = 7.6, J = 6.4, Trp-α-CH), 5.86 (1H, m, 
Gly-NH), 6.38 (1H, br d, J = 7.6, Trp-NH), 6.73 (1H, d, J = 16.7, alkene-CH), 7.18-7.24 
(2H, m, alkene-CH / Ar-H), 7.27-7.32 (2H, m, Ar-H), 7.38 (1H, d, J = 4.6, Ar-H), 7.44 
(2H, d, J = 8.0, Ar-H), 7.51 (1H, br d, J = 7.0, Ar-H), 8.13 (1H, d, J = 8.0, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 21.3 (Ar-CH3), 22.8 (Acetyl-CH3), 27.2 (Trp-CH2), 28.2 
(Boc-(CH3)3), 42.9 (Gly-CH2), 52.5 (Ester-CH3), 52.6 (Trp-α-CH), 84.0 (Boc-C), 114.2 
(Ar-C), 115.5 (Ar-C), 118.4 (Ar-C), 118.8 (alkene-C), 122.8 (Ar-C), 124.7 (Ar-C), 126.4 
(Ar-C), 127.0 (Ar-C), 128.5 (Ar-C), 129.4 (Ar-C), 129.9 (Ar-C), 132.4 (alkene-C), 133.9 
(Ar-C), 135.8 (Ar-C), 136.3 (Ar-C), 138.0 (Ar-C), 150.4 (C=O), 168.4 (C=O), 170.3 
(C=O), 171.8 (C=O).  
IR Umax /cm-1 (oil) 3286 m (N-H), 3053 w (C-H), 2978 w (C-H), 1728 s (Ester C=O), 1648 
m (amide C=O), 1235 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C30H36N3O6: 534.2599, found: 534.2602  
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4.16.2 Synthesis of modified peptide 23c 
 
Modified peptide 23c was prepared from Ac-Gly-Trp(Boc)-OMe (22) (0.100 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 23c and the di-olefinated peptide in a ratio of 14:1. Purification by 
flash column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes 
gave 23c as yellow solid (0.077 g, 59%); m.p. 150-152 °C, Rf 0.18 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.62 (9H, s, Boc-(CH3)3), 1.90 (3H, s, Acetyl-CH3), 3.35 
(1H, dd, J = 14.2, J = 6.6, Trp-CHH), 3.44 (1H, dd, J = 14.2, J = 6.6, Trp-CHH), 3.54 
(3H, s, Ester-CH3), 3.71 (1H, dd, J = 16.9, J = 5.0, Gly-CHH), 3.80-3.85 (4H, m, Ph-
OCH3 / Gly-CHH), 4.87 (1H, dt, J = 7.4, J = 6.6, Trp-α-CH), 5.92 (1H, br t, J = 5.0, Gly-
NH), 6.44 (1H, d, J = 7.4, Trp-NH), 6.70 (1H, d, J = 16.4, alkene-CH), 6.91 (2H, d, J = 
8.9, Ar-H), 7.15 (1H, d, J = 16.4, alkene-CH), 7.21-7.24 (1H, m, Trp-Ar-H), 7.26-7.30 
(1H, m, Trp-Ar-H), 7.36 (1H, d, J = 4.6, Ar-H), 7.46-7.50 (3H, m, Ar-H), 8.11 (1H, d, J = 
8.2, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (acety-CH3), 27.2 (Trp-CH2), 28.3 (Boc-(CH3)3), 
42.9 (Gly-CH2), 52.6 (Ester-CH3), 55.3 (Trp-α-CH), 84.0 (Boc-C), 113.8 (OMe), 114.2 
(Ar-C), 115.6 (Ar-C), 117.7 (Ar-C), 118.4 (Ar-C), 122.8 (Ar-C), 124.6 (Ar-C), 127.0 (Ar-
C), 127.8 (Ar-C), 128.5 (Ar-C), 129.5 (Ar-C), 130.0 (Ar-C), 132.1 (Ar-C), 135.8 (Ar-C), 
136.5 (Ar-C), 150.4 (C=O), 168.3 (C=O), 170.3 (C=O), 171.8 (C=O).   
IR Umax /cm-1 (solid) 3296 m (N-H), 3051 w (C-H), 2963 w (C-H), 1727 s (Ester C=O), 
1658 m (amide C=O), 1510 m (C=C), 1260 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C30H36N3O7: 550.2548, found: 550.2549  
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4.16.3 Synthesis of modified peptide 23d 
 
Modified peptide 23d was prepared from Ac-Gly-Trp(Boc)-OMe (22) (0.100 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained only the mono-olefinated 
peptide 23d. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 23d as a yellow oil (0.113 g, 87%); Rf 0.27 
(EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.63 (9H, s, Boc-(CH3)3), 1.92 (3H, s, Acetyl-CH3), 3.33 
(1H, dd, J = 14.4, J = 6.6, Trp-CHH), 3.41 (1H, dd, J = 14.4, J = 6.6, Trp-CHH), 3.53 
(3H, s, Ester-CH3), 3.72 (1H, dd, J = 16.7, J = 5.0, Gly-CHH), 3.83 (1H, dd, J = 16.7, J = 
5.0, Gly-CHH), 4.87 (1H, dt, J = 7.4, J = 6.6, Trp-α-CH), 6.01 (1H, br t, J = 5.0, Gly-NH), 
6.73 (1H, d, J = 16.9, alkene-CH), 7.22-7.24 (6H, m, alkene-CH / Ar-H), 7.46-7.52 (3H, 
m, Ar-H), 8.10 (1H, d, J = 8.2, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 27.4 (Trp-CH2), 28.2 (Boc-(CH3)3), 
43.0 (Gly-CH2), 52.6 (Ester-CH3), 52.6 (Trp-α-CH), 84.2 (Boc-C), 114.6 (Ar-C), 115.6 
(Ar-C), 118.5 (Ar-C), 122.9 (Ar-C), 124.9 (Ar-C), 127.0 (Ar-C), 127.7 (Ar-C), 128.5 (Ar-
C), 128.9 (Ar-C), 129.9 (Ar-C), 130.9 (Ar-C), 133.6 (Ar-C), 135.3 (Ar-C), 135.8 (Ar-C), 
150.3 (C=O), 168.4 (C=O), 170.4 (C=O), 171.8 (C=O).  
IR Umax /cm-1 (oil) 3281 m (N-H), 2950 w (C-H), 1728 s (Ester C=O), 1648 m (amide 
C=O), 1455 m (C-H).  
HRMS (ESI) [M+H]+ m/z calcd. for C29H33N3O6Cl: 554.2052, found: 554.2056. 
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4.16.4 Synthesis of modified peptide 23e 
 
Modified peptide 23e was prepared from Ac-Gly-Trp(Boc)-OMe (22) (0.100 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 23e and the di-olefinated peptide in a ratio of 13:1. Purification by 
flash column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes 
gave 23e as an off-white solid (0.099 g, 71%); m.p. 169-172 °C, Rf 0.36 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.63 (9H, s, Boc-(CH3)3), 1.91 (3H, s, Acetyl-CH3), 3.33 
(1H, dd, J = 14.6, J = 6.4, Trp-CHH), 3.41 (1H, dd, J = 14.6, J = 6.4, Trp-CHH), 3.53 
(3H, s, Ester-CH3), 3.74 (1H, dd, J = 16.9, J = 5.0, Gly-CHH), 3.85 (1H, dd, J = 16.9, J = 
5.0, Gly-CHH), 4.89 (1H, dt, J = 7.8, J = 6.6, Trp-α-CH), 6.10 (1H, br t, J = 5.0, Gly-NH), 
6.72 (1H, d, J = 7.8, Trp-NH), 6.81 (1H, d, J = 16.6, alkene-CH), 7.22-7.26 (1H, m, Ar-
H), 7.29-7.35 (2H, m, Ar-H), 7.45 (1H, d, J = 16.6, alkene-CH), 7.52 (1H, d, J = 7.3, Ar-
H), 7.63 (4H, dt, J = 8.2, J = 7.3, Ar-H), 8.11 (1H, d, J = 8.2, Ar-H).   
13C{1H} NMR (100 MHz, CDCl3) δ 22.8 (Acetyl-CH3), 27.6 (Trp-CH2), 28.2 (Boc-(CH3)3), 
43.0 (Gly-CH2), 52.6 (Ester-CH3), 52.6 (Trp-α-CH), 84.3 (Boc-C), 115.1 (Ar-C), 155.6 
(Ar-C), 118.6 (Ar-C), 122.5 (Ar-C), 123.0 (Ar-C), 125.1 (Ar-C), 125.6 (Ar-C), 126.6 (Ar-
C), 127.6 (Ar-C), 128.5 (Ar-C), 129.8 (Ar-C), 130.5 (Ar-C), 135.4 (Ar-C), 135.8 (Ar-C), 
140.3 (Ar-C), 150.3 (C=O), 168.4 (C=O), 170.5 (C=O), 171.9 (C=O).  
IR Umax /cm-1 (solid) 3282 m (N-H), 3070 w (C-H), 2980 w (C-H), 1728 s (Ester C=O), 
1647 m (amide C=O), 1541 m (C=C), 1237 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C30H33N3O6F3: 588.2316, found: 588.2312. 
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4.16.5 Synthesis of modified peptide 23f 
  
Modified peptide 23f was prepared from Ac-Gly-Trp(Boc)-OMe (22) (0.100 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained only the mono-olefinated 
peptide 23f. Purification by flash column chromatography (EtOAc) followed by 
recrystallisation from DCM / hexanes gave 23f as a yellow solid (0.105 g, 81%); m.p. 
144-147 °C, Rf 0.18 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.64 (9H, s, Boc-(CH3)3), 1.95 (3H, s, Acetyl-CH3), 3.31-
3.41 (2H, m, Trp-CH2), 3.52 (3H, s, Ester-CH3), 3.76 (1H, dd, J = 16.6, J = 5.0, Gly-NH), 
3.86 (1H, dd, J = 16.6, J = 5.0, Gly-CHH), 4.88 (1H, app q, J = 8.2, Trp-α-CH), 6.04 (1H, 
br t, J = 5.0, Gly-NH), 6.65 (1H, d, J = 8.2, Trp-NH), 6.83 (1H, d, J = 16.4, alkene-CH), 
7.23-7.27 (1H, m, Ar-H), 7.30-7.36 (2H, m, Ar-H), 7.49-7.53 (2H, m, alkene-CH / Ar-H), 
7.65 (4H, s, Ar-H), 8.09 (1H, d, J = 8.2, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 27.8 (Trp-CH2), 28.2 (Boc-(CH3)3), 
43.1 (Gly-CH2), 52.6 (Ester-CH3), 52.6 (Trp-α-CH), 84.5 (Boc-C), 110.9 (Ar-C), 115.5 
(Ar-C), 115.7 (Ar-C), 118.7 (Ar-C), 119.0 (Ar-C), 123.1 (Ar-C), 123.7 (Ar-C), 125.33 (Ar-
C), 127.0 (Ar-C), 129.8 (Ar-C), 130.0 (Ar-C), 132.5 (Ar-C), 135.8 (Ar-C), 141.4 (Ar-C), 
150.3 (C=O), 168.4 (C=O), 170.5 (C=O), 171.9 (C=O).    
IR Umax /cm-1 (solid) 3283 m (N-H), 3050 w (C-H), 2979 w (C-H), 2225 s (C≡N), 1728 s 
(Ester C=O), 1649 m (amide C=O), 1239 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C30H33N4O6: 545.2395, found: 545.2398. 
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4.17 Synthesis of dipeptides 25a-d  
4.17.1 Ac-Ala-Trp-OMe (24a) 
 
The peptide Ac-Ala-Trp-OMe (24a) was synthesised from L-tryptophan methyl ester 
hydrochloride (0.637 g, 2.50 mmol) and N-acetyl-L-alanine (0.131 g, 1.00 mmol), using 
the procedure in Section 4.12. The crude compound was recrystallised from DCM / 
hexanes to afford 24a as an off-white solid (0.315 g, 95%); m.p. 77-79 °C. 
1H NMR (400 MHz, CDCl3) δ 1.30 (3H, d, J = 6.9, Ala-CH3), 1.86 (3H, s, Acetyl-CH3), 
3.27-3.36 (2H, m, Trp-CH2), 4.48 (1H, dq, J = 7.3, J = 6.9, Ala-α-CH), 4.88 (1H, dt, J = 
7.8, J = 5.5, Trp-α-CH), 5.57 (1H, br d, J = 7.3, Ala-NH), 6.49 (1H, br d, J = 7.8, Trp-NH), 
7.03 (1H, d, Trp-Ar-H), 7.09-7.19 (1H, m, Trp-Ar-H), 7.16-7.20 (1H, m, Trp-Ar-H), 7.33-
7.36 (1H, m, Trp-Ar-H), 7.50-7.51 (1H, m, Trp-Ar-H), 8.18 (1H, br s, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 18.3 (Ala-CH3), 23.0 (Acetyl-CH3), 27.3 (Trp-CH2), 
48.7 (Ala-α-CH), 52.5 (Ester-CH3), 52.9 (Trp-α-CH), 109.6 (Ar-C), 111.3 (Ar-C), 118.5 
(Ar-C), 119.7 (Ar-C), 122.3 (Ar-C), 123.1 (Ar-C), 127.5 (Ar-C), 136.0 (Ar-C), 169.8 
(C=O), 171.8 (C=O), 172.0 (C=O).  
IR Umax /cm-1 (solid) 3276 m (N-H), 3060 w (C-H), 2976 w (C-H), 1723 s (Ester C=O), 
1631 m (amide C=O), 1550 m (C=C), 1405 m (C-H), 1256 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C17H22N3O4: 332.1605, found: 332.1605. 
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4.17.2 Ac-Leu-Trp-OMe (24b) 
 
The peptide Ac-Leu-Trp-OMe (24b) was synthesised from L-tryptophan methyl ester 
hydrochloride (0.637 g, 2.50 mmol) and N-acetyl-L-leucine (0.173 g, 1.00 mmol), using 
the procedure in Section 4.12. The crude compound was recrystallised from DCM / 
hexanes to afford 24b as a white solid (0.261 g, 78%); m.p. 79-81 °C. 
1H NMR (400 MHz, CDCl3) δ 0.84-0.86 (6H, m, Leu-CH3 (x2)), 1.48-1.64 (3H, m, (Leu-
CH/Leu-CH2), 1.80 (3H, s, Acetyl-CH3), 3.25-3.37 (2H, m, Trp-CH2), 3.64 (3H, s, Ester-
CH3), 4.56 (1H, dt, J = 8.0, J = 5.6, Leu-α-CH), 4.86 (1H, dt, J = 7.7, J = 5.4, Trp-α-CH), 
6.65 (1H, br d, J = 8.0, Leu-NH), 6.99 (1H, d, J = 2.1, Trp-Ar-H), 7.03-7.14 (2H, m, Trp-
Ar-H / Trp-NH), 7.10-7.16 (1H, br d, J = 7.7, Trp-Ar-H), 7.26-7.28 (1H, m, Trp-Ar-H), 7.49 
(1H, d, J = 7.7, Trp-Ar-H), 8.73 (1H, s, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.2 (Leu-CH3 x2), 22.9 (Leu-CH2), 23.1 (Acetyl-CH3), 
24.8 (Leu-CH(CH3)2), 27.5 (Trp-CH2), 41.3 (Leu-CH2), 51.7 (Leu-α-CH), 52.6 (Ester-
CH3), 52.9 (Trp-α-CH), 109.5 (Ar-C), 111.4 (Ar-C), 118.6 (Ar-C), 119.7 (Ar-C), 122.2 (Ar-
C), 123.5 (Ar-C), 127.6 (Ar-C), 136.1 (Ar-C), 170.2 (C=O), 172.0 (C=O), 172.1 (C=O).  
IR Umax /cm-1 (solid) 3226 m (N-H), 3058 w (C-H), 2954 w (C-H), 1733 s (Ester C=O), 
1638 m (amide C=O), 1541 m (C=C), 1452 m (C-H), 1254 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C20H28N3O4: 374.2074, found: 374.2069.  
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4.17.3 Ac-Phe-Trp-OMe (24c) 
 
The peptide Ac-Phe-Trp-OMe (24c) was synthesised from L-tryptophan methyl ester 
hydrochloride (0.637 g, 2.50 mmol) and N-acetyl-L-phenylalanine (0.207 g, 1.00 mmol), 
using the procedure in Section 4.12. The crude compound was recrystallised from DCM 
/ hexanes to afford 24c as an off-white solid (0.363 g, 89%); m.p. 75-76 °C. 
1H NMR (400 MHz, CDCl3) δ 1.70 (3H, s, Acetyl-CH3), 2.95 (1H, dd, J = 14.0, J = 6.7, 
Phe-CHH), 3.03 (1H, dd, J = 14.0, J = 6.7, Phe-CHH), 3.22 (2H, d, J = 5.5, Trp-CH2), 
3.62 (3H, s, Ester-CH3), 4.76 (1H, app q, J = 7.6, Phe-α-CH), 4.81-4.86 (1H, m, Trp-α-
CH), 6.41 (1H, d, J = 7.6, Phe-NH), 6.83 (1H, d, J = 7.8, Trp-NH), 6.86 (1H, d, J = 1.8, 
Ar-H), 7.02 (1H, t, J = 7.8, Ar-H), 7.09-7.14 (3H, m, Ar-H), 7.19-7.26 (4H, m, Ar-H), 7.37 
(1H, d, J = 7.8, Ar-H), 8.54 (1H, m, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.0 (Acetyl-CH3), 27.4 (Trp-CH2), 38.1 (Phe-CH2), 
52.4 (Ester-CH3), 52.9 (Trp-α-CH), 54.1 (Phe-α-CH), 109.5 (Ar-C), 111.4 (Ar-C), 118.4 
(Ar-C), 119.7 (Ar-C), 122.3 (Ar-C), 123.1 (Ar-C), 127.0 (Ar-C), 127.4 (Ar-C), 128.6 (Ar-
C), 129.4 (Ar-C), 136.0 (Ar-C), 136.4 (Ar-C), 169.9 (C=O), 170.3 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3275 m (N-H), 3024 w (C-H), 2989 w (C-H), 1727 s (Ester C=O), 
1646 m (amide C=O), 1550 m (C=C), 1401 m (C-H), 1220 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C23H26N3O4: 408.1918, found: 408.1914. 
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4.17.4 Ac-Met-Trp-OMe (24d) 
 
The peptide Ac-Met-Trp-OMe (24d) was synthesised from L-tryptophan methyl ester 
hydrochloride (0.637 g, 2.50 mmol) and N-acetyl-L-methionine (0.191 g, 1.00 mmol), 
using the procedure in Section 4.12. The crude compound was recrystallised from DCM 
/ hexanes to afford 24d as a white solid (0.376 g, 96%); m.p. 70-72 °C. 
1H NMR (400 MHz, CDCl3) δ 1.82-1.90 (4H, m, Acetyl-CH3 / Met-CHH), 1.96-2.02 (4H, 
m, Met-CH3 / Met-CHH), 2.48 (2H, br t, J = 7.4, Met-CH2), 3.26 (2H, br d, J = 5.6, Trp-
CH2), 3.65 (3H, s, Ester-CH3), 4.65-4.71 (1H, m, Met-α-CH), 4.82-4.87 (1H, m, Trp-α-
CH), 6.94 (1H, s, Trp-Ar-H), 7.01-7.08 (2H, m, Trp-Ar-H / Met-NH), 7.12 (1H, t, J = 7.6, 
Trp-Ar-H), 7.26 (1H, br d, J = 7.6, Trp-Ar-H), 7.32 (1H, br d, J = 7.6, Trp-NH), 7.49 (1H, 
br d, J = 7.6, Trp-Ar-H), 8.82 (1H, m, Trp-Ar-NH).      
13C{1H}  NMR (100 MHz, CDCl3) δ 14.9 (Met-CH3), 23.1 (Acetyl-CH3), 27.3 (Trp-CH2), 
29.9 (Met-CH2), 31.5 (Met-CH2), 51.9 (Met-α-CH), 52.5 (Ester-CH3), 52.8 (Trp-α-CH), 
109.5 (Ar-C), 111.4 (Ar-C), 118.4 (Ar-C), 119.7 (Ar-C), 122.3 (Ar-C), 123.1 (Ar-C), 127.4 
(Ar-C), 136.1 (Ar-C), 169.9 (C=O), 170.8 (C=O), 171.9 (C=O). 
IR Umax /cm-1 (solid) 3275 m (N-H), 3058 w (C-H), 2976 w (C-H), 1731 s (Ester C=O), 
1640 m (amide C=O), 1451 m (C-H), 1254 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C19H26N3O4S: 392.1639, found: 392.1640. 
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4.17.5 Ac-Ala-Trp(Boc)-OMe (25a) 
 
Peptide 25a was synthesised from Ac-Ala-Trp-OMe (24a) (0.249 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (EtOAc) 
followed by recrystallisation from DCM / hexanes gave 25a as an off-white solid (0.291 
g, 90%); m.p. 83-84 °C, Rf 0.19 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.33 (3H, d, J = 6.9, Ala-CH3), 1.66 (9H, s, Boc-(CH)3)3), 
1.90 (3H, s, Acetyl-CH3), 3.20 (1H, dd, J = 14.6, J = 5.5, Trp-CHH), 3.30 (1H, dd, J = 
14.6, J = 5.5, Trp-CHH), 3.71 (3H, s, Ester-CH3), 4.39-4.47 (1H, m, Ala-α-CH), 4.85-4.90 
(1H, m, Trp-α-CH), 5.91 (1H, br d, J = 7.3, Ala-NH), 6.59 (1H, br d, J = 7.3, Trp-NH), 
7.22 (1H, t, J = 7.3, Trp-Ar-H), 7.30 (1H, t, J = 7.3, Trp-Ar-H), 7.39 (1H, s, Trp-Ar-H), 
7.47 (1H, d, J = 7.3, Trp-Ar-H), 8.08-8.10 (1H, m, Trp-Ar-H),  
13C{1H} NMR (100 MHz, CDCl3) δ 18.1 (Ala-CH3), 22.8 (Acetyl-CH3), 27.2 (Trp-CH2), 
28.1 (Boc(CH3)3), 48.6 (Ala-α-CH), 52.4 (Ester-CH3), 52.6 (Trp-α-CH), 83.7 (Boc-C), 
114.8 (Ar-C), 115.2 (Ar-C), 118.7 (Ar-C),122.5 (Ar-C), 124.1 (Ar-C), 124.4 (Ar-C), 130.3 
(Ar-C), 135.1 (Ar-C), 149.5 (C=O), 170.0 (C=O), 171.7 (C=O), 172.3 (C=O). 
IR Umax /cm-1 (solid) 3286 m (N-H), 2933 w (C-H), 1728 s (Ester C=O), 1648 m (amide 
C=O), 1452 m (C-H), 1213 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C22H30N3O6: 432.2129, found: 432.2130. 
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4.17.6 Ac-Leu-Trp(Boc)-OMe (25b) 
 
Peptide 25b was synthesised from Ac-Leu-Trp-OMe (24b) (0.280 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (75% 
EtOAc / pet. ether) followed by recrystallisation from DCM / hexanes gave 25b as a 
white solid (0.337 g, 95%); m.p. 84-86 °C, Rf 0.20 (75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.86-0.91 (6H, m, Leu-CH3 (x2)), 1.46-1.50 (1H, m, Leu-
CH), 1.59-1.63 (2H, m, Leu-CH2), 1.66 (9H, s, Boc-(CH3)3), 1.91 (3H, s, Acetyl-CH3), 
3.19 (1H, dd, J = 14.7, J = 5.8, Trp-CHH),  3.26 (1H, dd, J = 14.7, J = 5.8, Trp-CHH), 
3.68 (3H, s, Ester-CH3), 4.49 (1H, dt, J = 8.4, J = 5.4, Leu-α-CH), 4.83-4.88 (1H, m, Trp-
α-CH), 6.24 (1H, br d, J = 8.4, Leu-NH), 6.93 (1H, br d, J = 7.3, Trp-NH), 7.20-7.24 (1H, 
m, Trp-Ar-H), 7.28-7.32 (1H, m, Trp-Ar-H), 7.46 (1H, s, Trp-Ar-H), 7.49 (1H, d, J = 7.7, 
Trp-Ar-H), 8.06-8.10 (1H, m, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.0 (Leu-CH3), 22.9 (Leu-CH3), 23.0 (Acetyl-CH3), 
24.7 (Leu-CH), 27.3 (Trp-CH2), 28.2 (Boc-(CH3)3), 41.0 (Leu-CH2), 51.6 (Leu-α-CH), 
52.5 (Ester-CH3), 52.6 (Trp-α-CH), 83.8 (Boc-C), 114.8 (Ar-C), 115.3 (Ar-C), 118.8 (Ar-
C), 122.6 (Ar-C), 124.3 (Ar-C), 124.5 (Ar-C), 130.4 (Ar-C), 135.2 (Ar-C), 149.6 (C=O), 
170.2 (C=O), 171.8 (C=O), 172.1 (C=O). 
IR Umax /cm-1 (solid) 3284 m (N-H), 2932 w (C-H), 1731 s (Ester C=O), 1647 m (amide 
C=O), 1526 m (C=C), 1452 m (C-H), 1254 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C25H36N3O6: 474.2599, found: 474.2595.  
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4.17.7 Ac-Phe-Trp(Boc)-OMe (25c) 
 
Peptide 25c was synthesised from Ac-Phe-Trp-OMe (24c) (0.306 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (75% 
EtOAc / pet. ether) followed by recrystallisation from DCM / hexanes gave 25c as a 
white solid (0.305 g, 80%); m.p. 79-81 °C, Rf 0.28 (75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.59 (9H, s, Boc-(CH3)3), 1.79 (3H, s, Acetyl-CH3), 2.93 
(1H, dd, J = 13.8, J = 7.4, Phe-CHH), 2.97-3.18 (2H, m, Phe-CHH / Trp-CHH), 3.13 (1H, 
dd, J = 14.8, J = 5.8, Trp-CHH), 3.59 (3H, s, Ester-CH3), 4.57 (1H, app q, J = 7.3, Phe-α-
CH), 4.75 (1H, dt, J = 7.6, J = 5.8, Trp-α-CH), 6.03 (1H, br d, J = 7.6, Trp-NH), 6.31 (1H, 
br d, J = 7.4, Phe-NH), 7.07-7.12 (3H, m, Ar-H), 7.13-7.22 (4H, m, Ar-H), 7.24-7.28 (2H, 
m, Ar-H), 8.01 (1H, m Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 27.3 (Trp-CH2), 28.1 (Boc-(CH3)3), 
38.0 (Phe-CH2), 52.4 (Ester-CH3), 52.6 (Trp-α-CH), 54.2 (Phe-α-CH), 83.7 (Boc-C), 
114.5 (Ar-C), 115.3 (Ar-C), 118.6 (Ar-C), 122.5 (Ar-C), 124.2 (Ar-C), 124.5 (Ar-C), 126.9 
(Ar-C), 128.5 (Ar-C), 129.2 (Ar-C), 130.2 (Ar-C), 135.2 (Ar-C), 136.3 (Ar-C), 149.5 
(C=O), 169.9 (C=O), 170.6 (C=O), 171.3 (C=O).   
IR Umax /cm-1 (solid) 3278 m (N-H), 3033 w (C-H), 2934 w (C-H), 1736 s (Ester C=O), 
1642 m (amide C=O), 1441 m (C-H), 1235 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C28H34N3O6: 508.2442, found: 508.2436. 
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4.17.8 Ac-Met-Trp(Boc)-OMe (25d) 
 
Peptide 25d was synthesised from Ac-Met-Trp-OMe (24d) (0.294 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (75% 
EtOAc / pet. ether) followed by recrystallisation from DCM / hexanes gave 25d as a 
white solid (0.262 g, 71%); m.p. 80-81 °C, Rf 0.17 (75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.59 (9H, s, Boc-(CH3)3), 1.84-1.88 (4H, m, Acetyl-CH3 / 
Met-CHH), 1.94-1.97 (4H, m, Met-CHH / Met-CH3), 2.42-2.52 (2H, m, Met-CH2), 3.13 
(1H, dd, J = 14.8, J = 6.2, Trp-CHH), 3.18 (1H, dd, J = 14.8, J = 6.2, Trp-CHH), 3.62 
(3H, s, Ester-CH3), 4.54 (1H, app q, J = 7.1, Met-α-CH), 4.78-4.82 (1H, m, Trp-α-CH), 
6.42 (1H, br d, J = 7.1, Met-NH), 6.98 (1H, br d, J = 7.7, Trp-NH), 7.12-7.16 (1H, m, Trp-
Ar-H), 7.20-7.24 (1H, m, Trp-Ar-H), 7.36 (1H, br s, Trp-Ar-H), 7.40 (1H, d, J = 7.9, Trp-
Ar-H), 8.01 (1H, m, Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 14.9 (Met-CH3), 22.9 (Acetyl-CH3), 27.2 (Trp-CH2), 
28.1 (Boc-(CH3)3), 29.8 (Met-CH2), 31.4 (Met-CH2), 51.8 (Met-α-CH), 52.4 (Ester-CH3), 
52.5 (Trp-α-CH), 83.7 (Boc-C), 114.6 (Ar-C), 115.2 (Ar-C), 118.6 (Ar-C),122.5 (Ar-
C),124.1 (Ar-C), 124.5 (Ar-C), 130.1 (Ar-C), 135.2 (Ar-C), 148.4 (C=O), 170.0 (C=O), 
171.1 (C=O), 171.5 (C=O)  
IR Umax /cm-1 (solid) 3287 m (N-H), 3050 w (C-H), 2978 w (C-H), 1739 s (Ester C=O), 
1636 m (amide C=O), 1445 m (C-H), 1220 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C24H34N3O6S: 492.2163, found: 492.2156.  
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4.18 Synthesis of modifed dipeptides 26a-d  
4.18.1 Synthesis of modified peptide 26a 
 
Modified peptide 26a was prepared from Ac-Ala-Trp(Boc)-OMe (25a) (0.103 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 26a and the di-olefinated peptide in a ratio of 14:1. Purification by 
flash column chromatography (75% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 26a as an off-white solid (0.086 g, 68%); m.p. 93-95 °C, Rf 0.26 
(75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.20 (3H, d, J = 7.0, Ala-CH3), 1.56 (9H, s, Boc-(CH3)3), 
1.79 (3H, s, Acetyl-CH3), 3.25-3.36 (2H, m, Trp-CH2), 3.48 (3H, s, Ester-CH3), 4.33 (1H, 
dq, J = 7.4, J = 7.0, Ala-α-CH), 4.81 (1H, dt, J = 7.8, J = 7.3, Trp-α-CH), 5.82 (1H, br d, J 
= 7.4, Ala-NH), 6.51 (1H, br d, J = 7.8, Trp-NH), 6.69 (1H, d, J = 16.7, alkene-CH), 7.15-
7.27 (4H, m, Ar-H/alkene-CH), 7.31 (2H, t, J = 7.4, Ar-H), 7.48 (3H, d, J = 7.4, Ar-H), 
8.06 (1H, d, J = 8.2, Ar-H).     
13C{1H} NMR (100 MHz, CDCl3) δ 18.3 (Ala-CH3), 23.1 (Acetyl-CH3), 27.5 (Trp-CH2), 
28.2 (Boc-(CH3)3), 48.5 (Ala-α-CH), 52.5 (Ester-CH3), 52.6 (Trp-α-CH), 84.1 (Boc-C), 
114.4 (Ar-C), 115.6 (Ar-C), 118.7 (Ar-C), 119.3 (alkene-CH), 122.8 (Ar-C), 124.7 (Ar-C), 
126.5 (Ar-C), 128.0 (Ar-C), 128.7 (Ar-C), 129.9 (Ar-C), 132.4 (alkene-CH), 135.8 (Ar-C), 
136.2 (Ar-C), 136.7 (Ar-C), 150.3 (C=O), 169.7 (C=O), 171.8 (C=O), 171.9 (C=O). 
IR Umax /cm-1 (solid) 3281 m (N-H), 3036 w (C-H), 2928 w (C-H), 1725 s (Ester C=O), 
1631 m (amide C=O), 1541 m (C=C), 1448 m (C-H), 1221 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C30H36N3O6: 534.2599, found: 534.2600.  
 180 
 
4.18.2 Synthesis of modified peptide 26b 
 
Modified peptide 26b was prepared from Ac-Leu-Trp(Boc)-OMe (25b) (0.113 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 26b and the di-olefinated peptide in a ratio of 19:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 26b as an off-white solid (0.085 g, 62%); m.p. 97-98°C, Rf 0.22 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.86-0.88 (6H, m, Leu-CH3 (x2)), 1.37-1.41 (1H, m, Leu-
CH), 1.54-1.59 (2H, m, Leu-CH2), 1.63 (9H, s, Boc-(CH3)3), 1.87 (3H, s, Acetyl-CH3), 
3.31-3.43 (2H, m, Trp-CH2), 3.57 (3H, s, Ester-CH3), 4.41 (1H, dt, J = 8.6, J = 5.4, Leu-
α-CH), 4.87 (1H, app q, J = 7.2, Trp-α-CH), 5.66 (1H, br d, J = 8.6, Leu-NH), 6.51 (1H, 
br d, J = 7.7, Trp-NH), 6.75 (1H, d, J = 16.6, alkene-CH), 7.24-7.33 (5H, m, Ar-H / 
alkene-CH), 7.39 (2H, t, J = 7.4, Ar-H), 7.56-7.58 (2H, m, Ar-H), 8.13 (1H, d, J = 8.3, Ar-
H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.0 (Leu-CH3), 22.8 (Leu-CH3), 23.1 (Acetyl-CH3), 
24.6 (Leu-CH), 27.7 (Trp-CH2), 28.3 (Boc-(CH3)3), 41.2 (Leu-CH2), 51.3 (Leu-α-CH), 
52.5 (Ester-CH3), 52.5 (Trp-α-CH), 84.0 (Boc-C), 114.5 (Ar-C), 115.6 (Ar-C), 118.7 (Ar-
C), 120.0 (alkene), 122.9 (Ar-C), 124.7 (Ar-C), 126.6 (Ar-C), 128.0 (Ar-C), 128.7 (Ar-C), 
129.9 (Ar-C), 132.4 (alkene), 135.8 (Ar-C), 136.2 (Ar-C), 136.8 (Ar-C), 150.4 (C=O), 
169.8 (C=O), 171.7 (C=O), 172.0 (C=O).  
IR Umax /cm-1 (solid) 3268 m (N-H), 2927 w (C-H), 1728 s (Ester C=O), 1647 m (amide 
C=O), 1451 m (C-H), 1255 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C33H42N3O6 576.3068, found: 576.3062. 
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4.18.3 Synthesis of modified peptide 26c 
 
Modified peptide 26c was prepared from Ac-Phe-Trp(Boc)-OMe (25c) (0.121 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 26c and the di-olefinated tryptophan residue in a ratio of 12:1. 
Purification by flash column chromatography (50% EtOAc / pet. ether) followed by 
recrystallisation from DCM / hexanes gave 26c as an off-white solid (0.075 g, 52%); 
m.p. 150-151 °C, Rf 0.31 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.62 (9H, s, Boc-(CH3)3), 1.82 (3H, s, Acetyl-CH3), 2.92 
(1H, dd, J = 13.7, J = 7.8, Phe-CHH), 3.00 (1H, dd, J = 13.7, J = 6.0, Phe-CHH), 3.23-
3.33 (2H, m, Trp-CH2), 3.50 (3H, s, Ester-CH3), 4.53-4.59 (1H, m, Phe-α-CH), 4.80 (1H, 
app q, J = 7.3, Trp-α-CH), 5.59-5.62 (1H, m, Phe-NH), 6.19-6.22 (1H, m, Trp-NH), 6.71 
(1H, d, J = 16.5, alkene-CH), 7.13-7.25 (6H, m, Ar-H), 7.26-7.30 (3H, m, Ar-H / alkene-
CH), 7.35-7.42 (3H, m, Ar-H), 7.53 (2H, d, J = 7.3, Ar-H), 8.11 (1H, d, J = 8.2, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 23.2 (Acetyl-CH3), 27.7 (Trp-CH2), 28.4 (Boc-(CH3)3), 
38.4 (Phe-CH2), 52.6 (Ester-CH3), 52.7 (Trp-α-CH), 54.4 (Phe-α-CH), 84.2 (Boc-C), 
114.4 (Ar-C), 115.7 (Ar-C), 118.7 (Ar-C), 120.0 (alkene-CH), 123.0 (Ar-C), 124.9 (Ar-C), 
126.7 (Ar-C), 127.1 (Ar-C), 128.1 (Ar-C), 128.7 (Ar-C), 128.9 (Ar-C), 129.4 (Ar-C), 130.0 
(Ar-C), 132.5 (alkene-CH), 135.9 (Ar-C), 136.2 (Ar-C), 136.5 (Ar-C), 136.9 (Ar-C), 150.5 
(C=O), 169.9 (C=O), 170.5 (C=O), 171.6 (C=O). 
IR Umax /cm-1 (solid) 3238 m (N-H), 3058 w (C-H), 2950 w (C-H), 1749 s (Ester C=O), 
1638 m (amide C=O), 1523 m (C=C), 1213 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C36H40N3O6: 610.2912, found: 610.2912. 
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4.18.4 Synthesis of modified peptide 26d 
 
Modified peptide 26d was prepared from Ac-Met-Trp(Boc)-OMe (25d) (0.117 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 26d and the di-olefinated peptide in a ratio of 8.1. Purification by flash 
column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 26d as an off-white solid (0.105 g, 74%); m.p. 94-96°C, Rf 0.15 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.63 (9H, s, Boc-(CH3)3), 1.86-1.90 (4H, m, Met-CHH / 
Acetyl-CH3), 1.93-1.97 (1H, m, Met-CH), 2.00 (3H, s, Met-CH3), 2.47-2.53 (2H, m, Met-
CH2), 3.35 (1H, dd, J = 14.5, J = 6.9, Trp-CHH), 3.41 (1H, dd, J = 14.5, J = 6.9, Trp-
CHH), 3.59 (3H, s, Ester-CH3), 4.54 (1H, dt, J = 7.3, J = 7.0, Met-α-CH), 4.87 (1H, dt, J 
= 7.3, J = 6.9, Trp-α-CH), 6.11 (1H, d, J = 7.3, Met-NH), 6.73-6.78 (2H, m, alkene-CH / 
Ar-H), 7.25-7.32 (3H, m, alkene-CH / Ar-H), 7.36-7.40 (2H, m, Ar-H), 7.54-7.57 (3H, m, 
Ar-H), 8.14 (1H, d, J = 8.4, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 14.8 (Met-CH3), 23.1 (Acetyl-CH3), 27.4 (Trp-CH2), 
28.2 (Boc-(CH3)3), 29.8 (Met-CH2), 31.4 (Met-CH2), 51.6 (Met-α-CH), 52.5 (Ester-CH3), 
52.6 (Trp-α-CH), 84.1 (Boc-C), 114.2 (Ar-C), 115.6 (Ar-C), 118.6 (Ar-C), 120.0 (alkene-
CH), 122.9 (Ar-C), 124.8 (Ar-C), 126.6 (Ar-C), 128.1 (Ar-C), 128.7 (Ar-C), 129.7 (Ar-C), 
132.6 (alkene-CH), 135.8 (Ar-C), 136.2 (Ar-C), 136.7 (Ar-C), 150.3 (C=O), 169.7 (C=O), 
170.7 (C=O), 171.8 (C=O). 
IR Umax /cm-1 (solid) 3282 m (N-H), 3060 w (C-H), 2927 w (C-H), 1743 s (Ester C=O), 
1646 m (amide C=O), 1459 m (C-H).  
HRMS (ESI) [M+H]+ m/z calcd. for C32H40N3O6S: 594.2632 found: 594.2631. 
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4.19 Synthesis of dipeptides 28a-d  
4.19.1 Ac-Trp-Leu-OMe (27a) 
 
The peptide Ac-Trp-Leu-OMe (27a) was synthesised from L-leucine methyl ester 
hydrochloride (0.454 g, 2.50 mmol) and N-acetyl-L-tryptophan (0.246 g, 1.00 mmol), 
using the procedure in Section 4.12. The crude compound was recrystallised from DCM 
/ hexanes to afford 27a as a yellow solid (0.295 g, 79%); m.p. 74-76 °C. 
1H NMR (400 MHz, CDCl3) δ 0.83-0.89 (6H, m, Leu-CH3 (x2)), 1.09-1.17 (1H, m, Leu-
CH), 1.46-1.53 (2H, m, Leu-CH2), 2.00 (3H, s, Acetyl-CH3), 3.14 (1H, dd, J = 14.5, J = 
8.3, Trp-CHH), 3.29-3.35 (1H, m, Trp-CHH), 3.66 (3H, s, Ester-CH3), 4.48 (1H, dt, J = 
8.3, J = 5.2, Trp-α-CH), 4.73-4.78 (1H, m, Leu-NH), 6.04-6.06 (1H, m, Trp-NH), 6.34-
6.35 (1H, m, Leu-NH), 7.12-7.16 (2H, m, Trp-Ar-H), 7.21 (1H, t, J = 7.6, Trp-Ar-H), 7.37 
(1H, d, J = 7.6, Trp-Ar-H), 7.75 (1H, d, J = 7.6, Trp-Ar-H), 8.17 (1H, m, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 22.6 (Leu-CH3), 23.3 (Acetyl-CH3), 
24.6 (Leu-CH), 28.5 (Trp-CH2), 41.4 (Leu-CH2), 50.9 (Leu-α-CH), 52.2 (Ester-CH3), 53.7 
(Trp-α-CH), 110.6 (Ar-C), 111.1 (Ar-C), 118.9 (Ar-C), 119.8 (Ar-C), 122.2 (Ar-C), 123.4 
(Ar-C), 127.4 (Ar-C), 136.1 (Ar-C), 169.9 (C=O), 171.0 (C=O), 172.8 (C=O). 
IR Umax /cm-1 (solid) 3274 m (N-H), 3058 w (C-H), 2918 w (C-H), 1735 s (Ester C=O), 
1640 m (amide C=O), 1433 m (C-H), 1340 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C20H28N3O4: 374.2074, found: 374.2077. 
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4.19.2 Ac-Trp-Met-OMe (27b) 
 
The peptide Ac-Trp-Met-OMe (27b) was synthesised from L-methionine methyl ester 
hydrochloride (0.499 g, 2.50 mmol) and N-acetyl-L-tryptophan (0.246 g, 1.00 mmol), 
using the procedure in Section 4.12. The crude compound was recrystallised from DCM 
/ hexanes to afford 27b as a yellow solid (0.348 g, 89%); m.p. 126-127 °C. 
1H NMR (400 MHz, CDCl3) δ 1.76-1.81 (1H, m, Met-CHH), 1.87 (3H, s, Met-CH3), 1.92-
1.98 (4H, m, Acetyl-CH3 / Met-CHH), 2.27 (2H, d, J = 7.7, Met-CH2), 3.10 (1H, dd, J = 
14.6, J = 7.6, Trp-CHH), 3.20 (1H, dd, J = 14.6, J = 5.4, Trp-CHH), 3.56 (3H, s, Ester-
CH3), 4.48 (1H, dt, J = 7.6, J = 5.4, Met-α-CH), 4.73 (1H, dt, J = 7.4, J = 5.4, Trp-α-CH), 
6.50 (1H, d, J = 7.7, Met-NH), 6.71 (1H, d, J = 7.4, Trp-NH), 7.00-7.03 (2H, m, Trp-Ar-
H), 7.09 (1H, t, J = 7.5, Trp-Ar-H), 7.26 (1H, d, J = 7.5, Trp-Ar-H), 7.56 (1H, d, J = 7.5, 
Trp-Ar-H), 8.47 (1H, br s, Trp-Ar-NH). 
13C{1H} NMR (100 MHz, CDCl3) δ 15.2 (Met-CH3), 23.1 (Acetyl-CH3), 28.3 (Met-CH2), 
29.6 (Met-CH2), 31.2 (Trp-CH2), 51.5 (Trp-α-CH), 52.4 (Ester-CH3), 53.9 (Met-α-CH), 
110.1 (Ar-C), 111.2 (Ar-C), 118.5 (Ar-C), 119.5 (Ar-C), 122.0 (Ar-C), 123.4 (Ar-C), 124.4 
(Ar-C), 136.1 (Ar-C), 170.2 (C=O), 171.4 (C=O), 171.7 (C=O). 
IR Umax /cm-1 (solid) 3291 m (N-H), 3054 w (C-H), 2914 w (C-H), 1743 s (Ester C=O), 
1631 m (amide C=O), 1431 m (C-H), 1224 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C19H26N3O4S: 392.1639, found: 392.1637. 
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4.19.3 Ac-Trp(Boc)-Leu-OMe (28a) 
 
Peptide 28a was synthesised from Ac-Trp-Leu-OMe (27a) (0.280 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (75% 
EtOAc / pet. ether) followed by recrystallisation from DCM / hexanes gave 28a as a 
white solid (0.464 g, 98%); m.p. 80-81 °C, Rf 0.21 (75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.85-0.88 (6H, m, Leu-CH3 (x2)), 1.49-1.55 (3H, m, Leu-
CH2 / Leu-CH), 1.65 (9H, s, Boc-(CH3)3), 1.99 (3H, s, Acetyl-CH3), 3.11 (1H, dd, J = 
14.5, J = 7.9, Trp-CHH), 3.20 (1H, dd, J = 14.5, J = 5.6, Trp-CHH), 3.66 (3H, s, Ester-
CH3), 4.46-4.51 (1H, m, Trp-α-CH), 4.79 (1H, dt, J = 7.6, J = 5.7, Leu-α-CH), 6.36 (1H, 
d, J = 7.9, Trp-NH), 6.53 (1H, d, J = 7.6, Leu-NH), 7.23 (1H, t, J = 7.1, Trp-Ar-H), 7.31 
(1H, t, J = 7.1, Trp-Ar-H), 7.50 (1H, br s, Trp-Ar-H), 7.67 (1H, d, J = 7.8, Trp-Ar-H), 8.12 
(1H, m, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Leu-CH3), 22.7 (Leu-CH3), 23.2 (Acetyl-CH3), 
24.7 (Leu-CH), 28.2 (Boc-(CH3)3), 28.2 (Trp-CH2),  41.4 (Leu-CH2), 50.9 (Leu-α-CH), 
52.3 (Ester-CH3), 53.2 (Trp-α-CH), 83.6 (Boc-C), 115.2 (Ar-C), 115.3 (Ar-C), 119.1 (Ar-
C), 122.7 (Ar-C), 124.5 (Ar-C), 124.6 (Ar-C), 130.3 (Ar-C), 135.4 (Ar-C), 149.6 (C=O), 
170.0 (C=O), 170.7 (C=O), 172.5 (C=O). 
IR Umax /cm-1 (solid) 3263 m (N-H), 3060 w (C-H), 2955 w (C-H), 1741 s (Ester C=O), 
1622 m (amide C=O), 1541 m (C=C), 1430 m (C-H), 1252 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C25H36N3O6: 474.2599, found: 474.2595. 
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4.19.4 Ac-Trp(Boc)-Met-OMe (28b) 
 
Peptide 28b was synthesised from Ac-Trp-Met-OMe (27b) (0.294 g, 0.75 mmol) using 
the procedure in Section 4.13. Purification by flash column chromatography (75% 
EtOAc / pet. ether) followed by recrystallisation from DCM / hexanes gave 28b as a 
white solid (0.398 g, 81%); m.p. 154-155 °C, Rf 0.19 (75% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.66 (9H, s, Boc-(CH3)3), 1.87-1.94 (1H, m, Met-CHH), 
2.00-2.09 (7H, m, Met-CHH / Met-CH3 / Acetyl-CH3), 2.38 (1H, br t, J = 7.3, Met-CH2), 
3.10 (1H, dd, J = 14.4, J = 8.0, Trp-CHH), 3.22 (1H, dd, J = 14.4, J = 5.5, Trp-CHH), 
3.66 (3H, s, Ester-CH3), 4.55 (1H, dt, J = 7.3, J = 5.0, Met-α-CH), 4.77 (1H, dt, J = 8.0, J 
= 5.5, Trp-α-CH), 6.49 (1H, d, J = 7.3, Met-NH), 6.57 (1H, d, J = 8.0, Trp-NH), 7.23 (1H, 
t, J = 7.5, Trp-Ar-H), 7.31 (1H, t, J = 7.5, Trp-Ar-H), 7.49 (1H, s, Trp-Ar-H), 7.65 (1H, d, J 
= 7.5, Trp-Ar-H), 8.10 (1H, m, Trp-Ar-H),       
13C{1H} NMR (100 MHz, CDCl3) δ 15.3 (Met-CH3), 23.2 (Acetyl-CH3), 28.1 (Boc-(CH3)3), 
28.2 (Trp-CH2), 29.7 (Met-CH2), 31.3 (Met-CH2), 51.6 (Trp-α-CH), 52.5 (Ester-CH3), 53.3 
(Met-α-CH),  83.6 (Boc-C), 115.1 (Ar-C), 115.2 (Ar-C), 119.0 (Ar-C), 122.7 (Ar-C), 124.5 
(Ar-C), 124.6 (Ar-C), 130.1 (Ar-C), 135.4 (Ar-C), 149.5 (C=O), 170.0 (C=O), 170.7 
(C=O), 171.4 (C=O).   
IR Umax /cm-1 (solid) 3291 m (N-H), 3055 w (C-H), 2915 w (C-H), 1743 s (Ester C=O), 
1631 m (amide C=O), 1431 m (C-H), 1224 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C24H34N3O6S: 492.2163, found: 492.2160. 
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4.20 Synthesis of modified peptides 29a-b 
4.20.1 Synthesis of modified peptide 29a 
 
Modified peptide 29a was prepared from Ac-Trp(Boc)-Leu-OMe (28a) (0.113 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 29a and the di-olefinated peptide in a ratio of 14:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 29a as an off-white solid (0.064 g, 47%); m.p. 94-97 °C, Rf 0.38 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.81-0.86 (6H, m, Leu-CH3 (x2)), 1.31-1.41 (1H, m, Leu-
CH), 1.43-1.47 (2H, m, Leu-CH2), 1.65 (9H, s, Boc-(CH3)3), 2.00 (3H, s, Acetyl-CH3), 
3.20 (1H, dd, J = 14.0, J = 9.7, Trp-CHH), 3.33 (1H, dd, J = 14.0, J = 5.6, Trp-CHH), 
3.50 (3H, s, Ester-CH3), 4.42 (1H, dt, J = 8.3, J = 5.6, Trp-α-CH), 4.77-4.83 (1H, m, Leu-
α-CH), 5.78 (1H, d, J = 8.3, Trp-NH), 6.55 (1H, d, J = 7.6, Leu-NH), 6.79 (1H, d, J= 16.6, 
alkene-CH), 7.25-7.34 (4H, m, alkene-CH / Ar-H), 7.35-7.39 (2H, m, Ar-H), 7.58 (2H, d, 
J = 7.1, Ar-H), 7.74 (1H, d, J = 7.1, Ar-H), 8.13 (1H, d, J = 7.7, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 22.0 (Leu-CH3), 22.5 (Leu-CH3), 23.2 (Acetyl-CH3), 
24.5 (Leu-CH), 28.2 (Boc-(CH3)3), 28.8 (Trp-CH2),  42.0 (Leu-CH2), 50.8 (Leu-α-CH), 
52.1 (Ester-CH3), 53.4 (Trp-α-CH), 83.8 (Boc-C), 114.8 (Ar-C), 115.5 (Ar-C), 118.9 (Ar-
C), 119.8 (alkene-CH), 123.1 (Ar-C), 124.8 (Ar-C), 126.6 (Ar-C), 127.9 (Ar-C), 128.7 (Ar-
C), 129.6 (Ar-C), 132.0 (alkene-CH), 135.9 (Ar-C), 136.2 (Ar-C), 136.9 (Ar-C), 150.4 
(C=O), 169.7 (C=O), 170.3 (C=O), 171.9 (C=O). 
IR Umax /cm-1 (solid) 3282 m (N-H), 3058 w (C-H), 2955 w (C-H), 1728 s (Ester C=O), 
1637 m (amide C=O), 1325 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C33H42N3O6: 576.3068, found: 576.3062. 
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4.20.2 Synthesis of modified peptide 29b 
 
Modified peptide 29b was prepared from Ac-Trp(Boc)-Met-OMe (28b) (0.117 g, 0.238 
mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained a mixture of the mono-
olefinated peptide 29b and the di-olefinated peptide in a ratio of 10:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 29b as an off-white solid (0.064 g, 45%); m.p. 100-103 °C, Rf 0.18 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.65 (9H, s, Boc-(CH3)3), 1.78-1.85 (1H, m, Met-CHH), 
1.94-2.01 (7H, m, Met-CHH / Met-CH3 / Acetyl-CH3), 2.28-2.35 (2H, m, Met-CH2), 3.19 
(1H, dd, J = 13.8, J = 9.8, Trp-CHH), 3.38 (1H, dd, J = 13.8, J = 5.5, Trp-CHH), 3.52 
(3H, s, Ester-CH3), 4.40 (1H, m, Trp-α-CH), 4.79 (1H, m, Met-α-CH), 6.00 (1H, br d, J = 
7.4, Trp-NH), 6.47 (1H, J = 7.4, Met-NH), 6.84 (1H, dd, J = 16.7, alkene-CH), 7.28-7.32 
(3H, m, alkene-CH / Ar-H), 7.35-7.40 (3H, m, Ar-H), 7.58-7.60 (2H, m, Ar-H), 7.69 (1H, 
d, J = 7.6, Ar-H), 8.12 (1H, d, J = 8.2, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 15.3 (Met-CH3), 23.2 (Acetyl-CH3), 28.3 (Boc-(CH3)3), 
28.8 (Trp-CH2), 29.5 (Met-CH2), 31.9 (Met-CH2), 51.6 (Met-α-CH), 52.4 (Ester-CH3), 
53.5 (Trp-α-CH), 83.9 (Boc-C), 114.8 (Ar-C), 115.6 (Ar-C), 118.8 (Ar-C), 119.7 (alkene-
CH), 123.1 (Ar-C), 124.8 (Ar-C), 126.6 (Ar-C), 127.9 (Ar-C), 128.7 (Ar-C), 129.6 (Ar-C), 
132.0 (alkene-CH), 136.0 (Ar-C), 136.1 (Ar-C), 136.9 (Ar-C), 150.4 (C=O), 169.7 (C=O), 
170.6 (C=O), 170.9 (C=O). 
IR Umax /cm-1 (solid) 3282 m (N-H), 3053 w (C-H), 2965 w (C-H), 1726 s (Ester C=O), 
1642 m (amide C=O), 1455 m (C-H), 1260 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C32H40N3O6S: 594.2632, found: 594.2635. 
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4.21  General procedure for the synthesis of tryptophan containing 
tripeptides 
 
Lithium hydroxide monohydrate (0.101 g, 2.40 mmol) was dissolved in Water (2 mL) and 
added to a solution of the dipeptide ester (0.80 mmol) in a 3:1 mixture of THF / MeOH (8 
mL). The solution was then stirred at room temperature for 8 h, followed by 
concentration to dryness in vacuo. The resulting residue was then acidified by the 
dropwise addition of 1M HCl (~2 mL), before extracting with EtOAc (4 x 10 mL). The 
organic layers were combined, dried (MgSO4), and concentrated to give a colourless oil. 
The crude dipeptide acid was carried through without further purification. The 
appropriate amino acid methyl ester hydrochloride (2.00 mmol) and K2CO3 (0.398 g, 
2.88 mmol) were dissolved in distilled water (30 mL) and stirred for 10 min at room 
temperature. The free amine was extracted with Et2O (3 x 20 mL), dried (MgSO4) and 
concentrated to dryness. The resulting residue was slurried in DCM (20 mL) before the 
dipeptide acid (0.80 mmol), HBTU (0.303 g, 0.80 mmol) and DIPEA (0.139 mL, 0.80 
mmol) were added. The suspension was then stirred for 16 h at room temperature. The 
suspension was then filtered and washed with 1M HCl (20 mL), sat. NaHCO3 (3 x 20 
mL) and water (20 mL). The organic layers were then dried (MgSO4) and concentration 
to dryness in vacuo. The resulting solid was triturated in Et2O (15 mL) and filtered to 
afford the corresponding tripeptide as a white solid. 
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4.21.1 Ac-Trp-Leu-Leu-OMe (30a) 
 
Peptide 30a was synthesised from Ac-Trp-Leu-OMe (27a) (0.299 g, 0.80 mmol) and L-
leucine methyl ester hydrochloride (0.363 g, 2.00 mmol), using the procedure in Section 
4.21. Purification by trituration (Et2O) afforded 30a as a white solid (0.370 g, 95%); 
m.p.187-188 °C. 
1H NMR (400 MHz, CDCl3) δ 0.83-0.86 (6H, m, Leu-(CH3)2), 0.92-0.94 (6H, m, Leu-
(CH3)2), 1.36-1.43 (1H, m, Leu-CHH), 1.48-1.55 (2H, m, Leu-CHH / Leu-CH(CH3)2),  
1.58-1.65 (3H, m, Leu-CH2 / Leu-CH(CH3)2), 1.97 (3H, s, Acetyl-CH3), 3.15 (1H, dd, J = 
14.6, J = 7.4, Trp-CHH), 3.28 (1H, dd, J = 14.6, J = 6.0, Trp-CHH), 3.73 (3H, s, Ester-
CH3), 4.40 (1H, m, Leu-α-CH), 4.56 (1H, dt, J = 8.4, J = 5.0, Leu-α-CH), 4.78 (1H, app q, 
J = 6.0, Trp-α-CH), 6.35-6.41 (2H, m, Leu-NH / Trp-NH), 6.54 (1H, d, J = 8.4, Leu-NH), 
7.08 (1H, m, Trp-Ar-H), 7.14 (1H, t, J = 7.9, Trp-Ar-H), 7.21 (1H, t, J = 7.9, Trp-Ar-H), 
7.36 (1H, d, J = 7.9, Trp-Ar-H), 7.72 (1H, d, J = 7.9, Ar-H), 8.23 (1H, br s, Trp-NH).  
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Leu-CH3), 22.0 (Leu-CH3), 22.7 (Leu-CH3), 22.8 
(Leu-CH3), 23.2 (Acetyl-CH3), 24.6 (Leu-CH2), 24.8 (Leu-CH2), 28.1 (Trp-CH2), 40.8 
(Leu-CH), 41.2 (Leu-CH), 50.7 (Leu-α-CH), 52.0 (Trp-α-CH), 52.3 (Ester-CH3), 53.8 
(Leu-α-CH), 110.4 (Ar-C), 111.3 (Ar-C), 118.8 (Ar-C), 119.8 (Ar-C), 122.4 (Ar-C), 123.3 
(Ar-C), 127.4 (Ar-C), 136.2 (Ar-C), 170.2 (C=O), 171.4 (C=O), 171.4 (C=O), 173.2 (C-
O).  
IR Umax /cm-1 (solid) 382 m (N-H), 3029 w (C-H), 2988 w (C-H), 1739 s (Ester C=O), 
1632 m (amide C=O), 1221 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C26H39N4O5: 487.2915, found: 487.2914. 
  
 191 
 
4.21.2 Ac-Leu-Trp-Leu-OMe (30b) 
 
Peptide 30b was synthesised from Ac-Leu-Trp-OMe (25b) (0.299 g, 0.80 mmol) and L-
leucine methyl ester hydrochloride (0.363 g, 2.00 mmol), using the procedure in Section 
4.21. Purification by trituration (Et2O) afforded 30b as a white solid (0.343 g, 88%); m.p. 
212-215 °C. 
1H NMR (400 MHz, CDCl3) δ 0.83-0.85 (6H, m, Leu-CH3 (x2)), 0.91 (6H, m, Leu-CH3 
(x2)), 1.37-1.69 (6H, m, Leu-CH (x2) / Leu-CH2 (x2)), 1.79 (3H, s, Acetyl-CH3), 3.17 (1H, 
dd, J = 14.6, J = 7.6, Trp-CHH), 3.36 (1H, dd, J = 14.6, J = 5.4, Trp-CHH), 3.67 (3H, s, 
Ester-CH3), 4.36-4.42 (1H, m, Leu-α-CH), 4.47 (1H, dt, J = 8.4, J = 5.0, Leu-α-CH), 4.73 
(1H, dt, J = 7.6, J = 5.4, Trp-α-CH), 5.69 (1H, d, J = 7.8, Leu-NH), 6.22 (1H, d, J = 8.4, 
Leu-NH), 6.70 (1H, d, J = 7.6, Trp-NH), 7.13-7.16 (2H, m, Trp-Ar-H), 7.21 (1H, J = 8.0, 
Trp-Ar-H), 7.38 (1H, d, J = 8.0, Trp-Ar-H), 7.72 (1H, d, J = 8.0, Trp-Ar-H), 8.14 (1H, br s, 
Trp-Ar-NH).   
13C{1H} NMR (100 MHz, CD3OD) δ 21.8 (Leu-CH3), 21.9 (Leu-CH3), 22.3 (Acetyl-CH3), 
23.3 (Leu-CH3), 23.3 (Leu-CH3), 25.7 (Leu-CH), 25.8 (Leu-CH), 28.4 (Trp-CH2), 41.4 
(Leu-CH2), 41.5 (Leu-CH2), 52.1 (Leu-α-CH), 52.6 (Ester-CH3), 53.4 (Trp-α-CH), 55.2 
(Leu-α-CH), 110.6 (Ar-C), 112.2 (Ar-C), 119.3 (Ar-C), 119.8 (Ar-C), 122.3 (Ar-C), 124.7 
(Ar-C), 128.9 (Ar-C), 138.0 (Ar-C), 173.5 (Ar-C), 173.8 (Ar-C), 174.3 (Ar-C), 147.5 (Ar-
C).  
IR Umax /cm-1 (solid) 3290 m (N-H), 3068 w (C-H), 2956 w (C-H), 1741 s (Ester C=O), 
1629 m (amide C=O), 1430 m (C-H), 1220 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C26H39N4O5: 487.2915, found: 487.2915. 
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4.21.3 Ac-Met-Trp-Met-OMe (30c) 
 
Peptide 30c was synthesised from Ac-Met-Trp-OMe (24d) (0.313 g, 0.80 mmol) and L-
methionine methyl ester hydrochloride (0.399 g, 0.80 mmol), using the procedure in 
Section 4.21. Purification by trituration (Et2O) afforded 30c as a white solid (0.335 g, 
80%); m.p. 191-193 °C. 
1H NMR (400 MHz, CDCl3) δ 1.77 (3H, s, Met-CH3), 1.89-1.97 (2H, m, Met-CH2), 2.00 
(3H, s, Acetyl-CH3), 2.03-2.06 (2H, m, Met-CH2), 2.09 (3H, s, Met-CH3), 2.23-2.29 (2H, 
m, Met-CH2), 2.49-2.61 (2H, m, Met-CH2), 3.17 (1H, dd, J = 14.5, J = 7.0, Trp-CHH), 
3.39 (1H, dd, J = 14.5, J = 5.5, Trp-CHH), 3.68 (3H, s, Ester-CH3), 4.51-4.60 (2H, m, 
Met-α-CH (x2)), 4.73-4.78 (1H, m, Trp-α-CH), 6.40 (1H, d, J = 7.3, Met-NH), 6.68 (1H, d, 
J = 7.8, Met-NH), 6.92 (1H, d, J = 7.7, Trp-NH), 7.10 (1H, d, J = 2.3, Trp-Ar-H), 7.12-
7.16 (1H, m, Trp-Ar-H), 7.18-7.22 (1H, m, Trp-Ar-H), 7.37 (1H, d, J = 7.6, Trp-Ar-H), 
7.64 (1H, d, J = 7.6, Trp-Ar-H), 8.27 (1H, br s, Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 15.2 (Met-CH3), 15.3 (Met-CH3), 22.8 (Acetyl-CH3), 
27.7 (Trp-CH2), 29.6 (Met-CH2), 30.2 (Met-CH2), 30.8 (Met-CH2), 31.0 (Met-CH2), 51.5 
(Met-α-CH), 52.5 (Ester-CH3), 52.9 (Met-α-CH), 54.0 (Trp-α-CH), 109.8 (Ar-C), 111.4 
(Ar-C), 118.6 (Ar-C), 119.8 (Ar-C), 122.3 (Ar-C), 123.8 (Ar-C), 127.4 (Ar-C), 136.2 (Ar-
C), 170.5 (C=O), 170.8 (C=O), 171.8 (C=O), 172.3 (C=O). 
IR Umax /cm-1 (solid) 3254 m (N-H), 3070 w (C-H), 2915 w (C-H), 17437 s (Ester C=O), 
1627 m (amide C=O), 1436 m (C-H), 1224 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C24H35N4O5S2: 523.2043, found: 523.2037. 
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4.21.4 Ac-Gly-Leu-Trp-OMe (30d) 
 
Peptide 30d was synthesised from Ac-Gly-Leu-OMe (12) (0.241 g, 0.80 mmol) and L-
tryptophan methyl ester hydrochloride (0.509 g, 2.00 mmol), using the procedure in 
Section 4.21. Purification by trituration (Et2O) afforded 30d as a white solid (0.255 g, 
74%); m.p. 144-146 °C. 
1H NMR (400 MHz, CDCl3) δ 0.86 (3H, d, J = 9.5, Leu-CH3), 0.88 (3H, d, J = 9.5, Leu-
CH3), 1.48-1.50 (1H, m, Leu-CHH), 1.57-1.63 (1H, m, Leu-CHH), 1.70-1.76 (1H, m, Leu-
CH(CH3)2), 1.91 (3H, s, Acetyl-CH3), 3.24 (1H, dd, J = 14.9, J = 6.3, Trp-CHH), 3.31 (1H, 
dd, J = 14.9, J = 5.0, Trp-CHH), 3.66-3.72 (1H, m, Gly-CHH), 3.70 (3H, s, Ester-CH3), 
3.80 (1H, dd, J = 16.8, J = 5.6, Gly-CHH), 4.58-4.60 (1H, m, Leu-α-CH), 4.88-4.93 (1H, 
m, Trp-α-CH), 6.28 (1H, br t, J = 5.3, Gly-NH), 6.70 (1H, br d, J = 8.6, Leu-NH), 6.98 
(1H, m, Trp-Ar-H), 7.05-7.10 (2H, m, Trp-Ar-H / Trp-NH), 7.16 (1H, t, J = 7.4, Trp-Ar-H), 
7.32 (1H, d, J = 7.4, Trp-Ar-H), 7.50 (1H, d, J = 7.4, Trp-Ar-H), 8.66 (1H, s, Trp-Ar-NH).   
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Leu-CH3 (x2)), 22.8 (Acetyl-CH3), 24.7 (Leu-
CH), 27.5 (Trp-CH2), 41.0 (Leu-CH2), 42.8 (Gly-CH2), 51.6 (Leu-α-CH), 52.5 (Ester-
CH3), 52.7 (Trp-α-CH), 109.3 (Ar-C), 111.4 (Ar-C), 118.3 (Ar-C), 119.4 (Ar-C), 122.1 (Ar-
C), 123.4 (Ar-C), 127.4 (Ar-C), 136.0 (Ar-C),169.0 (C=O), 171.0 (C=O), 171.9 (C=O), 
172.2 (C=O).  
IR Umax /cm-1 (solid) 3282 m (N-H), 3055 w (C-H), 2928 w (C-H), 1739 s (Ester C=O), 
1631 m (amide C=O), 1431 m (C-H). 
HRMS (ESI) [M+H]+ m/z calcd. for C22H31N4O5: 431.2289, found: 431.2286. 
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4.22.1 Ac-Trp(Boc)-Leu-Leu-OMe (31a) 
 
Peptide 31a was synthesised from Ac-Trp-Leu-Leu-OMe (30a) (0.268 g, 0.55 mmol) 
using the procedure in Section 4.13. Purification by flash column chromatography 
(EtOAc) followed by recrystallisation from DCM / hexanes gave 31a as a white solid. 
(0.284 g, 88%); m.p. 198-199 °C, Rf 0.16 (EtOAc). 
1H NMR (400 MHz, CD3OD) δ 0.88-0.95 (12H, m, Leu-CH3 (x4)), 1.52-1.63 (6H, m, Leu-
CH (x2) / Leu-CH2 (x2)), 1.67 (9H, s, Boc-(CH3)3), 1.91 (3H, s, Acetyl-CH3), 3.00 (1H, dd, 
J = 15.0, J = 8.2, Trp-CHH), 3.22 (1H, dd, J = 15.0, J = 5.1, Trp-CHH), 3.69 (3H, s, 
Ester-CH3), 4.39-4.45 (2H, m, Leu-α-CH (x2)), 4.71-4.75 (1H, m, Trp-α-CH), 7.21-7.24 
(1H, m, Trp-Ar-H), 7.26-7.30 (1H, m, Trp-Ar-H), 7.51 (1H, s, Trp-Ar-H), 7.65 (1H, d, J = 
8.0, Trp-Ar-H), 8.07 (1H, br d, J = 8.0, Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Leu-CH3), 22.1 (Leu-CH3), 22.6 (Leu-CH3), 22.7 
(Leu-CH3), 23.0 (Acetyl-CH3), 24.5 (Leu-CH), 24.9 (Leu-CH), 27.6 (Trp-CH2), 28.2 (Boc-
(CH3)3), 41.0 (Leu-CH2), 41.1 (Leu-CH2), 50.8 (Leu-α-CH), 51.9 (Trp-α-CH), 52.2 (Ester-
CH3), 53.1 (Leu-α-CH), 83.8 (Boc-C), 115.2 (Ar-C), 115.3 (Ar-C), 118.9 (Ar-C), 122.7 
(Ar-C), 124.3 (Ar-C), 124.5 (Ar-C), 130.3 (Ar-C), 135.3 (Ar-C), 149.7 (C=O), 170.4 
(C=O), 171.3 (C=O), 171.5 (C=O), 173.1 (C=O). 
IR Umax /cm-1 (solid) 3297 m (N-H), 2960 w (C-H), 1750 s (Ester C=O), 1628 m (amide 
C=O), 1246 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C31H47N4O7: 587.3439, found: 587.3441. 
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4.22.2 Ac-Leu-Trp(Boc)-Leu-OMe (31b) 
 
Peptide 31b was synthesised from Ac-Leu-Trp-Leu-OMe (30b) (0.268 g, 0.55 mmol) 
using the procedure in Section 4.13. Purification by flash column chromatography 
(EtOAc) followed by recrystallisation from DCM / hexanes gave 31b as a white solid. 
(0.287 g, 89%); m.p. 180-184 °C, Rf 0.14 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.84-0.91 (12H, m, Leu-CH3 (x4)), 1.42-1.61 (6H, m, Leu-
CH (x2) / Leu-CH2 (x2)), 1.66 (9H, s, Boc-(CH3)3), 1.90 (3H, s, Acetyl-CH3), 3.11-3.24 
(2H, m, Trp-CH2), 3.65 (3H, s, Ester-CH3), 4.43-4.52 (2H, m, Leu-α-CH (x2)), 4.73-4.79 
(1H, m, Trp-α-CH), 5.95 (1H, br d, J = 7.3, Leu-NH), 6.43 (1H, br d, J = 8.7, Trp-NH), 
6.90 (1H, br d, J = 7.8, Leu-NH), 7.24-7.34 (2H, m, Trp-Ar-H), 7.49 (1H, s, Trp-Ar-H), 
7.64 (1H, d, J = 7.8, Trp-Ar-H), 8.11 (1H, m, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 22.1 (Leu-CH3), 22.7 (Leu-CH3), 22.8 
(Leu-CH3), 22.9 (Acetyl-CH3), 24.7 (Leu-CH), 24.7 (Leu-CH), 27.7 (Trp-CH2), 28.2 (Boc-
(CH3)3), 41.1 (Leu-CH2), 41.2 (Leu-CH2), 50.8 (Leu-α-CH), 51.8 (Trp-α-CH), 52.2 (Ester-
CH3), 53.0 (Leu-α-CH), 83.7 (Boc-C), 115.2 (Ar-C), 115.3 (Ar-C), 119.1 (Ar-C), 122.7 
(Ar-C), 124.5 (Ar-C), 124.6 (Ar-C), 130.1 (Ar-C), 135.4 (Ar-C), 149.6 (C=O), 170.2 
(C=O), 170.3 (C=O), 172.0 (C=O), 172.6 (C=O). 
IR Umax /cm-1 (solid) 3254 m (N-H), 3073 w (C-H), 2957 w (C-H), 1720 s (Ester C=O), 
1631 m (amide C=O), 1545 m (C=C), 1439 m (C-H), 1291 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C31H47N4O7: 587.3439, found: 587.3441.  
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4.22.3 Ac-Met-Trp(Boc)-Met-OMe (31c) 
 
Peptide 31c was synthesised from Ac-Met-Trp-Met-OMe (30c) (0.268 g, 0.55 mmol) 
using the procedure in Section 4.13. Purification by flash column chromatography 
(EtOAc) followed by recrystallisation from DCM / hexanes gave 31c as a white solid. 
(0.287 g, 87%); m.p. 180-184 °C, Rf 0.35 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.63 (9H, s, Boc-(CH3)3), 1.88 (1H, dd, J = 14.6, J = 7.3 
Met-CHH), 1.92-1.94 (4H, m, Met-CH3 / Met-CHH), 1.96-1.99 (4H, m, Met-CH3 / Met-
CHH), 2.01-2.04 (4H, m, Acetyl-CH3 / Met-CHH), 2.33 (2H, t, J = 7.3, Met-CH2), 2.46-
2.51 (2H, m, Met-CH2), 3.09-3.20 (2H, m, Trp-CH2), 3.64 (3H, s, Ester-CH3), 4.54 (1H, 
dt, J = 7.3, J = 5.0, Met-α-CH), 4.66 (1H, dt, J = 7.3, J = 6.8, Met-α-CH),  4.82 (1H, dt, J 
= 7.5, J = 6.8, Trp-α-CH), 6.68 (1H, d, J = 7.8, Met-NH), 6.99 (1H, d, J = 7.8, Met-NH), 
7.18 (1H, t, J = 7.8, Trp-Ar-H), 7.25-7.30 (2H, m, Trp-Ar-H / Trp-NH), 7.48 (1H, s, trp-Ar-
H), 7.53 (1H, d, J = 7.8, Trp-Ar-H), 8.06 (1H, m, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 15.2 (Met-CH3), 15.3 (Met-CH3), 23.0 (Acetyl-CH3), 
28.0 (Trp-CH2), 28.1 (Boc-(CH3)3), 29.7 (Met-CH2), 30.0 (Met-CH2), 31.2 (Met-CH2), 31.5 
(Met-CH2), 51.5 (Met-α-CH), 52.3 (Ester-CH3), 52.4 (Met-α-CH), 53.3 (Trp-α-CH), 83.6 
(Boc-C), 115.0 (Ar-C), 115.2 (Ar-C), 118.9 (Ar-C), 122.6 (Ar-C), 124.5 (Ar-C), 124.6 (Ar-
C), 130.1 (Ar-C), 135.4 (Ar-C), 149.5 (C=O), 170.3 (C=O), 170.5 (C=O), 171.1 (C=O), 
171.6 (C=O). 
IR Umax /cm-1 (solid) 3260 m (N-H), 3069 w (C-H), 2919 w (C-H), 1728 s (Ester C=O), 
1631 m (amide C=O), 1453 m (C-H), 1224 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C29H43N4O7S2: 623.2568, found: 623.2571. 
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4.22.4 Ac-Gly-Leu-Trp(Boc)-OMe (31d) 
 
Peptide 31d was synthesised from Ac-Gly-Leu-Trp-OMe (30d) (0.237 g, 0.55 mmol) 
using the procedure in Section 4.13. Purification by flash column chromatography 
(EtOAc) followed by recrystallisation from DCM / hexanes gave 31d as a white solid. 
(0.181 g, 62%); m.p. 116-118 °C, Rf 0.10 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.88 (3H, d, J = 10.0, Leu-CH3), 0.91 (3H, d, J = 10.0, Leu-
CH3), 1.46-1.52 (1H, m, Leu-CH), 1.55-1.64 (2H, m, Leu-CH2), 1.68 (9H, s, Boc-(CH3)3), 
2.01 (3H, s, Acetyl-CH3), 3.19 (1H, dd, J = 14.8, J = 6.3, Trp-CHH), 3.27 (1H, dd, J = 
14.8, J = 6.3, Trp-CHH), 3.68 (3H, s, Ester-CH3), 3.80-3.92 (2H, m, Gly-CH2), 4.42-4.48 
(1H, m, Leu-α-CH), 4.88 (1H, dt, J = 7.4, J = 6.3, Trp-α-CH), 6.86-6.71 (2H, m, Gly-NH / 
Leu-NH), 6.94 (1H, d, J = 7.4, Trp-NH), 7.22 (1H, t, J = 7.4, Trp-Ar-H), 7.30 (1H, t, J = 
7.4, Trp-Ar-H), 7.42 (1H, s, Trp-Ar-H), 7.48 (1H, d, J = 7.4, Trp-Ar-H), 8.05 (1H, br d, 
Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 21.9 (Leu-CH3), 22.8 (Acetyl-CH3), 24.6 (Leu-CH), 
27.2 (Trp-CH2), 28.2 (Boc-(CH3)3), 40.4 (Leu-CH2), 43.2 (Gly-CH2), 51.7 (Leu-α-CH), 
52.4 (Ester-CH3), 52.5 (Trp-α-CH), 84.0 (Boc-C), 114.9 (Ar-C), 115.3 (Ar-C), 118.8 (Ar-
C), 122.6 (Ar-C), 124.3 (Ar-C), 124.5 (Ar-C), 130.4 (Ar-C), 135.1 (Ar-C), 149.9 (C=O), 
169.2 (C=O), 170.9 (C=O), 171.5 (C=O), 172.7 (C=O). 
IR Umax /cm-1 (solid) 3278 m (N-H), 3060 w (C-H), 2954 w (C-H), 1731 s (Ester C=O), 
1631 m (amide C=O), 1451 m (C-H), 1226 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C27H39N4O7: 531.2813, found: 531.2808.  
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4.23 Synthesis of modified tryptophan containing tripeptides 33a-d 
4.23.1 Synthesis of modified peptide 33a 
 
Modified peptide 33a was prepared from Ac-Trp(Boc)-Leu-Leu-OMe (32a) (0.140 g, 
0.238 mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in 
Section 4.14. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 33a and the mono-olefinated peptide in a ratio of 11:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 33a as an off-white solid (0.097 g, 59%); m.p. 165-167 °C, Rf 0.26 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.74-0.80 (12H, Leu-CH3 (x4)), 1.24-1.50 (6H, m, Leu-CH2 
(x2) / Leu-CH (x2)), 1.58 (Boc-(CH3)3), 1.85 (Acetyl-CH3), 3.21 (1H, dd, J = 14.3, J = 7.1, 
Trp-CHH), 3.28 (1H, dd, J = 14.3, J = 7.1, Trp-CHH), 3.60 (3H, s, Ester-CH3), 4.24 (1H, 
dt, J = 8.1, J = 5.7, Leu-α-CH), 4.33-4.39 (1H, m, Leu-α-CH), 4.72 (1H, app q, J = 7.3, 
Trp-α-CH), 6.12 (1H, br d, J = 8.1, Leu-NH), 6.20 (1H, br d, J = 7.9, Leu-NH), 6.25 (1H, 
br d, J = 7.3, Trp-NH), 6.69 (1H, d, J = 16.6, alkene-CH), 7.16-7.25 (4H, m, Ar-H), 7.28-
7.35 (3H, m, alkene-CH / Ar-H), 7.49 (2H, d, J = 7.5, Ar-H), 7.64 (1H, br d, J = 7.5, Ar-
H), 8.04 (1H, br d, J = 8.4, Ar-H).      
13C{1H} NMR (100 MHz, CDCl3) δ 21.0 (Leu-CH3), 21.0 (Leu-CH3), 21.6 (Leu-CH3), 21.7 
(Leu-CH3), 22.1 (Acetyl-CH3), 23.5 (Leu-CH), 23.8 (Leu-CH), 27.3 (Boc-(CH3)3), 28.7 
(Trp-CH2), 40.0 (Leu-CH2), 40.3 (Leu-CH2), 49.8 (Trp-α-CH), 50.8 (Leu-α-CH), 51.2 
(Leu-α-CH), 52.6 (Ester-CH3), 83.0 (Boc-C), 113.8 (Ar-C), 114.7 (Ar-C), 117.9 (Ar-C), 
119.1 (alkene-C), 122.0 (Ar-C), 123.9 (Ar-C), 125.6 (Ar-C), 127.0 (Ar-C), 127.8 (Ar-C), 
128.6 (Ar-C), 131.3 (alkene-C), 134.8 (Ar-C), 135.2 (Ar-C),135.8 (Ar-C), 149.4 (C=O), 
169.2 (C=O), 169.7 (C=O), 169.9 (C=O), 172.1 (C=O). 
IR Umax /cm-1 (solid) 3276 m (N-H), 2961 w (C-H), 1728 s (Ester C=O), 1631 m (amide 
C=O), 1541 m (C=C), 1455 m (C-H), 1258 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C39H52N4O7: 689.3909, found: 689.3908.  
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4.23.2 Synthesis of modified peptide 33b 
 
Modified peptide 33b was prepared from Ac-Leu-Trp(Boc)-Leu-OMe (32b) (0.140 g, 
0.238 mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in 
Section 4.14. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 33b and the mono-olefinated peptide in a ratio of 12:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 33b as an off-white solid (0.113 g, 69%); m.p. 100-104 °C, Rf 0.24 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.81 (3H, t, J = 6.2, Leu-CH3), 0.83 (3H, t, J = 6.2, Leu-
CH3),  0.87 (3H, d, J = 6.2, Leu-CH3), 0.88 (3H, d, J = 6.2, Leu-CH3), 1.36-1.47 (4H, m, 
Leu-CHH (x2) / Leu-CH (x2)), 1.51-1.59 (2H, m, Leu-CHH (x2)),  1.64 (9H, s, Boc-
(CH3)3), 1.91 (3H, s, Acetyl-CH3), 3.27-3.37 (2H, m, Trp-CH2), 3.55 (3H, s, Ester-CH3), 
4.39-4.48 (2H, m, Leu-α-CH / Trp-α-CH), 4.77 (1H, app q, J = 7.7, Leu-α-CH), 5.75 (1H, 
br d, J = 8.0, Leu-NH), 5.99 (1H, br d, J = 8.0, Trp-NH), 6.73-6.77 (2H, m, alkene-CH / 
Leu-NH), 7.25-7.32 (3H, m, alkene-CH / Ar-H), 7.36 (1H, d, J = 7.4, Ar-H), 7.38-7.40 
(2H, m, Ar-H), 7.58 (2H, d, J = 7.4, Ar-H), 7.71 (1H, br d, J = 7.4, Ar-H), 8.13 (1H, d, J = 
7.8, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.0 (Leu-CH3), 22.0 (Leu-CH3), 22.6 (Leu-CH3), 22.8 
(Leu-CH3), 23.1 (Acetyl-CH3), 24.6 (Leu-CH), 24.7 (Leu-CH), 28.0 (Trp-CH2), 28.2 (Boc-
(CH3)3), 41.3 (Leu-CH2), 41.6 (Leu-CH2), 50.8 (Leu-α-CH), 51.7 (Trp-α-CH), 52.2 (Ester-
CH3), 53.3 (Leu-α-CH), 83.9 (Boc-C), 114.8 (Ar-C), 115.6 (Ar-C), 119.0 (alkene-C), 
120.0 (Ar-C), 123.1 (Ar-C), 124.8 (Ar-C), 126.7 (Ar-C), 128.0 (Ar-C),128.7 (Ar-C), 129.5 
(Ar-C), 132.2 (alkene-C), 135.9 (Ar-C), 136.3 (Ar-C), 136.8 (Ar-C), 150.4 (C=O), 169.9 
(C=O), 170.0 (C=O), 171.8 (C=O), 172.2 (C=O).   
IR Umax /cm-1 (solid) 3273 m (N-H), 3056 w (C-H), 2957 w (C-H), 1730 s (Ester C=O), 
1627 m (amide C=O), 1541 m (C=C).  
HRMS (ESI) [M+H]+ m/z calcd. for C39H53N4O7: 689.3909, found: 689.3908.  
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4.23.3 Synthesis of modified peptide 33c  
 
Modified peptide 33c was prepared from Ac-Met-Trp(Boc)-Met-OMe (32c) (0.148 g, 
0.238 mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in 
Section 4.14. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 33c and the mono-olefinated peptide in a ratio of 19:1. Purification by 
flash column chromatography (50% EtOAc / pet. ether) followed by recrystallisation from 
DCM / hexanes gave 33c as an off-white solid (0.095 g, 55%); m.p. 144-146 °C, Rf 0.39 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.57 (9H, s, Boc-(CH3)3), 1.76-1.84 (2H, Met-CH2), 1.86 
(3H, s, Met-CH3), 1.92 (3H, s, Met-CH3), 1.95-1.97 (4H, s, Acetyl-CH3 / Met-CHH), 2.00-
2.08 (1H, m, Met-CHH), 2.19-2.28 (2H, m, Met-CH2), 2.35-2.45 (2H, m, Met-CH2),  3.22 
(1H, dd, J = 14.3, J = 8.6, Trp-CHH), 3.29 (1H, dd, J = 14.3, J = 6.8, Trp-CHH), 3.50 
(3H, s, Ester-CH3),  4.40 (1H, dt, J = 7.3, J = 5.7, Met-α-CH), 4.50 (1H, app q, J = 7.8, 
Trp-α-CH), 4.69 (1H, app q, J = 7.4, Met-α-CH), 6.18 (1H, d, J = 7.0, Met-NH), 6.20 (1H, 
d, J = 7.0, Met-NH), 6.71 (1H, d, J = 16.8, alkene-CH), 6.91 (1H, br d, J = 7.8, Trp-NH), 
7.16-7.33 (7H, m, alkene-CH / Ar-H), 7.51 (2H, d, J = 7.4, Ar-H), 7.59 (1H, d, J = 7.4, Ar-
H), 8.06 (1H, d, J = 7.4, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 15.1 (Met-CH3), 15.3 (Met-CH3), 23.1 (Acetyl-CH3), 
28.1 (Trp-CH2), 28.2 (Boc-(CH3)3), 29.6 (Met-CH2), 30.0 (Met-CH2),  31.4 (Met-CH2), 
31.6 (Met-CH2), 51.7 (Met-α-CH), 52.3 (Ester-CH3), 52.4 (Trp-α-CH), 53.6 (Met-α-CH), 
84.0 (Boc-C), 114.6 (Ar-C), 115.6 (Ar-C), 118.8 (Ar-C), 119.9 (alkene-C), 123.0 (Ar-C), 
124.8 (Ar-C), 126.7 (Ar-C), 128.0 (Ar-C), 128.7 (Ar-C), 129.5 (Ar-C), 132.3 (alkene-C), 
136.0 (Ar-C), 136.3 (Ar-C), 136.8 (Ar-C), 150.4 (C=O), 170.0 (C=O), 170.2 (C=O), 170.8 
(C=O), 171.2 (C=O). 
IR Umax /cm-1 (solid) 3275 m (N-H), 3060w (C-H), 2920 w (C-H), 1728 s (Ester C=O), 
1634 m (amide C=O), 1453 m (C-H), 1258 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C37H49N4O7S2: 725.3037, found: 725.3040.  
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4.23.4 Synthesis of modified peptide 33d 
 
Modified peptide 33d was prepared from Ac-Gly-Leu-Trp(Boc)-OMe (32d) (0.126 g, 
0.238 mmol) and styrene (0.109 mL, 0.952 mmol), using the general procedure in 
Section 4.14. The 1H NMR spectrum for the crude product contained a mixture of the di-
olefinated peptide 33d and the mono-olefinated peptide in a ratio of 20:1. Purification by 
flash column chromatography (EtOAc) followed by recrystallisation from DCM / hexanes 
gave 33d as an off-white solid (0.102 g, 68%); m.p. 165-167 °C, Rf 0.20 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 0.84 (3H, d, J = 9.0, Leu-CH3), 0.86 (3H, d, J = 9.0, Leu-
CH3), 1.49-1.57 (3H, m, Leu-CH / Leu-CH2), 1.64 (9H, s, Boc-(CH3)3), 1.97 (3H, s, 
Acetyl-CH3), 3.32 (1H, dd, J = 14.4, J = 7.3, Trp-CHH), 3.39 (1H, dd, J = 14.4, J = 7.3, 
Trp-CHH), 3.59 (3H, s, Ester-CH3), 3.69-3.83 (2H, m, Gly-CH2), 4.34-4.39 (1H, m, Leu-
α-CH), 4.88-4.93 (1H, m, Trp-α-CH), 6.31 (2H, br m, NH (x2)), 6.77 (1H, d, J = 16.6, 
alkene-CH), 7.15-7.23 (1H, m, Ar-H), 7.25-7.40 (6H, m, Ar-H / alkene-CH / NH), 7.56 
(2H, d, J = 8.0, Ar-H), 8.11 (1H, d, J = 8.0, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 21.8 (Leu-CH3), 22.8 (Leu-CH3), 22.8 (Acetyl-CH3), 
24.6 (Leu-CH), 27.6 (Trp-CH2), 28.3 (Boc-(CH3)3), 40.6 (Leu-CH2), 43.1 (Gly-CH2), 51.5 
(Leu-α-CH), 52.4 (Ester-CH3), 52.5 (Trp-α-CH), 84.2 (Boc-C), 114.6 (Ar-C), 115.4 (Ar-
C), 118.8 (Ar-C), 119.9 (alkene-C), 122.9 (Ar-C), 124.7 (Ar-C), 126.6 (Ar-C), 128.1 (Ar-
C), 128.8 (Ar-C), 129.9 (Ar-C), 132.4 (alkene-C), 135.8 (Ar-C), 136.2 (Ar-C), 136.7 (Ar-
C), 150.5 (C=O), 168.9 (C=O), 170.9 (C=O), 171.4 (C=O), 172.1 (C=O). 
IR Umax /cm-1 (solid) 3273 m (N-H), 3060 w (C-H), 2958 w (C-H), 1730 s (Ester C=O), 
1631 m (amide C=O), 1541 m (C=C), 1224 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C35H45N4O7: 633.3283, found: 633.3286. 
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4.24 Synthesis of unnatural tryptophan derived amino acids 
4.24.1 Synthesis of Ac-Trp-OMe (34) 
 
L-tryptophan methyl ester hydrochloride (0.300 g, 1.178 mmol) was slurried in THF (15 
mL) and cooled to 0 ˚C in an ice bath before the addition of NEt3 (0.197 mL, 1.414 
mmol). Acetic anhydride (0.223 mL, 2.356 mmol) was then added and heated to 80 ˚C 
for 2 h. The resulting solution was allowed to cool to room temperature before it was 
added to water (25 mL), and extracted with EtOAc (3 x 30 mL). The organic layers were 
combined and washed with 1M HCl (20 mL), sat. NaHCO3 solution (20 mL) and brine 
(20 mL). The organic layer was then dried (MgSO4), and reduced to a brown solid by 
rotary evaporation. The solid was then triturated (Et2O) and filtered to give a sandy 
brown solid (0.240 g, 78%), m.p. 154-155 °C. 
1H NMR (400 MHz, CDCl3) δ 1.95 (3H, s, Acetyl-CH3), 3.27-3.37 (2H, m, Trp-CH2), 3.70 
(3H, s, Ester-CH3), 4.95 (1H, dt, J = 7.8, J = 5.0, Trp-α-CH), 5.98 (1H, br d, J = 7.8, Trp-
NH), 6.97 (1H, d, J = 2.3, Trp-Ar-H), 7.10-7.13 (1H, m, Trp-Ar-H), 7.17-7.21 (1H, m, Ar-
H), 7.36 (1H, d, J = 7.5, Trp-Ar-H), 7.52 (1H, d, J = 7.5, Trp-Ar-H) 8.14 (1H, m, Trp-Ar-
NH).  
13C{1H} NMR (100 MHz, CDCl3) δ 23.3 (Acetyl-CH3), 27.6 (Trp-CH2), 52.4 (Ester-CH3), 
53.0 (Trp-α-CH), 110.1(Ar-C), 113.3 (Ar-C), 118.5 (Ar-C), 119.7 (Ar-C), 122.3 (Ar-C), 
122.6 (Ar-C), 127.7 (Ar-C), 136.0 (Ar-C), 169.7 (C=O), 172.4 (C=O).  
The data matches that previously reported.69 
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4.24.2 Preparation of Ac-Trp(Boc)-OMe (35) 
 
N-Acetyl-L-tryptophan methyl ester (0.200 g, 0.768 mmol) was dissolved in DCM (20 mL) 
and treated with NEt3 (0.129 mL, 0.922 mmol). A solution of Boc anhydride (0.335 g, 
1.537 mmol) in DCM (5 mL) was added dropwise to the peptide solution, and heated 
under reflux for 16 h. The solution was allowed to cool to room temperature, and 
concentrated by rotary evaporation. The crude compound was purified by flash column 
chromatography (50% EtOAc / pet. ether) to afforded 35 as a yellow oil (0.271 g, 98%); 
m.p. 57-59 ˚C, Rf 0.19 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.57 (Boc-(CH3)3), 1.88 (3H, s, Acetyl-CH3), 3.10 (1H, dd, J 
= 14.8, J = 5.5, Trp-CHH), 3.18 (1H, dd, J = 14.8, J = 5.5, Trp-CHH), 3.60 (3H, s, Ester-
CH3), 4.84 (1H, dt, J = 7.7, J = 5.5, Trp-α-CH), 6.27 (1H, br d, J = 7.7, Trp-NH), 7.13 
(1H, t, J = 7.7, Trp-Ar-H), 7.21 (1H, t, J = 7.7, Trp-Ar-H), 7.29 (1H, br s, Trp-Ar-H), 7.38 
(1H, d, J = 7.7, Trp-Ar-H), 8.01 (1H, br d, J = 6.3, Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 27.1 (Trp-CH2), 28.0 (Boc-(CH3)3), 
52.3 (Ester-CH3), 52.5 (Trp-α-CH), 83.6 (Boc-C), 114.8 (Ar-C), 115.1 (Ar-C), 118.6 (Ar-
C), 122.4 (Ar-C), 123.8 (Ar-C), 124.4 (Ar-C), 130.4 (Ar-C), 135.1 (Ar-C), 149.4 (C=O), 
169.7 (C=O), 172.0 (C=O). 
IR Umax /cm-1 (solid) 3286 m (N-H), 2978 w (C-H), 1727 s (Ester C=O), 1654 m (amide 
C=O), 1452 m (C-H), 1227 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C19H25N2O5: 361.1758, found: 361.1755. 
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4.24.3 Synthesis of amino acid (35a) 
 
Modified amino acid 35a was prepared from Ac-Trp(Boc)-OMe (35) (0.058 g, 0.161 
mmol) and styrene (0.074 mL, 0.644 mmol), using the general procedure in Section 
4.14. The 1H NMR spectrum for the crude product contained only mono-olefinated 
peptide 35a and the peptide starting material only. There was no evidence of the di-
olefinated product. Purification by flash column chromatography (50% EtOAc / pet. 
ether) followed by recrystallisation from DCM / hexanes gave 35a as an off-white solid 
(0.029 g, 39%); m.p. 55-56 °C, Rf 0.37 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.64 (9H, s, Boc-(CH3)3), 1.88 (3H, s, Acetyl-CH3), 3.38 
(2H, d, J = 6.4, Trp-CH2), 3.51 (3H, s, Ester-CH3), 4.93 (1H, dt, J = 7.6, J = 6.4, Trp-α-
CH), 6.02 (1H, br d, J = 7.6, Trp-NH), 6.79 (1H, d, J = 16.6, alkene-CH), 7.23-7.33 (4H, 
m, Ar-H /alkene-CH), 7.38 (2H, m, Ar-H), 7.55 (3H, m, Ar-H), 8.12 (1H, d, J = 8.4, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.1 (Acetyl-CH3), 27.6 (Trp-CH2), 28.3 (Boc-(CH3)3), 
52.4 (Ester-CH3), 52.5 (Trp-α-CH), 84.0 (Boc-C), 114.6 (Ar-C), 115.5 (Ar-C), 118.7 (Ar-
C), 119.8 (alkene-CH), 122.8 (Ar-C), 124.7 (Ar-C), 126.5 (Ar-C), 128.0 (Ar-C), 128.8 (Ar-
C), 130.1 (Ar-C), 132.4 (alkene-CH), 135.8 (Ar-C), 136.0 (Ar-C), 136.8 (Ar-C), 150.4 
(C=O), 169.6 (C=O), 172.4 (C=O). 
IR Umax /cm-1 (solid) 378 m (N-H), 2976 w (C-H), 1726 s (Ester C=O), 1655 m (amide 
C=O), 1359 m (C-H), 1206 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C27H31N2O5: 463.2227, found: 463.2225. 
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4.25 Preparation of silyl protected peptides 36a-b 
4.25.1 Ac-Gly-Trp(TIPS)-OMe (36a) 
 
Ac-Gly-Trp-OMe (20) (0.100 g, 0.359 mmol) was dissolved in dry THF (10 mL) and 
cooled in a dry ice/acetone bath. NaHMDS (1M in THF, 0.359 mL, 0.359 mmol) was 
added dropwise at -78 ˚C and left to stir for 1 h. Triisopropylsilyl chloride (0.092 mL, 
0.431 mmol) was added and left to gradually warm to room temperature for 24 h. The 
solution was added to water (30 mL) and extracted with EtOAc (4 x 30 mL), dried 
(MgSO4) and concentrated to a brown oil in vacuuo. The oil was purified by flash column 
chromatography (EtOAc) and reduced down to give 36a as a yellow oil (0.114 g, 67%), 
Rf 0.27 (EtOAc). 
1H NMR (400 MHz, CDCl3) δ 1.12 (18H, dd, J = 7.3, J = 1.6, TIPS-(CH3)6), 1.67 (3H, 
septet, J = 7.3, TIPS-CH x3), 1.94 (3H, s, Acetyl-CH3), 3.25-3.35 (2H, m, Trp-CH3), 3.66 
(3H, s, Ester-CH3), 3.83-3.94 (2H, m, Gly-CH2), 4.94 (1H, dt, J = 7.8, J = 5.7, Trp-α-CH), 
6.30 (1H, br t, J = 4.3, Gly-NH), 6.57 (1H, br d, J = 7.8, Trp-NH), 7.02 (1H, s, Trp-Ar-H), 
7.10-7.17 (2H, m, Trp-Ar-H), 7.46-7.52 (2H, m, Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 12.7 (TIPS-CH x3), 18.0 (TIPS-CH3), 22.8 (Acetyl-
CH3), 27.6 (Trp-CH2), 42.8 (Gly-CH2), 52.3 (Ester-CH3), 53.2 (Trp-α-CH), 111.6 (Ar-C), 
114.1 (Ar-C), 118.2 (Ar-C), 119.8 (Ar-C), 121.7 (Ar-C), 129.7 (Ar-C), 130.9 (Ar-C), 141.1 
(Ar-C), 168.4 (C=O), 170.3 (C=O), 172.0 (C=O). 
IR Umax /cm-1 (oil) 3286 m (N-H), 2946 s (C-H), 2868 s (C-H), 1743 s (Ester C=O), 1647 
m (C=C), 1450 m (C-H), 1211 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C25H40N3O4Si: 474.2783, found: 474.2777.  
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4.25.2 Ac-Gly-Trp(TBDMS)-OMe (36b) 
 
Ac-Gly-Phe-OMe (20) (0.100 g, 0.359 mmol) was dissolved in dry THF (10 mL) and 
cooled in a dry ice/acetone bath. NaHMDS (1M in THF, 0.359 mL, 0.359 mmol) was 
added dropwise to the solution and stirred for 1 h at -78 ˚C. tert-butyldimethylsilyl 
chloride (0.065 g, 0.431 mmol) was added and left to gradually warm to room 
temperature for 24 h. The solution was added to water (30 mL) and extracted with 
EtOAc (4 x 30 mL), dried (MgSO4) and concentrated to a brown oil in vacuuo. The oil 
was purified by flash column chromatography (50% EtOAc / pet. ether) and reduced 
down to afford 36b as a yellow oil (0.102 g, 66%), Rf 0.41 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 0.58 (6H, s, TBDMS-CH3 (x2)), 0.90 (9H, s, TBDMS-
C(CH3)3), 1.94 (3H, s, Acetyl-CH3), 3.23-3.34 (2H, m, Trp-CH2), 3.67 (3H, s, Ester-CH3), 
3.85 (1H, dd, J = 16.8, 5.0, Gly-CHH), 3.91 (1H, dd, J = 16.8, 5.0, Gly-CHH), 4.90 (1H, 
dt, J = 7.8, 5.7, Trp-α-CH), 6.46 (1H, br t, J = 5.0, Gly-NH),  6.73 (br d, J = 7.8, Trp-NH), 
6.97 (1H, s, Trp-Ar-H), 7.09-7.17 (2H, m, Trp-Ar-H), 7.46-7.51 (2H, m, Trp-Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ -4.06 (TBDMS-CH3 x3), 19.4 (TBDMS-C), 22.8 
(Acetyl-CH3), 26.2 (TBDMS-(CH3)3), 27.5 (Trp-CH2), 42.9 (Gly-CH2), 52.3 (Ester-CH2), 
53.2 (Trp-α-CH), 111.7 (Ar-C), 114.0 (Ar-C), 118.2 (Ar-C), 119.7 (Ar-C), 121.6 (Ar-C), 
129.6 (Ar-C), 130.8 (Ar-C), 141.2 (Ar-C), 168.6 (C=O), 170.4 (C=O), 172.0 (C=O). 
IR Umax /cm-1 (oil) 3050 s (C-H), 2935 s (C-H), 2835 s (C-H), 1743 s (Ester C=O), 1657 m 
(C=C), 1433 m (C-H), 1255 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C22H34N3O4Si: 432.2313, found: 432.2319. 
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4.26 Synthesis of Ac-Trp(Pym)-OMe (39) 
 
N-Acetyl-L-tryptophan methyl ester (0.200 g, 0.768 mmol) was dissolved in dry DMF (10 
mL) and cooled to 0 °C in an ice bath. NaH (60% in oil) (0.034 mg, 0.768 mmol) was 
added in portions to the solution, and left to stir for 1 h at 0 ˚C. 2-chloropyridine (0.106 g, 
0.922 mmol) was added and the resulting suspension was left to gradually warm to 
room temperature for 24 h. The solution was added to water (30 mL) and extracted with 
EtOAc (4 x 30 mL), dried (MgSO4) and concentrated to a brown solid in vacuo. The solid 
was purified by flash column chromatography (50% EtOAc / pet. ether), to afford 
modified amino acid 39a as a yellow solid (0.148 g, 57%), m.p. 154-155 °C; Rf 0.41 
(50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.91 (3H, s, Acetyl-CH3), 3.23 (1H, dd, J = 14.3, J = 5.5, 
Trp-CHH), 3.29 (1H, dd, J = 14.3, J = 5.5, Trp-CHH), 3.65 (3H, s, Ester-CH3), 4.92 (1H, 
dt, J = 7.8, J = 5.5, Trp-α-CH), 6.07 (1H, br d, J = 7.8, Trp-NH), 6.96 (1H, t, J = 4.8, Ar-
H), 7.15-7.19 (1H, m, Trp-Ar-H), 7.25-7.29 (1H, m, Trp-Ar-H), 7.45 (1H, br d, J = 7.7, 
Trp-Ar-H), 7.99 (1H, s, Trp-Ar-H), 8.59 (2H, d, J = 4.8, Ar-H), 8.71 (1H, d, J = 8.4 , Trp-
Ar-H).   
13C{1H} NMR (100 MHz, CDCl3) δ  23.2 (Acetyl-CH3), 27.4 (Trp-CH2), 52.4 (Ester-CH3), 
52.7 (Trp-α-CH), 114.3 (Ar-C), 116.1 (Ar-C), 116.4 (Ar-C), 118.5 (Ar-C), 122.0 (Ar-C), 
124.0 (Ar-C), 124.1 (Ar-C), 131.1 (Ar-C), 135.5 (Ar-C), 157.4 (Ar-C), 158.1 (Ar-C), 169.8 
(C=O), 172.2 (C=O). 
IR Umax /cm-1 (solid) 3291 m (N-H), 3050 s (C-H), 2955 s (C-H), 1735 s (Ester C=O), 
1660 m (C=C), 1456 m (C-H), 1211 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C18H19N4O3: 339.1452, found: 339.1455. 
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4.27 Synthesis of modified peptides 43a-e 
4.27.1 Synthesis of Ac-Trp(Boc)-Phe-OMe (42) 
 
Peptide 42 was synthesised from Ac-Trp-Phe-OMe (9f) (0.306 g, 0.75 mmol) using the 
general procedure described in Section 4.13. Purification by flash column 
chromatography (75% EtOAc / pet. ether) followed by recrystallisation from DCM / 
hexanes gave 42 as a white solid (0.381 g, 94%); m.p. 89-93 °C, Rf 0.25 (75% EtOAc / 
pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.65 (9H, s, Boc-(CH3)3), 1.98 (3H, s, Acetyl-CH3), 2.94 
(1H, dd, J = 13.7, J = 6.0, Phe-CHH), 3.01-3.08 (2H, m, Phe-CHH/Trp-CHH), 3.20 (1H, 
dd, J = 14.6, J = 5.5, Trp-CHH), 3.63 (3H, s, Ester-CH3), 4.66-4.71 (2H, m, Ph-α-CH/Trp-
α-CH), 6.09 (1H, br d, J = 7.3, Trp-NH), 6.21 (1H, br d, J = 7.3, Phe-NH), 6.90-6.92 (2H, 
m, Phe-Ar-H), 7.15-7.18 (3H, m, Phe-Ar-H), 7.22-7.26 (1H, m, Trp-Ar-H), 7.32 (1H, t, J = 
8.2, Trp-Ar-H), 7.45 (1H, s, Trp-Ar-H), 7.64 (1H, d, J = 7.8¸ Trp-Ar-H), 8.11-8.13 (1H, m, 
Trp-Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.2 (Acetyl-CH3), 28.1 (Trp-CH2), 28.2 (Boc-(CH3)3), 
37.8 (Phe-CH2), 52.3 (Ester-CH3), 53.3 (Trp-α-CH), 53.4 (Phe-α-CH), 83.6 (Boc-C), 
115.2 (Ar-C), 115.3 (Ar-C), 119.0 (Ar-C), 122.7 (Ar-C), 124.5 (Ar-C), 124.6 (Ar-C), 127.1 
(Ar-C), 128.5 (Ar-C), 129.1 (Ar-C), 130.1 (Ar-C), 135.3 (Ar-C), 135.4 (Ar-C), 149.5 
(C=O), 169.9 (C=O), 170.3 (C=O), 171.0 (C=O). 
IR Umax /cm-1 (solid) 3276 m (N-H), 3056 w (C-H), 2986 w (C-H), 1735 s (Ester C=O), 
1639 m (amide C=O), 1457 m (C-H), 1341 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C28H34N3O6: 508.2442, found: 508.2446. 
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4.27.2  Olefination of Ac-Trp(Boc)-Phe-OMe 43a-e 
 
Ac-Trp(Boc)-Phe-OMe (42) (0.182 g, 0.359 mmol), Pd(OAc)2 (8 mg, 0.036 mmol, 10 
mol%), AgOAc (0.150 g, 0.898 mmol) and styrene (0.165 mL, 1.436 mmol) were stirred 
together in toluene (3 mL) at 100 °C for 6 h. The reaction was then allowed to cool to 
room temperature and filtered through a plug of Celite© before the filtrate was 
concentrated to dryness. The resulting residue was purified by column chromatography 
and recrystallized in DCM / hexanes to afford products 43a-e.  
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4.27.3 Synthesis of modified peptide 43a 
 
Modified peptide 43a was prepared from Ac-Trp(Boc)-Phe-OMe (42) (0.100 g, 0.197 
mmol) and styrene (0.087 mL, 0.788 mmol), using the general procedure in Section 
4.27.2. Purification by flash column chromatography (50% EtOAc / pet. ether) followed 
by recrystallisation from DCM / hexanes gave 43a as an off-white solid (0.035 g, 16%); 
m.p. 117-118 °C, Rf 0.22 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.56 (9H, s, Boc-(CH3)3), 1.74 (3H, s, Acetyl-CH3), 2.94 
(1H, dd, J = 14.4, J = 8.2, Phe-CHH), 2.98-3.09 (2H, m, Phe-CHH / Trp-CHH), 3.20 (1H, 
dd, J = 14.0, J = 6.4, Trp-CHH), 3.47 (3H, s, Ester-CH3), 4.52-4.60 (2H, m, Phe-α-CH / 
Trp-α-CH), 6.14-6.20 (2H, m, Phe-NH / Trp-NH), 6.79 (1H, d, J = 7.6, Ar-H), 6.87 (1H, d, 
J = 16.1, alkene-CH), 7.00 (1H, t, J = 7.3, Ar-H), 7.13 (2H, app q, J = 7.6, Ar-H), 7.19-
7.23 (3H, m, Ar-H / alkene-CH), 7.26-7.32 (3H, m, Ar-H), 7.45-7.52 (4H, m, Ar-H), 8.02 
(1H, m, Ar-H).   
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 28.1 (Trp-CH2), 28.1 (Boc-(CH3)3), 
35.0 (Phe-CH2), 52.3 (Ester-CH3), 53.2 (α-CH), 53.3 (α-CH), 83.5 (Boc-C), 115.1 (Ar-C), 
115.2 (Ar-C), 119.0 (Ar-C), 122.6 (Ar-C), 124.4 (Ar-C), 124.5 (Ar-C), 125.1 (Ar-C), 125.7 
(alkene-C), 126.5 (Ar-C), 126.6 (Ar-C), 127.5 (Ar-C), 127.6 (Ar-C), 127.8 (Ar-C), 128.7 
(Ar-C), 130.1 (Ar-C), 130.4 (Ar-C), 130.5 (Ar-C), 133.3 (alkene-C), 136.5 (Ar-C), 137.2 
(Ar-C), 149.4 (C=O), 169.9 (C=O), 170.4 (C=O), 171.1 (C=O).  
IR Umax /cm-1 (solid) 3280 m (N-H), 2963 w (C-H), 1731 s (Ester C=O), 1638 m (amide 
C=O), 1452 m (C-H), 1258 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C36H40N3O6: 610.2912, found: 610.2912. 
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4.27.4 Synthesis of modified peptide 43b 
 
Modified peptide 43b was prepared from Ac-Trp(Boc)-Phe-OMe (42) (0.100 g, 0.197 
mmol) and styrene (0.087 mL, 0.788 mmol), using the general procedure in Section 
4.27.2. Purification by flash column chromatography (50% EtOAc / pet. ether) followed 
by recrystallisation from DCM / hexanes gave 43b as an off-white solid (0.048 g, 22%); 
m.p. 152-153 °C, Rf 0.29 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.55 (9H, s, Boc-(CH3)3), 1.90 (3H, s, Acetyl-CH3), 2.79 
(1H, dd, J = 13.8, J = 6.0, Phe-CHH), 2.90 (1H, dd, J = 13.8, J = 6.0, Phe-CHH), 3.12 
(1H, dd, J = 14.1, J = 9.7, Trp-CHH), 3.25 (1H, dd, J = 14.0, J = 5.6, Trp-CHH), 3.37 
(3H, s, Ester-CH3), 4.45-4.50 (1H, m, Trp-α-CH), 4.63-4.68 (1H, m, Phe-α-CH), 5.87 
(1H, br d, J = 7.8, Trp-NH), 6.42 (1H, br d, J = 7.4, Phe-NH), 6.75 (1H, d, J = 16.7, 
alkene-CH), 6.83-6.85 (2H, m, Ar-H), 7.08-7.10 (2H, m, Ar-H), 7.16-7.22 (4H, m, Ar-H), 
7.28-7.31 (3H, m, Ar-H), 7.48-7.58 (3H, m, Ar-H), 8.02 (1H, br d, J = 8.2, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 23.1 (Acetyl-CH3), 28.2 (Boc-(CH3)3), 28.6 (Trp-CH2),  
38.1 (Phe-CH2), 52.1 (Ester-CH3), 53.5 (α-CH), 53.5 (α-CH), 83.9 (Boc-C), 114.9 (Ar-C), 
115.4 (Ar-C), 118.8 (Ar-C), 119.7 (alkene-C), 123.0 (Ar-C), 124.7 (Ar-C), 126.6 (alkene-
C), 127.0 (Ar-C), 127.9 (Ar-C), 128.4 (Ar-C), 128.7 (Ar-C), 129.1 (Ar-C), 129.7 (Ar-C), 
132.1 (alkene-C), 135.4 (Ar-C), 135.9 (Ar-C), 136.0 (Ar-C), 136.9 (Ar-C), 150.4 (C=O), 
169.7 (C=O), 170.4 (C=O), 170.4 (C=O).  
IR Umax /cm-1 (solid) 3282 m (N-H), 3060 w (C-H), 2963 w (C-H), 1726 s (Ester C=O), 
1642 m (amide C=O), 1522 m (C=C), 1258 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C36H40N3O6: 610.2912, found: 610.2912. 
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4.27.5 Synthesis of modified peptide 43c 
 
Modified peptide 43c was prepared from Ac-Trp(Boc)-Phe-OMe (42) (0.100 g, 0.197 
mmol) and styrene (0.087 mL, 0.788 mmol), using the general procedure in Section 
4.27.2. Purification by flash column chromatography (50% EtOAc / pet. ether) followed 
by recrystallisation from DCM / hexanes gave 43c as an off-white solid (0.018 g, 7%); 
m.p. 120-122 °C, Rf 0.39 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.62 (9H, s, Boc-(CH3)3), 1.80 (3H, s, Acetyl-CH3), 2.96 
(1H, dd, J = 14.5, J = 8.2, Trp-CHH), 3.12 (1H, dd, J = 14.5, J = 8.2, Trp-CHH), 3.34-
3.37 (2H, m, Phe-CH2), 3.41 (3H, s, Ester-CH3), 4.57-4.68 (2H, m, Trp-α-CH / Phe-α-
CH), 6.12 (1H, br d, J = 7.3, Trp-NH), 6.17 (1H, br d, J = 7.7, Phe-NH), 6.96 (2H, d, J = 
16.0, alkene-CH), 7.12 (1H, t, J = 7.4, Ar-H), 7.23-7.31 (4H, m, Ar-H / alkene-CH), 7.33-
7.42 (6H, m, Ar-H /alkene-CH), 7.50-7.57 (8H, m, Ar-H), 8.08 (1H, d, J = 8.1, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.1 (Acetyl-CH3), 28.3 (Boc-(CH3)3), 28.4 (Trp-CH2),  
31.6 (Phe-CH2), 52.7 (Phe-α-CH), 53.1 (Ester-CH3), 53.5 (Trp-α-CH), 83.7 (Boc-C), 
115.3 (Ar-C), 119.1 (Ar-C), 119.7 (Ar-C), 122.8 (Ar-C), 123.1 (Ar-C), 124.6 (Ar-C), 125.7 
(Ar-C), 126.1 (alkene-C), 126.9 (Ar-C), 127.7 (Ar-C), 128.0 (Ar-C), 128.9 (Ar-C), 130.3 
(Ar-C), 130.4 (Ar-C), 131.7 (alkene-C), 132.1 (Ar-C), 137.3 (Ar-C), 137.9 (Ar-C), 149.6 
(C=O), 169.9 (C=O), 170.4 (C=O), 171.3 (C=O).  
IR Umax /cm-1 (solid) 3282 m (N-H), 3055 w (C-H), 2965 w (C-H), 1728 s (Ester C=O), 
1638 m (amide C=O), 1451 m (C-H), 1258 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C44H46N3O6: 712.3381, found: 712.3375. 
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4.27.6 Synthesis of modified peptide 43d 
 
Modified peptide 43d was prepared from Ac-Trp(Boc)-Phe-OMe (42) (0.100 g, 0.197 
mmol) and styrene (0.087 mL, 0.788 mmol), using the general procedure in Section 
4.27.2. Purification by flash column chromatography (50% EtOAc / pet. ether) followed 
by recrystallisation from DCM / hexanes gave 43d as an off-white solid (0.033 g, 13%); 
m.p. 100-102 °C, Rf 0.45 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.62 (9H, s, Boc-(CH3)3), 1.77 (3H, s, Acetyl-CH3), 3.04 
(1H, dd, J = 14.2, J = 5.2, Phe-CHH), 3.11 (1H, dd, J = 14.0, J = 10.0, Trp-CHH), 3.23 
(1H, dd, J = 14.2, J = 7.2, Phe-CHH), 3.32-3.41 (1H, m, Trp-CHH), 3.38 (3H, s, Ester-
CH3), 4.48-4.52 (1H, m, Trp-α-CH), 4.61-4.67 (1H, m, Phe-α-CH), 5.82 (1H, br d, J = 
7.2, Trp-NH), 6.33 (1H, br d, J = 7.2, Phe-NH), 6.61-6.85 (2H, m, alkene-CH / Ar-H), 
6.98 (1H, d, J = 16.0, alkene-CH), 7.17-7.40 (13H, m, Ar-H / alkene-CH), 7.55-7.63 (5H, 
m, Ar-H), 8.08 (1H, d, J = 8.4, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 22.9 (Acetyl-CH3), 28.2 (Boc-(CH3)3), 28.8 (Trp-CH2),  
35.2 (Phe-CH2), 52.2 (Ester-CH3), 53.5 (α-CH),  53.5 (α-CH), 83.8 (Boc-C), 115.0 (Ar-C), 
115.4 (Ar-C), 118.8 (Ar-C), 119.6 (alkene-C), 123.0 (Ar-C), 124.7 (Ar-C), 125.2 (Ar-C), 
125.6 (Ar-C), 126.6 (Ar-C), 126.7 (Ar-C), 127.4 (Ar-C), 127.5 (Ar-C), 127.7 (Ar-C), 127.8 
(Ar-C), 128.7 (Ar-C), 130.3 (Ar-C), 130.4 (Ar-C), 131.9 (Ar-C), 133.3 (alkene-C), 135.9 
(Ar-C), 135.9 (Ar-C), 136.6 (Ar-C), 136.9 (Ar-C), 137.4 (Ar-C), 150.4 (C=O), 169.6 
(C=O), 170.3 (C=O), 170.5 (C=O).   
IR Umax /cm-1 (solid) 3282 m (N-H), 2976 w (C-H), 1726 s (Ester C=O), 1645 m (amide 
C=O), 1541 m (C=C), 1233 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C44H46N3O6: 712.3381, found: 712.3382. 
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4.27.7 Synthesis of modified peptide 43e 
 
Modified peptide 43e was prepared from Ac-Trp(Boc)-Phe-OMe (42) (0.100 g, 0.197 
mmol) and styrene (0.087 mL, 0.788 mmol), using the general procedure in Section 
4.27.2. Purification by flash column chromatography (50% EtOAc / pet. ether) followed 
by recrystallisation from DCM / hexanes gave 43e as an off-white solid (0.018 g, 6%); 
m.p.106-108 °C, Rf 0.61 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.60 (9H, s, Boc-(CH3)3), 1.82 (3H, s, Acetyl-CH3), 3.10 
(1H, dd, J = 13.8, J = 10.0, Trp-CHH), 3.21 (3H, s, Ester-CH3), 3.26-3.44 (3H, m, Trp-
CHH / Phe-CH2), 4.55 (1H, dt, J = 7.8, J = 6.4, Trp-α-CH), 4.65-4.71 (1H, m, Phe-α-CH), 
5.90 (1H, br d, J = 7.8, Trp-NH), 6.36 (1H, br d, J = 7.3, Phe-NH), 6.81 (1H, d, J = 16.7, 
Trp-alkene-CH), 6.95 (2H, d, J = 16.0, Phe-alkene-CH), 7.10 (2H, t, J = 7.8, Ar-H), 7.20-
7.31 (7H, m, Ar-H / alkene-CH), 7.36-7.41 (7H, m, Ar-H / alkene-CH), 7.50-7.61 (8H, m, 
Ar-H), 8.05 (1H, d, J = 7.8, Ar-H). 
13C{1H} NMR (100 MHz, CDCl3) δ 23.1 (Acetyl-CH3), 28.4 (Boc-(CH3)3), 29.8 (Trp-CH2), 
31.9 (Phe-CH2), 52.6 (Ester-CH3), 53.1 (α-CH), 53.8 (α-CH), 84.0 (Boc-C), 115.1 (Ar-C), 
115.4 (Ar-C), 118.9 (alkene-C), 119.7 (Ar-C), 123.1 (Ar-C), 123.2 (Ar-C), 124.8 (Ar-C), 
125.6 (Ar-C), 126.1 (alkene-C), 126.8 (Ar-C), 126.9 (Ar-C), 127.5 (Ar-C), 127.9 (Ar-C), 
128.8 (Ar-C), 128.9 (Ar-C), 128.9 (Ar-C), 129.6 (Ar-C), 131.4 (alkene-C), 131.8 (alkene-
C), 136.0 (Ar-C), 137.5 (Ar-C), 137.9 (Ar-C), 150.4 (C=O), 169.7 (C=O), 170.3 (C=O), 
170.6 (C=O). There are two Ar-C signals missing; presumably these overlap with other 
signals in the spectrum. 
IR Umax /cm-1 (solid) 3308 m (N-H), 3026 w (C-H), 2963 w (C-H), 1726 s (Ester C=O), 
1655 m (amide C=O), 1508 m (C=C), 1450 m (C-H), 1237 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C52H52N3O6: 814.3851, found: 814.3852. 
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4.28 Synthesis of modified peptide 45 
4.28.1 Synthesis of Ac-Trp(TIPS)-Phe-OMe (44) 
 
Ac-Trp-Phe-OMe (9h) (0.200 g, 0.394 mmol) was dissolved in dry THF (10 mL) and 
cooled in a dry ice/acetone bath. NaHMDS (1M in THF, 0.394 mL, 0.394 mmol) was 
added dropwise at -78 ˚C and left to stir for 1 h. Triisopropylsilyl chloride (0.084 mL, 
0.394 mmol) was added and left to gradually warm to room temperature for 24 h. The 
solution was added to water (30 mL) and extracted with EtOAc (4 x 30 mL), dried 
(MgSO4) and concentrated to a brown oil in vacuuo. The oil was purified by flash column 
chromatography (50% EtOAc / pet. ether) and reduced down to afford 44 a yellow oil 
(0.162 g, 73%), Rf 0.31 (50% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.10 (18H, d, J = 7.3, TIPS-(CH3)2 (x3)), 1.86 (3H, septet, J 
= 7.5, TIPS-CH (x3)),  1.89 (3H, s, Acetyl-CH3), 2.95 (1H, dd, J = 13.7, J = 5.9, Phe-
CHH), 3.05 (1H, dd, J = 13.7, J = 5.9, Phe-CHH), 3.20 (2H, d, J = 6.9, Trp-CH2), 3.62 
(3H, s, Ester-CH3), 4.67-4.78 (2H, m, Phe-α-CH / Trp-α-CH), 6.26 (1H, d, J = 7.3, Phe-
NH), 6.47 (1H, d, J = 7.8, Trp-NH), 6.94-6.97 (2H, m, Phe-Ar-H), 7.08-7.13 (3H, m, Ar-
H), 7.18-7.20 (3H, m, Ar-H), 7.46 (1H, d, J = 8.2, Trp-Ar-H), 7.58 (1H, d, J = 8.2, Trp-Ar-
H).  
13C{1H} NMR (100 MHz, CDCl3) δ 12.8 (TIPS-CH), 18.2 (TIPS-CH3), 23.2 (Acetyl-CH3), 
28.0 (Trp-CH2), 37.9 (Phe-CH2), 52.3 (Ester-CH3), 53.5 (α-CH), 53.6 (α-CH), 112.4 (Ar-
C), 114.1 (Ar-C), 118.7 (Ar-C), 119.9 (Ar-C), 121.7 (Ar-C), 127.2 (Ar-C), 128.6 (Ar-C), 
129.3 (Ar-C), 130.1 (Ar-C), 131.1 (Ar-C), 135.8 (Ar-C), 141.3 (Ar-C), 170.2 (C=O), 171.1 
(C=O), 171.4 (C=O). 
IR Umax /cm-1 (oil) 3280 m (N-H), 3062 w (C-H), 2946 w (C-H), 2866 w (C-H), 1746 s 
(Ester C=O), 1638 m (amide C=O), 1541 m (C=C), 1452 m (C-H).  
HRMS (ESI) [M+H]+ m/z calcd. for C32H46N3O4Si: 564.3252, found: 564.3250. 
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4.28.2 Synthesis of modified peptide 45 
 
Ac-Trp(TIPS)-Phe-OMe (44) (0.065 g, 0.115 mmol), Pd(OAc)2 (2.6 mg, 0.012 mmol, 10 
mol%), AgOAc (0.096 g, 0.576 mmol) and styrene (0.063 mL, 0.461 mmol) were stirred 
together in t-amyl-OH (1 mL) at 130 °C for 12 h. The reaction was then allowed to cool 
to room temperature and filtered through a plug of Celite© before the filtrate was 
concentrated to dryness. The 1H NMR spectrum for the crude product showed only the 
di-olefinated peptide. Purification by flash column chromatography (30% EtOAc / pet. 
ether) to afford 45 as a yellow oil (0.043 g, 49%); Rf 0.35 (30% EtOAc / pet. ether). 
1H NMR (400 MHz, CDCl3) δ 1.04-1.06 (18H, d, J = 7.6, TIPS-(CH3)2 (x3)), 1.55-1.63 
(3H, m, TIPS-CH (x3)), 1.83 (3H, s, Acetyl-CH3), 3.16 (2H, br d, J = 6.0, Phe-CH2), 3.28 
(1H, dd, J = 14.2, J = 8.1, Trp-CHH), 3.39 (3H, s, Ester-CH3), 3.46 (1H, dd, J = 14.2, J = 
6.3, Trp-CHH), 4.61-4.72 (2H, m, Phe-α-CH / Trp-α-CH), 6.05 (1H, br d, J = 8.1, Trp-
NH), 6.44 (1H, br d, J = 7.2, Phe-NH), 6.99-7.10 (5H, m, alkene-CH / Ar-H), 7.26-7.32 
(2H, m, Ar-H), 7.36-7.42 (5H, m, Ar-H), 7.46-7.54 (4H, m, alkene-CH / Ar-H), 7.56-7.62 
(6H, m, Ar-H).  
13C{1H} NMR (100 MHz, CDCl3) δ 12.6 (TIPS-CH), 18.0 (TIPS-CH3), 23.1 (Acetyl-CH3), 
27.9 (Trp-CH2), 31.7 (Phe-CH2), 52.5 (Ester-CH3), 53.1 (Trp-α-CH), 53.8 (Phe-α-CH), 
112.3 (Ar-C), 113.9 (Ar-C), 118.4 (Ar-C), 119.7 (Ar-C), 121.5 (Ar-C), 125.5 (Ar-C), 126.0 
(alkene-C), 126.8 (Ar-C), 127.5 (Ar-C), 127.8 (Ar-C), 128.7 (Ar-C), 129.8 (Ar-C), 131.0 
(Ar-C), 131.6 (Ar-C), 131.8 (alkene-C), 137.2 (Ar-C), 137.8 (Ar-C), 141.1 (Ar-C), 169.9 
(C=O), 170.8 (C=O), 171.4 (C=O).  
IR Umax /cm-1 (oil) 3249 m (N-H), 3058 w (C-H), 2948 w (C-H), 2866 w (C-H), 1743 s 
(Ester C=O), 1629 m (amide C=O), 1508 m (C=C), 1211 s (C-O).  
HRMS (ESI) [M+H]+ m/z calcd. for C48H58N3O4Si: 768.4191, found: 768.4190. 
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